-DOCSTART- -X- O O 

miR-33a - ADJ O 
Mediates - PROPN O 
the - DET O 
Anti - PROPN O 
- - ADJ O 
Tumor - PROPN O 
Effect - PROPN O 
of - ADP O 
Lovastatin PROPN - B-MEDICINE 
in - ADP O 
Osteosarcoma PROPN - B-GPE 
by - ADP O 
Targeting - VERB O 
CYR61 - PROPN O 
. - PUNCT O 

Lovastatin ADV - B-MEDICINE 
, - PUNCT O 
not - ADV O 
simvastatin - ADJ O 
, - PUNCT O 
corrects - VERB O 
core - ADJ O 
phenotypes - NOUN O 
in - ADP O 
the - DET O 
fragile - ADJ O 
X - NOUN O 
mouse - NOUN O 
model - NOUN O 

A - DET O 
controlled - VERB O 
and - CCONJ O 
progressive - ADJ O 
walking - NOUN O 
program - NOUN O 
for - ADP O 
older - ADJ O 
women - NOUN O 
treated - VERB O 
with - ADP O 
Lovastatin PROPN - B-MEDICINE 
may - VERB O 
induce - VERB O 
a - DET O 
boost - NOUN O 
of - ADP O 
brain - NOUN O 
activity - NOUN O 
linked - VERB O 
to - ADP O 
HDL PROPN - B-ORG 
- PUNCT - I-ORG 
C PROPN - I-ORG 
, - PUNCT O 
which - ADJ O 
could - VERB O 
delay - VERB O 
cognitive - ADJ O 
impairment - NOUN O 
. - PUNCT O 

Lovastatin PROPN - B-MEDICINE 
showed - VERB O 
significant - ADJ O 
antioxidant - NOUN O 
property - NOUN O 
with - ADP O 
IC50 - PROPN O 
: - PUNCT O 

Lovastatin PROPN - B-MEDICINE 
had - VERB O 
no - DET O 
effect - NOUN O 
on - ADP O 
feed - NOUN O 
digestibility - NOUN O 
and - CCONJ O 
minor - ADJ O 
effect - NOUN O 
on - ADP O 
rumen - NOUN O 
microbiota - NOUN O 
, - PUNCT O 
and - CCONJ O 
specifically - ADV O 
did - VERB O 
not - ADV O 
reduce - VERB O 
the - DET O 
populations - NOUN O 
of - ADP O 
total - ADJ O 
methanogens - NOUN O 
and - CCONJ O 
Methanobacteriales PROPN - B-PERSON 
( - PUNCT O 
responsible - ADJ O 
for - ADP O 
CH4 PROPN - B-ORG 
production - NOUN O 
) - PUNCT O 
. - PUNCT O 

Lovastatin PROPN - B-MEDICINE 
residues - NOUN O 
were - VERB O 
detected - VERB O 
in - ADP O 
tissues - NOUN O 
of - ADP O 
goats - NOUN O 
fed - VERB O 
6 NUM - B-QUANTITY 
mg NOUN - I-QUANTITY 
lovastatin ADJ - I-QUANTITY 
/ - SYM O 
kg - VERB O 
BW - VERB O 
at - ADP O 
between ADP - B-MONEY 
0.01 NUM - I-MONEY 
to ADP - I-MONEY 
0.03 NUM - I-MONEY 
μg PROPN - I-MONEY 
/ SYM - I-MONEY 
g NOUN - I-MONEY 
, PUNCT - I-MONEY 
which ADJ - I-MONEY 
are VERB - I-MONEY 
very ADV - I-MONEY 
low ADJ - I-MONEY 
. PUNCT - I-MONEY 

Enhanced - VERB O 
production - NOUN O 
of - ADP O 
Lovastatin PROPN - B-MEDICINE 
by - ADP O 
filamentous - ADJ O 
fungi - NOUN O 
through - ADP O 
solid - ADJ O 
state - NOUN O 
fermentation - NOUN O 
. - PUNCT O 

A - DET O 
Synergistic - ADJ O 
Anti - PROPN O 
- - PROPN O 
Cancer - PROPN O 
Effect - PROPN O 
of - ADP O 
Troglitazone - PROPN O 
and - CCONJ O 
Lovastatin PROPN - B-MEDICINE 
in - ADP O 
a - DET O 
Human PROPN - B-ORG 
Anaplastic PROPN - I-ORG 
Thyroid PROPN - I-ORG 
Cancer PROPN - I-ORG 
Cell PROPN - B-ORG 
Line PROPN - I-ORG 
and - CCONJ O 
in - ADP O 
a - DET O 
Mouse - PROPN O 
Xenograft - PROPN O 
Model - PROPN O 
. - PUNCT O 

In - ADP O 
this - DET O 
study - NOUN O 
, - PUNCT O 
we - PRON O 
designed - VERB O 
an - DET O 
innovative - ADJ O 
ternary - ADJ O 
cocktail - NOUN O 
chemotherapy - NOUN O 
by - ADP O 
using - VERB O 
Lovastatin PROPN - B-MEDICINE 
( - PUNCT O 
L)-loaded - ADJ O 
Janus PROPN - B-ORG 
camptothecin - NOUN O 
- - PUNCT O 
floxuridine - NOUN O 
conjugate - NOUN O 
( - PUNCT O 
CF - PROPN O 
) - PUNCT O 
nanocapsules - PROPN O 
( - PUNCT O 
NCs - PROPN O 
) - PUNCT O 
with - ADP O 
ultrahigh - ADJ O 
drug - NOUN O 
loading - NOUN O 
capacity - NOUN O 
. - PUNCT O 

Enhanced - ADJ O 
Single - PROPN O 
- - PUNCT O 
Step - PROPN O 
Bioproduction - PROPN O 
of - ADP O 
the - DET O 
Simvastatin - PROPN O 
Precursor - PROPN O 
Monacolin PROPN - B-PERSON 
J PROPN - I-PERSON 
in - ADP O 
an - DET O 
Industrial - PROPN O 
Strain - PROPN O 
of - ADP O 
Aspergillus - PROPN O 
terreus - NOUN O 
by - ADP O 
Employing PROPN - B-ORG 
the DET - I-ORG 
Evolved PROPN - I-ORG 
Lovastatin PROPN - I-MEDICINE 
Hydrolase PROPN - I-ORG 
. - PUNCT O 

Lovastatin PROPN - B-MEDICINE 
fails - VERB O 
to - PART O 
improve - VERB O 
motor - NOUN O 
performance - NOUN O 
and - CCONJ O 
survival - NOUN O 
in - ADP O 
methyl - NOUN O 
- - PUNCT O 
CpG - NOUN O 
- - PUNCT O 
binding - VERB O 
protein2-null - NOUN O 
mice - NOUN O 
. - PUNCT O 

Lovastatin PROPN - B-MEDICINE 
synergizes - VERB O 
with - ADP O 
itraconazole - NOUN O 
against - ADP O 
planktonic - ADJ O 
cells - NOUN O 
and - CCONJ O 
biofilms - NOUN O 
of - ADP O 
Candida PROPN - B-GPE 
albicans - NOUN O 
through - ADP O 
the - DET O 
regulation - NOUN O 
on - ADP O 
ergosterol - NOUN O 
biosynthesis - NOUN O 
pathway - NOUN O 
. - PUNCT O 

Lovastatin PROPN - B-MEDICINE 
is - VERB O 
a - DET O 
3-hydroxy-3-methylglutaryl NUM - B-QUANTITY 
- PUNCT - I-QUANTITY 
CoA NOUN - I-QUANTITY 
reductase - NOUN O 
inhibitor - NOUN O 
that - ADJ O 
is - VERB O 
clinically - ADV O 
used - VERB O 
for - ADP O 
the - DET O 
prevention - NOUN O 
of - ADP O 
cardiovascular - ADJ O 
diseases - NOUN O 
. - PUNCT O 

Lovastatin PROPN - B-MEDICINE 
also - ADV O 
inhibited - VERB O 
the - DET O 
phosphorylation - NOUN O 
of - ADP O 
inhibitor - NOUN O 
of - ADP O 
nuclear - ADJ O 
factor - NOUN O 
  - SPACE O 
( - PUNCT O 
NF)-κBα - PROPN O 
and - CCONJ O 
the - DET O 
translocation - NOUN O 
of - ADP O 
NF PROPN - B-ORG 
- - PUNCT O 
κB - VERB O 
into - ADP O 
the - DET O 
nucleus - NOUN O 
. - PUNCT O 

Lovastatin PROPN - B-MEDICINE 
induced - VERB O 
Kruppel PROPN - B-ORG 
like - ADP O 
factor - NOUN O 
2 NUM - B-CARDINAL 
( - PUNCT O 
KLF2 PROPN - B-ORG 
) - PUNCT O 
, - PUNCT O 
Kruppel PROPN - B-NORP 
like - ADP O 
factor - NOUN O 
6 NUM - B-CARDINAL 
( - PUNCT O 
KLF6 - PROPN O 
) - PUNCT O 
and - CCONJ O 
Ras PROPN - B-PERSON 
homolog - NOUN O 
family - NOUN O 
member - NOUN O 
B - NOUN O 
( - PUNCT O 
RHOB PROPN - B-ORG 
) - PUNCT O 
genes - NOUN O 
and - CCONJ O 
preferentially - ADV O 
led - VERB O 
to - ADP O 
viability - NOUN O 
reduction - NOUN O 
of - ADP O 
Cisplatin PROPN - B-ORG 
- - PUNCT O 
resistant - ADJ O 
cells - NOUN O 
. - PUNCT O 

Influence - NOUN O 
of - ADP O 
Fatty - PROPN O 
Acid - PROPN O 
Modification - NOUN O 
on - ADP O 
Uptake - PROPN O 
of - ADP O 
Lovastatin PROPN - B-MEDICINE 
- - PUNCT O 
Loaded - ADJ O 
Reconstituted - PROPN O 
High - PROPN O 
Density - PROPN O 
Lipoprotein - PROPN O 
by - ADP O 
Foam PROPN - B-PERSON 
Cells PROPN - I-PERSON 
. - PUNCT O 

The - DET O 
response - NOUN O 
of - ADP O 
MdIPT PROPN - B-ORG 
, - PUNCT O 
MdCKX PROPN - B-ORG 
, - PUNCT O 
and - CCONJ O 
MdPIN1 PROPN - B-ORG 
genes - NOUN O 
to - ADP O 
various - ADJ O 
treatments - NOUN O 
( - PUNCT O 
6-BA - NUM O 
, - PUNCT O 
decapitation - NOUN O 
and - CCONJ O 
Lovastatin PROPN - B-MEDICINE 
, - PUNCT O 
an - DET O 
inhibitor - NOUN O 
of - ADP O 
CKs - NOUN O 
synthesis - NOUN O 
) - PUNCT O 
that - ADJ O 
impact - NOUN O 
branching - VERB O 
were - VERB O 
also - ADV O 
investigated - VERB O 
. - PUNCT O 

Results - NOUN O 
indicated - VERB O 
that - ADP O 
most - ADJ O 
of - ADP O 
the - DET O 
MdIPT PROPN - B-ORG 
and - CCONJ O 
MdCKX PROPN - B-ORG 
, - PUNCT O 
and - CCONJ O 
MdPIN1 PROPN - B-ORG 
genes - NOUN O 
were - VERB O 
upregulated - VERB O 
by - ADP O 
6-BA - NUM O 
and - CCONJ O 
decapitation - NOUN O 
treatment - NOUN O 
, - PUNCT O 
but - CCONJ O 
inhibited - VERB O 
by - ADP O 
Lovastatin PROPN - B-MEDICINE 
, - PUNCT O 
a - DET O 
compound - NOUN O 
that - ADJ O 
effectively - ADV O 
suppresses - VERB O 
axillary - ADJ O 
bud - NOUN O 
outgrowth - NOUN O 
induced - VERB O 
by - ADP O 
decapitation - NOUN O 
. - PUNCT O 

MdCKX8 - PROPN O 
and - CCONJ O 
MdCKX10 PROPN - B-GPE 
, - PUNCT O 
however - ADV O 
, - PUNCT O 
exhibited - VERB O 
little - ADJ O 
response - NOUN O 
to - ADP O 
decapitation - NOUN O 
, - PUNCT O 
but - CCONJ O 
were - VERB O 
significantly - ADV O 
up - ADV O 
- - PUNCT O 
regulated - VERB O 
by - ADP O 
6-BA NUM - B-PERSON 
and - CCONJ O 
Lovastatin PROPN - B-MEDICINE 
, - PUNCT O 
a - DET O 
finding - NOUN O 
that - ADJ O 
warrants - VERB O 
further - ADJ O 
investigation - NOUN O 
in - ADP O 
order - NOUN O 
to - PART O 
understand - VERB O 
their - ADJ O 
function - NOUN O 
in - ADP O 
bud - NOUN O 
- - PUNCT O 
outgrowth - NOUN O 
. - PUNCT O 

Protection - NOUN O 
against - ADP O 
the DET - B-ORG 
Neurotoxic PROPN - I-ORG 
Effects PROPN - I-ORG 
of ADP - I-ORG 
β PROPN - I-ORG 
- PUNCT - I-ORG 
Amyloid PROPN - I-ORG 
Peptide PROPN - I-ORG 
on ADP - I-ORG 
Cultured PROPN - I-ORG 
Neuronal PROPN - I-ORG 
Cells PROPN - I-ORG 
by - ADP O 
Lovastatin PROPN - B-MEDICINE 
Involves PROPN - I-ORG 
Elevated PROPN - I-ORG 
Expression NOUN - I-ORG 
of - ADP O 
α7 - ADJ O 
Nicotinic PROPN - B-ORG 
Acetylcholine PROPN - I-ORG 
Receptors PROPN - I-ORG 
and - CCONJ O 
Activating - PROPN O 
Phosphorylation - PROPN O 
of - ADP O 
Protein PROPN - B-GPE 
Kinases PROPN - I-GPE 
. - PUNCT O 

Lovastatin PROPN - B-MEDICINE 
promotes - VERB O 
myelin - ADJ O 
formation - NOUN O 
in - ADP O 
NPC1 PROPN - B-LOC 
mutant - ADJ O 
oligodendrocytes - NOUN O 
. - PUNCT O 

Lovastatin PROPN - B-MEDICINE 
inhibits - VERB O 
visceral - ADJ O 
allodynia - NOUN O 
and - CCONJ O 
increased - VERB O 
colonic - ADJ O 
permeability - NOUN O 
induced - VERB O 
by - ADP O 
lipopolysaccharide - NOUN O 
or - CCONJ O 
repeated - VERB O 
water - NOUN O 
avoidance - NOUN O 
stress - NOUN O 
in - ADP O 
rats - NOUN O 
. - PUNCT O 

Lovastatin PROPN - B-MEDICINE 
increases - VERB O 
IDE PROPN - B-ORG 
release - NOUN O 
from - ADP O 
BV-2 - PROPN O 
cells - NOUN O 
as - ADP O 
reported - VERB O 
, - PUNCT O 
but - CCONJ O 
this - DET O 
release - NOUN O 
is - VERB O 
mirrored - VERB O 
by - ADP O 
LDH PROPN - B-ORG 
release - NOUN O 
. - PUNCT O 

Lovastatin PROPN - B-MEDICINE 
suppresses - VERB O 
hyperexcitability - NOUN O 
and - CCONJ O 
seizure - NOUN O 
in - ADP O 
Angelman PROPN - B-PERSON 
syndrome - NOUN O 
model - NOUN O 
. - PUNCT O 

and - CCONJ O 
Diaporthe - PROPN O 
ampelina - ADV O 
( - PUNCT O 
Endophytic PROPN - B-ORG 
Fungus PROPN - I-ORG 
) - PUNCT O 
with - ADP O 
Reference PROPN - B-ORG 
to - ADP O 
Lovastatin PROPN - B-MEDICINE 
Production PROPN - I-ORG 
. - PUNCT O 

Here - ADV O 
, - PUNCT O 
we - PRON O 
report - VERB O 
that - ADP O 
the - DET O 
cholesterol - NOUN O 
, - PUNCT O 
fatty - ADJ O 
acid - NOUN O 
, - PUNCT O 
and - CCONJ O 
triglyceride - NOUN O 
synthesis - NOUN O 
pathways - NOUN O 
regulated - VERB O 
by - ADP O 
S1P PROPN - B-ORG 
is - VERB O 
involved - VERB O 
in - ADP O 
SFTSV - PROPN O 
replication - NOUN O 
, - PUNCT O 
using - VERB O 
CHO PROPN - B-ORG 
- - PUNCT O 
K1 - PROPN O 
cell - NOUN O 
line - NOUN O 
( - PUNCT O 
SRD-12B - PROPN O 
) - PUNCT O 
that - DET O 
is - VERB O 
deficient - ADJ O 
in - ADP O 
site - NOUN O 
1 NUM - B-CARDINAL 
protease - NOUN O 
( - PUNCT O 
S1P - PROPN O 
) - PUNCT O 
enzymatic - ADJ O 
activity - NOUN O 
, - PUNCT O 
PF-429242 PROPN - B-ORG 
, - PUNCT O 
a - DET O 
small - ADJ O 
compound - NOUN O 
targeting - VERB O 
S1P - NOUN O 
enzymatic - ADJ O 
activity - NOUN O 
, - PUNCT O 
and - CCONJ O 
Fenofibrate PROPN - B-ORG 
and - CCONJ O 
Lovastatin PROPN - B-MEDICINE 
, - PUNCT O 
which - ADJ O 
inhibit - VERB O 
triglyceride - NOUN O 
and - CCONJ O 
cholesterol - NOUN O 
synthesis - NOUN O 
, - PUNCT O 
respectively - ADV O 
. - PUNCT O 

Lovastatin PROPN - B-MEDICINE 
impaired - VERB O 
the - DET O 
binding - NOUN O 
of - ADP O 
the - DET O 
transcription - NOUN O 
factors - VERB O 
c X - B-PERSON 
- PUNCT - I-PERSON 
Jun NOUN - I-PERSON 
and - CCONJ O 
Sp1 - PROPN O 
to - ADP O 
the - DET O 
MACC1 PROPN - B-PRODUCT 
promoter - NOUN O 
, - PUNCT O 
thereby - ADV O 
inhibiting - VERB O 
MACC1 PROPN - B-PRODUCT 
transcription - NOUN O 
. - PUNCT O 

Lovastatin ADJ - B-MEDICINE 
- - PUNCT O 
specific - ADJ O 
production - NOUN O 
( - PUNCT O 
SP PROPN - B-ORG 
) - PUNCT O 
was - VERB O 
used - VERB O 
as - ADP O 
an - DET O 
indicator - NOUN O 
of - ADP O 
the - DET O 
physiological - ADJ O 
status - NOUN O 
, - PUNCT O 
and - CCONJ O 
different - ADJ O 
model - NOUN O 
culture - NOUN O 
systems - NOUN O 
were - VERB O 
used - VERB O 
to - PART O 
evaluate - VERB O 
the - DET O 
impact - NOUN O 
of - ADP O 
potential - ADJ O 
solid - ADJ O 
- - PUNCT O 
state - NOUN O 
fermentation - NOUN O 
( - PUNCT O 
SSF PROPN - B-ORG 
) - PUNCT O 
environmental - ADJ O 
stimuli - NOUN O 
. - PUNCT O 

The - DET O 
Effects - NOUN O 
of - ADP O 
Tocotrienol - PROPN O 
and - CCONJ O 
Lovastatin PROPN - B-MEDICINE 
Co PROPN - I-ORG 
- PUNCT - I-ORG 
Supplementation PROPN - I-ORG 
on ADP - I-ORG 
Bone PROPN - I-ORG 
Dynamic PROPN - I-ORG 
Histomorphometry PROPN - I-ORG 
and - CCONJ O 
Bone - PROPN O 
Morphogenetic - PROPN O 
Protein-2 - PROPN O 
Expression - PROPN O 
in - ADP O 
Rats - PROPN O 
with - ADP O 
Estrogen - PROPN O 
Deficiency - PROPN O 
. - PUNCT O 

Lovastatin PROPN - B-MEDICINE 
administration - NOUN O 
to - ADP O 
rats - NOUN O 
decreased - VERB O 
hepatic - ADJ O 
cholesterol - NOUN O 
content - NOUN O 
, - PUNCT O 
disrupted - VERB O 
lipid - NOUN O 
rafts - NOUN O 
and - CCONJ O 
decreased - VERB O 
insulin - NOUN O 
- - PUNCT O 
induced - VERB O 
Ca2 - NOUN O 
+ - SYM O 
signaling - VERB O 
in - ADP O 
hepatocytes - NOUN O 
, - PUNCT O 
and - CCONJ O 
delayed - VERB O 
liver - NOUN O 
regeneration - NOUN O 
after - ADP O 
PH - PROPN O 
. - PUNCT O 

Correction - NOUN O 
: - PUNCT O 
Combined - VERB O 
Treatment - PROPN O 
with - ADP O 
Troglitazone - PROPN O 
and - CCONJ O 
Lovastatin PROPN - B-MEDICINE 

Lovastatin PROPN - B-MEDICINE 
administration - NOUN O 
at - ADP O 
12 NUM - B-DATE 
weeks NOUN - I-DATE 
prevented - VERB O 
further - ADJ O 
RGC - PROPN O 
loss - NOUN O 
and - CCONJ O 
RNFL PROPN - B-ORG 
thinning - VERB O 
both - CCONJ O 
immediately - ADV O 
and - CCONJ O 
8 NUM - B-DATE 
weeks NOUN - I-DATE 
after - ADP O 
treatment - NOUN O 
completion - NOUN O 
. - PUNCT O 

Lovastatin PROPN - B-MEDICINE 
Reduces PROPN - I-ORG 
Stemness PROPN - I-ORG 
via - ADP O 
Epigenetic - PROPN O 
Reprograming - PROPN O 
of - ADP O 
BMP2 PROPN - B-GPE 
and - CCONJ O 
GATA2 PROPN - B-PERSON 
in - ADP O 
Human - PROPN O 
Endometrium - PROPN O 
and - CCONJ O 
Endometriosis - PROPN O 
. - PUNCT O 

Lovastatin PROPN - B-MEDICINE 
( - PUNCT O 
LOV PROPN - B-ORG 
) - PUNCT O 
, - PUNCT O 
an - DET O 
antihyperlipidimic - ADJ O 
agent - NOUN O 
, - PUNCT O 
is - VERB O 
characterized - VERB O 
by - ADP O 
low - ADJ O 
solubility - NOUN O 
/ - SYM O 
poor - ADJ O 
dissolution - NOUN O 
and - CCONJ O 
, - PUNCT O 
thus - ADV O 
, - PUNCT O 
low - ADJ O 
bioavailability - NOUN O 
( - PUNCT O 
< - X O 
5 NUM - B-PERCENT 
% NOUN - I-PERCENT 
) - PUNCT O 
. - PUNCT O 

Stabilization - NOUN O 
and - CCONJ O 
Amorphization - PROPN O 
of - ADP O 
Lovastatin PROPN - B-MEDICINE 
Using - VERB O 
Different - ADJ O 
Types - PROPN O 
of - ADP O 
Silica - PROPN O 
. - PUNCT O 

Lovastatin PROPN - B-MEDICINE 
is - VERB O 
a - DET O 
prodrug - NOUN O 
that - ADJ O 
is - VERB O 
hydrolysed - VERB O 
in - ADP O 
vivo - NOUN O 
to - ADP O 
β - DET O 
- - PUNCT O 
hydroxy - NOUN O 
acid - NOUN O 
lovastatin NOUN - B-MEDICINE 
, - PUNCT O 
which - ADJ O 
inhibits - VERB O 
3-hydroxy-3-methylglutaryl NUM - B-QUANTITY 
- PUNCT - I-QUANTITY 
coenzyme NOUN - I-QUANTITY 
A - NOUN O 
( - PUNCT O 
HMG PROPN - B-ORG 
- PUNCT - I-ORG 
Co NOUN - I-ORG 
- PUNCT - I-ORG 
A NOUN - I-ORG 
) - PUNCT O 
reductase - NOUN O 
( - PUNCT O 
HMGR - PROPN O 
) - PUNCT O 
, - PUNCT O 
thereby - ADV O 
lowering - VERB O 
cholesterol - NOUN O 
in - ADP O 
humans - NOUN O 
. - PUNCT O 

Lovastatin PROPN - B-MEDICINE 
is - VERB O 
the - DET O 
first ADJ - B-ORDINAL 
licensed - ADJ O 
drug - NOUN O 
to - PART O 
exclusively - ADV O 
affect - VERB O 
the - DET O 
growth - NOUN O 
of - ADP O 
methanogens - NOUN O 
whilst - ADP O 
protecting - VERB O 
the - DET O 
bacterial - ADJ O 
microbiota - NOUN O 
. - PUNCT O 

Lovastatin PROPN - B-MEDICINE 
as - ADP O 
a - DET O 
member - NOUN O 
of - ADP O 
3-hydroxy-3-methylglutaryl NUM - B-QUANTITY 
- PUNCT - I-QUANTITY 
coenzyme NOUN - I-QUANTITY 
A - NOUN O 
( - PUNCT O 
HMG PROPN - B-ORG 
- PUNCT - I-ORG 
CoA PROPN - I-ORG 
) - PUNCT O 

Lovastatin PROPN - B-MEDICINE 
Inhibits VERB - I-ORG 
Cancer - PROPN O 
Stem - PROPN O 
Cells - PROPN O 
and - CCONJ O 
Sensitizes VERB - B-PERSON 
to - ADP O 
Chemo- - PROPN O 
and - CCONJ O 
Photodynamic PROPN - B-ORG 
Therapy PROPN - I-ORG 
in - ADP O 
Nasopharyngeal PROPN - B-LOC 
Carcinoma PROPN - I-LOC 
. - PUNCT O 

LC - PROPN O 
- - PUNCT O 
MS - NOUN O 
Method - PROPN O 
for - ADP O 
Studying - VERB O 
the - DET O 
Pharmacokinetics - PROPN O 
and - CCONJ O 
Bioequivalence - PROPN O 
of - ADP O 
Clonidine PROPN - B-MEDICINE 
Hydrochloride PROPN - I-MEDICINE 
in - ADP O 
Healthy PROPN - B-ORG 
Male PROPN - I-ORG 
Volunteers PROPN - I-ORG 
. - PUNCT O 

Clonidine PROPN - B-ORG 
Hydrochloride PROPN - I-ORG 
Injection PROPN - I-ORG 
( - PUNCT O 
Duraclon PROPN - B-ORG 
) - PUNCT O 
is - VERB O 
a - DET O 
clear - ADJ O 
, - PUNCT O 
colorless - ADJ O 
, - PUNCT O 
preservative - NOUN O 
- - PUNCT O 
free - ADJ O 
, - PUNCT O 
pyrogen - NOUN O 
free - ADJ O 
, - PUNCT O 
aqueous - ADJ O 
solution - NOUN O 
of - ADP O 
clonidine ADJ - B-MEDICINE 
hydrochloride NOUN - I-MEDICINE 
. - PUNCT O 

Clonidine PROPN - B-ORG 
Hydrochloride PROPN - I-ORG 
Injection PROPN - I-ORG 
, - PUNCT O 
as - ADP O 
formulated - VERB O 
, - PUNCT O 
does - VERB O 
not - ADV O 
require - VERB O 
protection - NOUN O 
from - ADP O 
light - NOUN O 
, - PUNCT O 
oxygen - NOUN O 
, - PUNCT O 
or - CCONJ O 
freezing - VERB O 
. - PUNCT O 

Glipizide PROPN - B-MEDICINE 
is - VERB O 
a - DET O 
second ADJ - B-ORDINAL 
- - PUNCT O 
generation - NOUN O 
oral - ADJ O 
hypoglycemic - ADJ O 
medicine - NOUN O 
for - ADP O 
the - DET O 
cure - NOUN O 
of - ADP O 
type - NOUN O 
II NUM - B-ORG 
diabetes - NOUN O 
because - ADP O 
of - ADP O 
its - ADJ O 
capability - NOUN O 
to - PART O 
selectively - ADV O 
stimulate - VERB O 
insulin - NOUN O 
secretion - NOUN O 
from - ADP O 
β - NOUN O 
- - PUNCT O 
cells - NOUN O 
. - PUNCT O 

Glipizide PROPN - B-MEDICINE 
sensitizes - VERB O 
lung - NOUN O 
cancer - NOUN O 
cells - NOUN O 
to - ADP O 
TRAIL - PROPN O 
- - PUNCT O 
induced - VERB O 
apoptosis - NOUN O 
via - ADP O 
Akt PROPN - B-ORG 
/ SYM - I-ORG 
mTOR PROPN - I-ORG 
/ SYM - I-ORG 
autophagy NOUN - I-ORG 
pathways - NOUN O 
. - PUNCT O 

Glipizide PROPN - B-MEDICINE 
served - VERB O 
as - ADP O 
the - DET O 
reference - NOUN O 
exposure - NOUN O 
, - PUNCT O 
as - ADP O 
its - ADJ O 
effects - NOUN O 
are - VERB O 
believed - VERB O 
to - PART O 
be - VERB O 
highly - ADV O 
pancreas - NOUN O 
specific - ADJ O 
. - PUNCT O 

Glipizide PROPN - B-MEDICINE 
( - PUNCT O 
GPZ - PROPN O 
) - PUNCT O 
, - PUNCT O 
a - DET O 
Biopharmaceutical PROPN - B-ORG 
Classification PROPN - I-ORG 
System PROPN - I-ORG 
class - NOUN O 
II PROPN - B-ORG 
model - NOUN O 
drug - NOUN O 
, - PUNCT O 
was - VERB O 
selected - VERB O 
for - ADP O 
solubility - NOUN O 
and - CCONJ O 
dissolution - NOUN O 
rate - NOUN O 
study - NOUN O 
. - PUNCT O 

Sentinel - PROPN O 
Modular - PROPN O 
Program - PROPN O 
for - ADP O 
Propensity PROPN - B-ORG 
Score PROPN - I-ORG 
- PUNCT - I-ORG 
Matched PROPN - I-ORG 
Cohort - PROPN O 
Analyses - PROPN O 
: - PUNCT O 
Application - NOUN O 
to - ADP O 
Glyburide - PROPN O 
, - PUNCT O 
Glipizide PROPN - B-MEDICINE 
, - PUNCT O 
and - CCONJ O 
Serious PROPN - B-PERSON 
Hypoglycemia PROPN - I-PERSON 
. - PUNCT O 

Pharmacokinetic - ADJ O 
parameters - NOUN O 
were - VERB O 
analyzed - VERB O 
based - VERB O 
on - ADP O 
plasma - NOUN O 
concentrations - NOUN O 
of - ADP O 
Glibenclamide PROPN - B-GPE 
from - ADP O 
all - ADJ O 
the - DET O 
groups - NOUN O 
by - ADP O 
LC PROPN - B-NORP 
- PUNCT - I-NORP 
HRMS PROPN - I-NORP 
methods - NOUN O 
using - VERB O 
Glipizide PROPN - B-MEDICINE 
as - ADP O 
an - DET O 
internal - ADJ O 
standard - NOUN O 
. - PUNCT O 

Here - ADV O 
we - PRON O 
show - VERB O 
that - ADP O 
treatment - NOUN O 
with - ADP O 
Acarbose PROPN - B-PERSON 
, - PUNCT O 
but - CCONJ O 
not - ADV O 
Glipizide PROPN - B-MEDICINE 
, - PUNCT O 
increases - VERB O 
the - DET O 
ratio - NOUN O 
between - ADP O 
primary - ADJ O 
BAs - NOUN O 
and - CCONJ O 
secondary - ADJ O 
BAs - NOUN O 
and - CCONJ O 
plasma - NOUN O 
levels - NOUN O 
of - ADP O 
unconjugated - ADJ O 
BAs - NOUN O 
in - ADP O 
treatment - NOUN O 
- - PUNCT O 
naive - ADJ O 
type - NOUN O 
2 NUM - B-CARDINAL 
diabetes - NOUN O 
( - PUNCT O 
T2D - PROPN O 
) - PUNCT O 
patients - NOUN O 
, - PUNCT O 
which - ADJ O 
may - VERB O 
beneficially - ADV O 
affect - VERB O 
metabolism - NOUN O 
. - PUNCT O 

Influence - NOUN O 
of - ADP O 
Single - PROPN O 
and - CCONJ O 
Multi - PROPN O 
Dose - PROPN O 
Treatment - PROPN O 
of - ADP O 
Glipizide PROPN - B-MEDICINE 
on - ADP O 
Pharmacokinetics - PROPN O 
and - CCONJ O 
Pharmacodynamics - PROPN O 
of - ADP O 
Irbesartan - PROPN O 
in - ADP O 
Normal PROPN - B-GPE 
and - CCONJ O 
Hypertensive - PROPN O 
Rats - PROPN O 
. - PUNCT O 

Glipizide PROPN - B-MEDICINE 
used - VERB O 
in - ADP O 
the - DET O 
treatment - NOUN O 
of - ADP O 
diabetes - NOUN O 
was - VERB O 
selected - VERB O 
as - ADP O 
model - NOUN O 
drug - NOUN O 
, - PUNCT O 
and - CCONJ O 
was - VERB O 
successfully - ADV O 
loaded - VERB O 
into - ADP O 
commercial - ADJ O 
polyvinyl - NOUN O 
alcohol - NOUN O 
( - PUNCT O 
PVA PROPN - B-ORG 
) - PUNCT O 
filaments - NOUN O 
by - ADP O 
HME PROPN - B-ORG 
method - NOUN O 
. - PUNCT O 

Glipizide PROPN - B-MEDICINE 
blocks - VERB O 
renal - ADJ O 
interstitial - ADJ O 
fibrosis - NOUN O 
by - ADP O 
inhibiting - VERB O 
AKT PROPN - B-ORG 
signaling - VERB O 
pathway - NOUN O 
. - PUNCT O 

Glipizide PROPN - B-MEDICINE 
( - PUNCT O 
0.6 NUM - B-CARDINAL 
or - CCONJ O 
2 NUM - B-CARDINAL 
  - SPACE O 
mg - NOUN O 
/ - SYM O 
kg - NOUN O 
) - PUNCT O 
was - VERB O 
not - ADV O 
able - ADJ O 
to - PART O 
reduce - VERB O 
the - DET O 
glucose - NOUN O 
level - NOUN O 
in - ADP O 
wolframin - NOUN O 
- - PUNCT O 
deficient - ADJ O 
animals - NOUN O 
. - PUNCT O 

Study - NOUN O 
of - ADP O 
the DET - B-ORG 
Mucoadhesive PROPN - I-ORG 
Potential PROPN - I-ORG 
of ADP - I-ORG 
Carbopol PROPN - I-ORG 
Polymer PROPN - I-ORG 
in - ADP O 
the DET - B-ORG 
Preparation PROPN - I-ORG 
of ADP - I-ORG 
Microbeads PROPN - I-ORG 
Containing VERB - I-ORG 
the DET - I-ORG 
Antidiabetic PROPN - I-ORG 
Drug PROPN - I-ORG 
Glipizide PROPN - I-MEDICINE 
. - PUNCT O 

Glipizide PROPN - B-MEDICINE 
was - VERB O 
found - VERB O 
to - PART O 
be - VERB O 
a - DET O 
low - ADJ O 
- - PUNCT O 
solubility - NOUN O 
compound - NOUN O 
. - PUNCT O 

Glipizide PROPN - B-MEDICINE 
, - PUNCT O 
a - DET O 
second ADJ - B-ORDINAL 
- - PUNCT O 
generation - NOUN O 
sulfonylurea - NOUN O 
, - PUNCT O 
has - VERB O 
been - VERB O 
widely - ADV O 
used - VERB O 
for - ADP O 
the - DET O 
treatment - NOUN O 
of - ADP O 
type - NOUN O 
2 NUM - B-CARDINAL 
diabetes - NOUN O 
. - PUNCT O 

We - PRON O 
found - VERB O 
that - ADP O 
Glipizide PROPN - B-MEDICINE 
suppressed - VERB O 
both - DET O 
angiogenesis - NOUN O 
in - ADP O 
yolk - NOUN O 
- - PUNCT O 
sac - NOUN O 
membrane - NOUN O 
( - PUNCT O 
YSM - PROPN O 
) - PUNCT O 
and - CCONJ O 
blood - NOUN O 
island - NOUN O 
formation - NOUN O 
during - ADP O 
developmental - ADJ O 
vasculogenesis - NOUN O 
. - PUNCT O 

Glipizide PROPN - B-MEDICINE 
did - VERB O 
not - ADV O 
affect - VERB O 
either - CCONJ O 
the - DET O 
process - NOUN O 
of - ADP O 
epithelial - ADJ O 
to - ADP O 
mesenchymal - ADJ O 
transition - NOUN O 
( - PUNCT O 
EMT PROPN - B-ORG 
) - PUNCT O 
or - CCONJ O 
mesoderm - NOUN O 
cell - NOUN O 
migration - NOUN O 
. - PUNCT O 

Cost - NOUN O 
of - ADP O 
Achieving - VERB O 
Combined - PROPN O 
Improvements - PROPN O 
in - ADP O 
HbA1c - PROPN O 
and - CCONJ O 
Weight PROPN - B-ORG 
without - ADP O 
Hypoglycaemia PROPN - B-ORG 
over - ADP O 
4 - NUM O 
Years - NOUN O 
in - ADP O 
a - DET O 
Post - PROPN O 
- - PROPN O 
Hoc - PROPN O 
Analysis - PROPN O 
of - ADP O 
Dapagliflozin - PROPN O 
+ - CCONJ O 
MET - PROPN O 
Vs - PROPN O 
Glipizide PROPN - B-MEDICINE 
+ - CCONJ O 
MET PROPN - B-ORG 
. - PUNCT O 

The - DET O 
Study - PROPN O 
to - PART O 
Understand - VERB O 
the - DET O 
Genetics - PROPN O 
of - ADP O 
the - DET O 
Acute - PROPN O 
Response - PROPN O 
to - ADP O 
Metformin - PROPN O 
and - CCONJ O 
Glipizide PROPN - B-MEDICINE 
in - ADP O 
Humans PROPN - B-GPE 
( - PUNCT O 
SUGAR - PROPN O 
- - PUNCT O 
MGH - PROPN O 
, - PUNCT O 
NCT01762046 PROPN - B-DATE 
) - PUNCT O 
is - VERB O 
a - DET O 
novel - ADJ O 
resource - NOUN O 
of - ADP O 
genetic - ADJ O 
and - CCONJ O 
biochemical - ADJ O 
data - NOUN O 
following - VERB O 
glipizide NOUN - B-MEDICINE 
and - CCONJ O 
metformin - NOUN O 
administration - NOUN O 
. - PUNCT O 

Glipizide PROPN - B-MEDICINE 
dissolution - NOUN O 
improved - VERB O 
significantly - ADV O 
( - PUNCT O 
p - VERB O 
  - SPACE O 
< - X O 
  - SPACE O 
0.001 - NUM O 
) - PUNCT O 
from - ADP O 
the - DET O 
solid - ADJ O 
SNEDDS - NOUN O 
( - PUNCT O 
∼100 NOUN - B-PERCENT 
% NOUN - I-PERCENT 
in - ADP O 
15 NUM - B-CARDINAL 
  - SPACE O 
min - NOUN O 
) - PUNCT O 
as - ADP O 
compared - VERB O 
to - ADP O 
the - DET O 
pure - ADJ O 
drug - NOUN O 
( - PUNCT O 
18.37 NUM - B-PERCENT 
% NOUN - I-PERCENT 
) - PUNCT O 
and - CCONJ O 
commercial - ADJ O 
product - NOUN O 
( - PUNCT O 
65.82 NUM - B-CARDINAL 
) - PUNCT O 
respectively - ADV O 
. - PUNCT O 

Glipizide PROPN - B-MEDICINE 
, - PUNCT O 
an - DET O 
antidiabetic - ADJ O 
drug - NOUN O 
, - PUNCT O 
suppresses - VERB O 
tumor - NOUN O 
growth - NOUN O 
and - CCONJ O 
metastasis - NOUN O 
by - ADP O 
inhibiting - VERB O 
angiogenesis - NOUN O 
. - PUNCT O 

Glipizide PROPN - B-MEDICINE 
, - PUNCT O 
but - CCONJ O 
not - ADV O 
tolbutamide - NOUN O 
or - CCONJ O 
glyburide - ADV O 
, - PUNCT O 
pretreated - VERB O 

PHARMACEUTICAL - NOUN O 
COMPOSITIONS - NOUN O 
OF - ADP O 
URSODIOL NOUN - B-MEDICINE 

Histopathological - ADJ O 
examination - NOUN O 
showed - VERB O 
numerous - ADJ O 
branched - ADJ O 
hyphae - NOUN O 
, - PUNCT O 
and - CCONJ O 
tissue - NOUN O 
culture - NOUN O 
yielded - VERB O 
a - DET O 
Rhizopus PROPN - B-MEDICINE 
microsporus - NOUN O 
- - PUNCT O 
related - VERB O 
fungus - NOUN O 
. - PUNCT O 

Multiple ADJ - B-PERSON 
Skin NOUN - I-PERSON 
Abscesses NOUN - I-PERSON 
Caused VERB - I-PERSON 
by - ADP O 
Rhizopus PROPN - B-MEDICINE 
sp - PART O 
. - PUNCT O 

Rhizopus NOUN - B-MEDICINE 
stolonifer - NOUN O 
is - VERB O 
an - DET O 
opportunistic - ADJ O 
fungus - NOUN O 
that - ADJ O 
causes - VERB O 
respiratory - ADJ O 
infections - NOUN O 
, - PUNCT O 
sinusitis - NOUN O 
, - PUNCT O 
and - CCONJ O 
otomycosis - NOUN O 
. - PUNCT O 

We - PRON O 
evaluated - VERB O 
the - DET O 
effect - NOUN O 
of - ADP O 
aPDT - PROPN O 
by - ADP O 
using - VERB O 
methylene - ADJ O 
blue - ADJ O 
( - PUNCT O 
MB - NOUN O 
) - PUNCT O 
combined - VERB O 
with - ADP O 
a - DET O 
light - ADJ O 
emitting - VERB O 
diode - NOUN O 
( - PUNCT O 
LED - PROPN O 
) - PUNCT O 
on - ADP O 
the - DET O 
viability - NOUN O 
of - ADP O 
Rhizopus PROPN - B-MEDICINE 
oryzae - NOUN O 
, - PUNCT O 
as - ADV O 
well - ADV O 
as - ADP O 
the - DET O 
antifungal - ADJ O 
susceptibility - NOUN O 
after - ADP O 
aPDT - NOUN O 
treatment - NOUN O 
in - ADP O 
vitro - NOUN O 
. - PUNCT O 

This - DET O 
study - NOUN O 
investigated - VERB O 
effects - NOUN O 
of - ADP O 
the - DET O 
simultaneous - ADJ O 
application - NOUN O 
of - ADP O 
thymol - NOUN O 
and - CCONJ O 
salicylic - ADJ O 
acid - NOUN O 
( - PUNCT O 
SIMTSA - PROPN O 
) - PUNCT O 
on - ADP O 
the - DET O 
target - NOUN O 
sites - NOUN O 
of - ADP O 
Rhizopus PROPN - B-MEDICINE 
stolonifer - NOUN O 
, - PUNCT O 
as - ADV O 
well - ADV O 
as - ADP O 
the - DET O 
defenceenzymes - NOUN O 
of - ADP O 
postharvest - NOUN O 
tomato - NOUN O 
, - PUNCT O 
when - ADV O 
applied - VERB O 
as - ADP O 
edible - ADJ O 
coating - NOUN O 
. - PUNCT O 

Protection - NOUN O 
effect - NOUN O 
of - ADP O 
polyols - NOUN O 
on - ADP O 
Rhizopus NOUN - B-MEDICINE 
chinensis - NOUN O 
lipase - NOUN O 
counteracting - VERB O 
the - DET O 
deactivation - NOUN O 
from - ADP O 
high - ADJ O 
pressure - NOUN O 
and - CCONJ O 
high - ADJ O 
temperature - NOUN O 
treatment - NOUN O 
. - PUNCT O 

With - ADP O 
the - DET O 
help - NOUN O 
of - ADP O 
" - PUNCT O 
interface - ADJ O 
activation - NOUN O 
" - PUNCT O 
by - ADP O 
adding - VERB O 
sucrose - ADJ O 
esters-11 - NOUN O 
as - ADP O 
surfactant - ADJ O 
, - PUNCT O 
lipase - NOUN O 
from - ADP O 
Rhizopus PROPN - B-MEDICINE 
oryzae - NOUN O 
was - VERB O 
successfully - ADV O 
immobilized - VERB O 
onto - ADP O 
the - DET O 
carrier - NOUN O 
with - ADP O 
great - ADJ O 
enhancement - NOUN O 
of - ADP O 
activity - NOUN O 
. - PUNCT O 

An - DET O 
extracellular - ADJ O 
polysaccharide - NOUN O 
( - PUNCT O 
EPS1 - PROPN O 
- - PUNCT O 
1 - NUM O 
) - PUNCT O 
of - ADP O 
Rhizopus PROPN - B-MEDICINE 
nigricans - NOUN O 
was - VERB O 
found - VERB O 
to - PART O 
enhance - VERB O 
immunity - NOUN O 
and - CCONJ O 
reduce - VERB O 
colon - NOUN O 
cancer - NOUN O 
cell - NOUN O 
proliferation - NOUN O 
. - PUNCT O 

The - DET O 
inhibitory - ADJ O 
effect - NOUN O 
of - ADP O 
polysaccharide - NOUN O 
from - ADP O 
Rhizopus PROPN - B-MEDICINE 
nigricans - NOUN O 
on - ADP O 
colitis - NOUN O 
- - PUNCT O 
associated - VERB O 
colorectal - ADJ O 
cancer - NOUN O 
. - PUNCT O 

Application - PROPN O 
and - CCONJ O 
Analysis - PROPN O 
of - ADP O 
Rhizopus PROPN - B-MEDICINE 
oryzae - VERB O 
Mycelia PROPN - B-PERSON 
Extending PROPN - I-PERSON 
Characteristic PROPN - I-PERSON 
in - ADP O 
Solid PROPN - B-GPE 
- - PUNCT O 
state - NOUN O 
Fermentation NOUN - B-ORG 
for ADP - I-ORG 
Producing VERB - I-ORG 
Glucoamylase PROPN - I-ORG 
. - PUNCT O 

Evaluation - NOUN O 
of - ADP O 
the - DET O 
antifungal - ADJ O 
activity - NOUN O 
of - ADP O 
individual - ADJ O 
and - CCONJ O 
combined - VERB O 
monoterpenes - NOUN O 
against - ADP O 
Rhizopus PROPN - B-MEDICINE 
stolonifer - NOUN O 
and - CCONJ O 
Absidia PROPN - B-ORG 
coerulea - NOUN O 
. - PUNCT O 

Rhizopus NOUN - B-MEDICINE 
delemar - NOUN O 
causes - VERB O 
devastating - VERB O 
mucormycosis - NOUN O 
in - ADP O 
immunodeficient - ADJ O 
individuals - NOUN O 
. - PUNCT O 

CRISPR - PROPN O 
- - PUNCT O 
Cas9 - PROPN O 
induces - VERB O 
point - NOUN O 
mutation - NOUN O 
in - ADP O 
the - DET O 
mucormycosis - NOUN O 
fungus - NOUN O 
Rhizopus PROPN - B-MEDICINE 
delemar - NOUN O 
. - PUNCT O 

We - PRON O 
present - VERB O 
a - DET O 
case - NOUN O 
of - ADP O 
a - DET O 
68-year NUM - B-MONEY 
- PUNCT - I-MONEY 
old ADJ - I-MONEY 
patient - NOUN O 
with - ADP O 
cutaneous - ADJ O 
mucormycosis - NOUN O 
due - ADJ O 
to - ADP O 
Rhizopus PROPN - B-MEDICINE 
pusillus - NOUN O 
. - PUNCT O 

Mycologically - ADV O 
proven - VERB O 
invasive - ADJ O 
fungal - ADJ O 
infections - NOUN O 
were - VERB O 
defined - VERB O 
as - ADP O 
there - ADV O 
were - VERB O 
the - DET O 
histologic - ADJ O 
evidence - NOUN O 
of - ADP O 
tissue - NOUN O 
invasion - NOUN O 
of - ADP O 
hyphae - NOUN O 
and - CCONJ O 
the - DET O 
recovery - NOUN O 
of - ADP O 
Aspergillus PROPN - B-ORG 
species - NOUN O 
or - CCONJ O 
agents - NOUN O 
of - ADP O 
mucormycosis - NOUN O 
( - PUNCT O 
Rhizopus PROPN - B-MEDICINE 
spp - NOUN O 
. - PUNCT O 

Anti ADJ - B-PERSON 
- ADJ - I-PERSON 
Aspergillus ADJ - I-PERSON 
mouse - NOUN O 
monoclonal - ADJ O 
antibody - NOUN O 
( - PUNCT O 
1:50 NUM - B-TIME 
; - PUNCT O 
clone - ADJ O 
WF - PROPN O 
- - PUNCT O 
AF-1 - PROPN O 
; - PUNCT O 
LSBio PROPN - B-ORG 
, - PUNCT O 
WA PROPN - B-ORG 
, - PUNCT O 
USA PROPN - B-GPE 
) - PUNCT O 
and - CCONJ O 
anti - ADJ O 
- - ADJ O 
Rhizopus ADJ - B-MEDICINE 
arrhizus - ADJ O 
mouse - NOUN O 
monoclonal - ADJ O 
antibody - NOUN O 
( - PUNCT O 
1:100 NUM - B-CARDINAL 
; - PUNCT O 
clone - ADJ O 
WSSA PROPN - B-ORG 
- - PUNCT O 
RA-1 - PROPN O 
; - PUNCT O 

Iron - NOUN O 
restriction - NOUN O 
inside - ADP O 
macrophages - NOUN O 
regulates - VERB O 
pulmonary - ADJ O 
host - NOUN O 
defense - NOUN O 
against - ADP O 
Rhizopus PROPN - B-MEDICINE 
species - NOUN O 
. - PUNCT O 

We - PRON O 
report - VERB O 
a - DET O 
case - NOUN O 
of - ADP O 
eczema - NOUN O 
- - PUNCT O 
like - ADJ O 
cutaneous - ADJ O 
mucormycosis - NOUN O 
caused - VERB O 
by - ADP O 
Rhizopus PROPN - B-MEDICINE 
arrhizus - PROPN O 
. - PUNCT O 

Among - ADP O 
them - PRON O 
, - PUNCT O 
Lactobacillus PROPN - B-ORG 
, PUNCT - I-ORG 
Aspergillus PROPN - I-ORG 
, PUNCT - I-ORG 
Pichia PROPN - I-ORG 
, PUNCT - I-ORG 
Saccharomyces - PROPN O 
, - PUNCT O 
Rhizopus PROPN - B-MEDICINE 
were - VERB O 
the - DET O 
main - ADJ O 
contributors - NOUN O 
of - ADP O 
proteins - NOUN O 
by - ADP O 
metaproteomics - NOUN O 
analysis - NOUN O 
. - PUNCT O 

Whereas - ADV O 
, - PUNCT O 
only - ADV O 
Lactobacillus PROPN - B-ORG 
, - PUNCT O 
Pichia PROPN - B-PERSON 
, - PUNCT O 
Rhizopus PROPN - B-MEDICINE 
appeared - VERB O 
as - ADP O 
key - ADJ O 
actors - NOUN O 
for - ADP O 
saccharification - NOUN O 
by - ADP O 
secreting - VERB O 
three NUM - B-CARDINAL 
glycosidases - NOUN O 
and - CCONJ O 
two NUM - B-CARDINAL 
glycosyltransferases - NOUN O 
, - PUNCT O 
and - CCONJ O 
it - PRON O 
indicated - VERB O 
they - PRON O 
were - VERB O 
the - DET O 
key - ADJ O 
saccharifying - NOUN O 
microbiota - NOUN O 
in - ADP O 
Jiuqu PROPN - B-GPE 
. - PUNCT O 

Especially - ADV O 
, - PUNCT O 
Rhizopus PROPN - B-MEDICINE 
secreted - VERB O 
the - DET O 
most - ADV O 
abundant - ADJ O 
glucoamylase - NOUN O 
. - PUNCT O 

Rhizopus NOUN - B-MEDICINE 
microsporus - NOUN O 
, - PUNCT O 
the - DET O 
main - ADJ O 
producer - NOUN O 
of - ADP O 
glucoamylase - NOUN O 
, - PUNCT O 
was - VERB O 
positively - ADV O 
correlated - VERB O 
with - ADP O 
volumetric - ADJ O 
weight - NOUN O 
of - ADP O 
Jiuqu PROPN - B-GPE 
. - PUNCT O 

We - PRON O 
describe - VERB O 
the - DET O 
first ADJ - B-ORDINAL 
case - NOUN O 
of - ADP O 
a - DET O 
patient - NOUN O 
with - ADP O 
occupational - ADJ O 
exposure - NOUN O 
to - ADP O 
Rhizopus PROPN - B-MEDICINE 
that - ADJ O 
received - VERB O 
post - ADJ O 
- - ADJ O 
exposure - ADJ O 
prophylaxis - NOUN O 
with - ADP O 
oral - ADJ O 
isavuconazole - NOUN O 
. - PUNCT O 

Post - ADJ O 
- - ADJ O 
exposure - ADJ O 
prophylaxis - NOUN O 
with - ADP O 
isavuconazole - NOUN O 
after - ADP O 
occupational - ADJ O 
exposure - NOUN O 
to - ADP O 
Rhizopus PROPN - B-MEDICINE 
. - PUNCT O 

PCR - NOUN O 
analysis - NOUN O 
from - ADP O 
these - DET O 
inflammatory - ADJ O 
foci - NOUN O 
yielded - VERB O 
Rhizopus PROPN - B-MEDICINE 
arrhizus - PROPN O 
( - PUNCT O 
syn - NOUN O 
. - PUNCT O 

Mucormycosis NOUN - B-ORG 
outbreak - NOUN O 
due - ADP O 
to - ADP O 
Rhizopus PROPN - B-MEDICINE 
microsporus - NOUN O 
after - ADP O 
arthroscopic - ADJ O 
anterior - ADJ O 
cruciate - NOUN O 
ligament - NOUN O 
reconstruction - NOUN O 
surgery - NOUN O 
evaluated - VERB O 
by - ADP O 
RAPD PROPN - B-ORG 
and - CCONJ O 
MALDI PROPN - B-ORG 
- PUNCT - I-ORG 
TOF PROPN - I-ORG 
Mass PROPN - I-ORG 
spectrometry - NOUN O 
. - PUNCT O 

Rhizopus NOUN - B-MEDICINE 
spp - NOUN O 
are - VERB O 
the - DET O 
most - ADV O 
common - ADJ O 
etiological - ADJ O 
agents - NOUN O 
of - ADP O 
mucormycosis - NOUN O 
, - PUNCT O 
causing - VERB O 
over - ADP O 
90 NUM - B-PERCENT 
% NOUN - I-PERCENT 
mortality - NOUN O 
in - ADP O 
disseminated - VERB O 
infection - NOUN O 
. - PUNCT O 

Rhizopus PROPN - B-MEDICINE 
spp - NOUN O 
has - VERB O 
not - ADV O 
been - VERB O 
extensively - ADV O 
explored - VERB O 
. - PUNCT O 

Here - ADV O 
we - PRON O 
show - VERB O 
that - ADP O 
co - NOUN O 
- - ADJ O 
culturing - ADJ O 
  - SPACE O 
Rhizopus PROPN - B-MEDICINE 
microsporus - NOUN O 
and - CCONJ O 
  - SPACE O 
Pseudomonas PROPN - B-GPE 
aeruginosa - NOUN O 
results - VERB O 
in - ADP O 
the - DET O 
inhibition - NOUN O 
of - ADP O 
spore - ADJ O 
germination - NOUN O 
. - PUNCT O 

Rhizopus PROPN - B-MEDICINE 
microsporus - NOUN O 
  - SPACE O 
germination - NOUN O 
through - ADP O 
sequestration - NOUN O 
of - ADP O 
free - ADJ O 
environmental - ADJ O 
iron - NOUN O 

The - DET O 
review - NOUN O 
highlights - VERB O 
the - DET O 
current - ADJ O 
achievements - NOUN O 
in - ADP O 
( - PUNCT O 
i - NOUN O 
) - PUNCT O 
diagnostics - NOUN O 
and - CCONJ O 
management - NOUN O 
of - ADP O 
mucormycosis - NOUN O 
, - PUNCT O 
( - PUNCT O 
ii - PUNCT O 
) - PUNCT O 
the - DET O 
study - NOUN O 
of - ADP O 
the - DET O 
interaction - NOUN O 
of - ADP O 
Mucorales PROPN - B-GPE 
with - ADP O 
cells - NOUN O 
of - ADP O 
the - DET O 
innate - ADJ O 
immune - ADJ O 
system - NOUN O 
, - PUNCT O 
( - PUNCT O 
iii - PUNCT O 
) - PUNCT O 
the - DET O 
assessment - NOUN O 
of - ADP O 
the - DET O 
virulence - NOUN O 
of - ADP O 
Mucorales PROPN - B-PERSON 
in - ADP O 
vertebrate - NOUN O 
and - CCONJ O 
invertebrate - ADJ O 
infection - NOUN O 
models - NOUN O 
, - PUNCT O 
and - CCONJ O 
( - PUNCT O 
iv - X O 
) - PUNCT O 
the - DET O 
determination - NOUN O 
of - ADP O 
virulence - NOUN O 
factors - NOUN O 
that - ADJ O 
are - VERB O 
key - ADJ O 
players - NOUN O 
in - ADP O 
the - DET O 
infection - NOUN O 
process - NOUN O 
, - PUNCT O 
for - ADP O 
example - NOUN O 
, - PUNCT O 
high - ADJ O 
- - PUNCT O 
affinity - NOUN O 
iron - NOUN O 
permease - NOUN O 
( - PUNCT O 
FTR1 PROPN - B-ORG 
) - PUNCT O 
, - PUNCT O 
spore - ADJ O 
coat - NOUN O 
protein - NOUN O 
( - PUNCT O 
CotH - PROPN O 
) - PUNCT O 
, - PUNCT O 
alkaline - NOUN O 
Rhizopus PROPN - B-MEDICINE 
protease - NOUN O 
enzyme - ADJ O 
( - PUNCT O 
ARP - PROPN O 
) - PUNCT O 
, - PUNCT O 
ADP - PROPN O 
- - PUNCT O 
ribosylation - NOUN O 
factor - NOUN O 
( - PUNCT O 
ARF PROPN - B-ORG 
) - PUNCT O 
, - PUNCT O 
dihydrolipoyl - NOUN O 
dehydrogenase - NOUN O 
, - PUNCT O 
calcineurin - PROPN O 
( - PUNCT O 
CaN - VERB O 
) - PUNCT O 
, - PUNCT O 
serine - NOUN O 
and - CCONJ O 
aspartate - NOUN O 
proteases - NOUN O 
( - PUNCT O 
SAPs - PROPN O 
) - PUNCT O 
. - PUNCT O 

Rhizopus NOUN - B-MEDICINE 
species - NOUN O 
are - VERB O 
especially - ADV O 
important - ADJ O 
as - ADP O 
plant - NOUN O 
and - CCONJ O 
animal - NOUN O 
pathogens - NOUN O 
and - CCONJ O 
bioindustrial - NOUN O 
fermenters - NOUN O 
for - ADP O 
food - NOUN O 
and - CCONJ O 
metabolite - NOUN O 
production - NOUN O 
. - PUNCT O 

A - DET O 
dataset - NOUN O 
of - ADP O 
192 NUM - B-CARDINAL 
orthologous - ADJ O 
genes - NOUN O 
was - VERB O 
used - VERB O 
to - PART O 
construct - VERB O 
a - DET O 
phylogenetic - ADJ O 
tree - NOUN O 
of - ADP O 
21 NUM - B-CARDINAL 
Rhizopus PROPN - B-MEDICINE 
strains - NOUN O 
, - PUNCT O 
classified - VERB O 
into - ADP O 
four NUM - B-CARDINAL 
species - NOUN O 
isolated - VERB O 
from - ADP O 
habitats - NOUN O 
of - ADP O 
industrial - ADJ O 
, - PUNCT O 
medical - ADJ O 
and - CCONJ O 
environmental - ADJ O 
importance - NOUN O 
. - PUNCT O 

The - DET O 
phylogeny - NOUN O 
indicates - VERB O 
that - ADP O 
the - DET O 
genus - ADJ O 
Rhizopus PROPN - B-MEDICINE 
consists - VERB O 
of - ADP O 
three NUM - B-CARDINAL 
major - ADJ O 
clades - NOUN O 
, - PUNCT O 
with - ADP O 
R. PROPN - B-NORP 
microsporus - NOUN O 
as - ADP O 
the - DET O 
basal - ADJ O 
species - NOUN O 
and - CCONJ O 
the - DET O 
sister - NOUN O 
lineage - NOUN O 
to - ADP O 
R. PROPN - B-NORP 
stolonifer - NOUN O 
and - CCONJ O 
two NUM - B-CARDINAL 
closely - ADV O 
related - VERB O 
species - NOUN O 
R. PROPN - B-NORP 
arrhizus - NOUN O 
and - CCONJ O 
R. PROPN - B-NORP 
delemar - VERB O 
A - DET O 
comparative - ADJ O 
analysis - NOUN O 
of - ADP O 
the - DET O 
mating - NOUN O 
type - NOUN O 
locus - NOUN O 
across - ADP O 
Rhizopus PROPN - B-MEDICINE 
reveals - VERB O 
that - ADP O 
its - ADJ O 
structure - NOUN O 
is - VERB O 
flexible - ADJ O 
even - ADV O 
between - ADP O 
different - ADJ O 
species - NOUN O 
in - ADP O 
the - DET O 
same - ADJ O 
genus - NOUN O 
, - PUNCT O 
but - CCONJ O 
shows - VERB O 
similarities - NOUN O 
between - ADP O 
Rhizopus PROPN - B-MEDICINE 
and - CCONJ O 
other - ADJ O 
mucoralean - NOUN O 
fungi - NOUN O 
. - PUNCT O 

Phylogenetic - ADJ O 
and - CCONJ O 
Phylogenomic - ADJ O 
Definition - PROPN O 
of - ADP O 
Rhizopus PROPN - B-MEDICINE 
Species - PROPN O 
. - PUNCT O 

VATS - NOUN O 
was - VERB O 
performed - VERB O 
and - CCONJ O 
cultured - VERB O 
lung - NOUN O 
tissue - NOUN O 
grew - VERB O 
Rhizopus PROPN - B-MEDICINE 
species - NOUN O 
. - PUNCT O 

Among - ADP O 
the - DET O 
isolates - NOUN O 
, - PUNCT O 
13 NUM - B-CARDINAL 
were - VERB O 
identified - VERB O 
as - ADP O 
Rhizopus PROPN - B-MEDICINE 
arrhizus - PROPN O 
var - NOUN O 
. - PUNCT O 

arrhizus - PROPN O 
, - PUNCT O 
10 NUM - B-CARDINAL 
R. PROPN - B-NORP 
arrhizus - PROPN O 
var - NOUN O 
. - PUNCT O 
delemar - VERB O 
, - PUNCT O 
two NUM - B-CARDINAL 
Rhizopus PROPN - B-MEDICINE 
microsporus - NOUN O 
, - PUNCT O 
one NUM - B-CARDINAL 
Lichtheimia PROPN - B-NORP 
corymbifera - NOUN O 
, - PUNCT O 
three NUM - B-CARDINAL 
Lichtheimia PROPN - B-NORP 
ramosa - NOUN O 
, - PUNCT O 
and - CCONJ O 
one NUM - B-CARDINAL 
Syncephalastrum PROPN - B-NORP 
racemosum - NOUN O 
. - PUNCT O 

We - PRON O 
also - ADV O 
identified - VERB O 
the - DET O 
optimal - ADJ O 
constituents - NOUN O 
of - ADP O 
the - DET O 
medium - NOUN O 
on - ADP O 
which - ADJ O 
the - DET O 
normal - ADJ O 
rapid - ADJ O 
growth - NOUN O 
of - ADP O 
Rhizopus PROPN - B-MEDICINE 
sp - X O 
. - PUNCT O 
was - VERB O 
completely - ADV O 
inhibited - VERB O 
. - PUNCT O 

Effect - NOUN O 
of - ADP O 
β PROPN - B-PRODUCT 
- PUNCT - I-PRODUCT 
Aminobutyric PROPN - I-PRODUCT 
Acid PROPN - I-PRODUCT 
on ADP - I-PRODUCT 
Disease PROPN - I-PRODUCT 
Resistance PROPN - I-PRODUCT 
Against ADP - I-PRODUCT 
Rhizopus PROPN - I-MEDICINE 
Rot - PROPN O 
in - ADP O 
Harvested PROPN - B-GPE 
Peaches PROPN - I-GPE 
. - PUNCT O 

Rhizopus NOUN - B-MEDICINE 
delemar - NOUN O 
is - VERB O 
an - DET O 
invasive - ADJ O 
fungal - ADJ O 
pathogen - NOUN O 
, - PUNCT O 
responsible - ADJ O 
for - ADP O 
the - DET O 
frequently - ADV O 
fatal - ADJ O 
disease - NOUN O 
mucormycosis - NOUN O 
. - PUNCT O 

Germination - PROPN O 
, - PUNCT O 
a - DET O 
crucial - ADJ O 
mechanism - NOUN O 
by - ADP O 
which - ADJ O 
spores - NOUN O 
of - ADP O 
Rhizopus NOUN - B-MEDICINE 
delemar - VERB O 
infect - ADJ O 
and - CCONJ O 
cause - NOUN O 
disease - NOUN O 
, - PUNCT O 
is - VERB O 
a - DET O 
key - ADJ O 
developmental - ADJ O 
process - NOUN O 
that - ADJ O 
transforms - VERB O 
the - DET O 
dormant - ADJ O 
spore - ADJ O 
state - NOUN O 
into - ADP O 
a - DET O 
vegetative - ADJ O 
one - NOUN O 
. - PUNCT O 

This - DET O 
study - NOUN O 
provides - VERB O 
a - DET O 
greater - ADJ O 
understanding - NOUN O 
of - ADP O 
the - DET O 
regulation - NOUN O 
of - ADP O 
germination - NOUN O 
and - CCONJ O 
highlights - NOUN O 
processes - NOUN O 
involved - VERB O 
in - ADP O 
transforming - VERB O 
Rhizopus PROPN - B-MEDICINE 
delemar - NOUN O 
from - ADP O 
a - DET O 
single - ADJ O 
to - ADP O 
a - DET O 
multicellular - ADJ O 
organism - NOUN O 
. - PUNCT O 

Pathways - NOUN O 
of - ADP O 
pathogenicity - NOUN O 
: - PUNCT O 
The - DET O 
transcriptional - ADJ O 
stages - NOUN O 
of - ADP O 
germination - NOUN O 
in - ADP O 
the - DET O 
fatal - ADJ O 
fungal - ADJ O 
pathogen - NOUN O 
Rhizopus NOUN - B-MEDICINE 
delemar - PROPN O 

XJ-1 PROPN - B-GPE 
( - PUNCT O 
MG018715 - PROPN O 
) - PUNCT O 
and - CCONJ O 
GS-1 - PROPN O 
( - PUNCT O 
MG018714 PROPN - B-PERSON 
) - PUNCT O 
showed - VERB O 
99 NUM - B-PERCENT 
% NOUN - I-PERCENT 
homology - NOUN O 
with - ADP O 
the - DET O 
sequence - NOUN O 
of - ADP O 
Rhizopus ADJ - B-MEDICINE 
oryzae - NOUN O 
( - PUNCT O 
DQ641279 - PROPN O 
and - CCONJ O 
DQ119031 - PROPN O 
) - PUNCT O 
. - PUNCT O 

Rhizopus NOUN - B-MEDICINE 
head - NOUN O 
rot - NOUN O 
of - ADP O 
sunflower - NOUN O 
has - VERB O 
also - ADV O 
been - VERB O 
reported - VERB O 
to - PART O 
reduce - VERB O 
the - DET O 
quality - NOUN O 
and - CCONJ O 
yield - NOUN O 
of - ADP O 
sunflower - ADJ O 
in - ADP O 
the DET - B-GPE 
United PROPN - I-GPE 
States PROPN - I-GPE 
, - PUNCT O 
Canada PROPN - B-GPE 
, - PUNCT O 
Israel PROPN - B-GPE 
, - PUNCT O 
Pakistan PROPN - B-GPE 
, - PUNCT O 
Australia PROPN - B-GPE 
, - PUNCT O 
India PROPN - B-GPE 
, - PUNCT O 
Italy PROPN - B-GPE 
, - PUNCT O 
Egypt PROPN - B-GPE 
, - PUNCT O 
and - CCONJ O 
the - DET O 
former - ADJ O 
Soviet PROPN - B-GPE 
Union PROPN - I-GPE 
( - PUNCT O 
Sanogo PROPN - B-PERSON 
et PROPN - I-PERSON 
al PROPN - I-PERSON 
. PUNCT - I-PERSON 
2010 - NUM O 
; - PUNCT O 
Shtienberg PROPN - B-GPE 
1997 NUM - I-GPE 
) - PUNCT O 
. - PUNCT O 

In - ADP O 
this - DET O 
study - NOUN O 
, - PUNCT O 
a - DET O 
homogeneous - ADJ O 
polysaccharide - NOUN O 
( - PUNCT O 
RPS-1 - PROPN O 
) - PUNCT O 
was - VERB O 
extracted - VERB O 
from - ADP O 
liquid - NOUN O 
- - PUNCT O 
cultured - VERB O 
mycelia - NOUN O 
of - ADP O 
Rhizopus PROPN - B-MEDICINE 
nigricans - NOUN O 
. - PUNCT O 

Rhizopus NOUN - B-MEDICINE 
nigricans - NOUN O 
polysaccharide - VERB O 
activated - ADJ O 
macrophages - NOUN O 
and - CCONJ O 
suppressed - VERB O 
tumor - NOUN O 
growth - NOUN O 
in - ADP O 
CT26 - PROPN O 
tumor - NOUN O 
- - PUNCT O 
bearing - NOUN O 
mice - NOUN O 
. - PUNCT O 

Bronchoalveolar - PROPN O 
lavage - NOUN O 
fluid - NOUN O 
samples - NOUN O 
( - PUNCT O 
n - NOUN O 
= - SYM O 
450 NUM - B-CARDINAL 
) - PUNCT O 
from - ADP O 
374 NUM - B-CARDINAL 
patients - NOUN O 
with - ADP O 
pneumonia - NOUN O 
and - CCONJ O 
immunosuppressive - ADJ O 
conditions - NOUN O 
were - VERB O 
analyzed - VERB O 
using - VERB O 
a - DET O 
combination - NOUN O 
of - ADP O 
3 NUM - B-CARDINAL 
quantitative - ADJ O 
PCR PROPN - B-ORG 
assays - NOUN O 
targeting - VERB O 
the - DET O 
main - ADJ O 
genera - NOUN O 
involved - VERB O 
in - ADP O 
mucormycosis - NOUN O 
in - ADP O 
France PROPN - B-GPE 
( - PUNCT O 
Rhizomucor PROPN - B-ORG 
, - PUNCT O 
Mucor PROPN - B-ORG 
/ SYM - I-ORG 
Rhizopus PROPN - I-MEDICINE 
, - PUNCT O 
and - CCONJ O 
Lichtheimia PROPN - B-ORG 
) - PUNCT O 
. - PUNCT O 

Overall - ADV O 
, - PUNCT O 
23 NUM - B-CARDINAL 
IFIs - NOUN O 
occurred - VERB O 
in - ADP O 
23 NUM - B-CARDINAL 
recipients - NOUN O 
( - PUNCT O 
8 NUM - B-PERCENT 
% NOUN - I-PERCENT 
) - PUNCT O 
at - ADP O 
mean - NOUN O 
283 NUM - B-DATE 
days NOUN - I-DATE 
post - NOUN O 
- - ADJ O 
HT - NOUN O 
( - PUNCT O 
range - NOUN O 
2–1,579 NUM - B-DATE 
days NOUN - I-DATE 
) - PUNCT O 
, - PUNCT O 
including - VERB O 
seven NUM - B-QUANTITY 
Aspergillus PROPN - I-QUANTITY 
( - PUNCT O 
one NUM - B-CARDINAL 
occurring - NOUN O 
after - ADP O 
VORI - PROPN O 
completion - NOUN O 
) - PUNCT O 
, - PUNCT O 
seven NUM - B-CARDINAL 
invasive - ADJ O 
Candida PROPN - B-GPE 
( - PUNCT O 
five NUM - B-CARDINAL 
with - ADP O 
candidemia - NOUN O 
) - PUNCT O 
, - PUNCT O 
two NUM - B-CARDINAL 
Rhizopus PROPN - B-MEDICINE 
, - PUNCT O 
one NUM - B-CARDINAL 
Cunninghamella PROPN - B-ORG 
, - PUNCT O 
two NUM - B-CARDINAL 
histoplasma - NOUN O 
, - PUNCT O 
two NUM - B-CARDINAL 
blastomyces - NOUN O 
, - PUNCT O 
one NUM - B-CARDINAL 
Cryptococcus PROPN - B-ORG 
, - PUNCT O 
and - CCONJ O 
one NUM - B-CARDINAL 
multifocal - ADJ O 
cutaneous - ADJ O 
Alternaria PROPN - B-ORG 
. - PUNCT O 
  - SPACE O 

We - PRON O 
sought - VERB O 
to - PART O 
identify - VERB O 
the - DET O 
nasal - NOUN O 
and - CCONJ O 
lung - NOUN O 
epithelial - ADJ O 
cell - NOUN O 
receptors - NOUN O 
interacting - VERB O 
with - ADP O 
Rhizopus PROPN - B-MEDICINE 
during - ADP O 
tissue - NOUN O 
invasion - NOUN O 
. - PUNCT O 

NGS PROPN - B-ORG 
plasma - VERB O 
testing - NOUN O 
identified - VERB O 
a - DET O 
pathogen - NOUN O 
which - ADJ O 
was - VERB O 
cultured - VERB O 
from - ADP O 
infected - ADJ O 
tissue - NOUN O 
or - CCONJ O 
blood - NOUN O 
in - ADP O 
4 NUM - B-CARDINAL 
of - ADP O 
6 - NUM O 
proven - VERB O 
cases - NOUN O 
; - PUNCT O 
one NUM - B-CARDINAL 
patient - NOUN O 
with - ADP O 
localized - ADJ O 
cutaneous - ADJ O 
Rhizopus PROPN - B-MEDICINE 
had - VERB O 
negative - ADJ O 
NGS PROPN - B-ORG 
results - NOUN O 
. - PUNCT O 

Pathways - PROPN O 
of - ADP O 
Pathogenicity - PROPN O 
: - PUNCT O 
Transcriptional - PROPN O 
Stages - PROPN O 
of - ADP O 
Germination - PROPN O 
in - ADP O 
the - DET O 
Fatal - PROPN O 
Fungal - PROPN O 
Pathogen - PROPN O 
Rhizopus PROPN - B-MEDICINE 
delemar - PROPN O 
. - PUNCT O 

Author - NOUN O 
Correction - PROPN O 
: - PUNCT O 
Iron - NOUN O 
restriction - NOUN O 
inside - ADP O 
macrophages - NOUN O 
regulates - VERB O 
pulmonary - ADJ O 
host - NOUN O 
defense - NOUN O 
against - ADP O 
Rhizopus PROPN - B-MEDICINE 
species - NOUN O 
. - PUNCT O 

2 - NUM O 
, - PUNCT O 
Rhizopus PROPN - B-MEDICINE 
sp - PROPN O 
. - PUNCT O 

The - DET O 
aim - NOUN O 
of - ADP O 
this - DET O 
work - NOUN O 
was - VERB O 
to - PART O 
evaluate - VERB O 
the - DET O 
effect - NOUN O 
of - ADP O 
six NUM - B-CARDINAL 
environmental - ADJ O 
friendly - ADJ O 
disinfectants - NOUN O 
against - ADP O 
Monilinia PROPN - B-GPE 
fructicola - NOUN O 
, - PUNCT O 
Penicillium - PROPN O 
expansum - NOUN O 
, - PUNCT O 
Rhizopus PROPN - B-MEDICINE 
spp - NOUN O 
. - PUNCT O 
, - PUNCT O 
and - CCONJ O 
Alternaria PROPN - B-GPE 
spp - NOUN O 
. - PUNCT O 

Rhizopus NOUN - B-MEDICINE 
spp - NOUN O 
. - PUNCT O 

In - ADP O 
vitro - ADJ O 
antimold - ADJ O 
activity - NOUN O 
of - ADP O 
annatto - NOUN O 
natural - ADJ O 
dye - NOUN O 
against - ADP O 
Aspergillus PROPN - B-ORG 
niger - ADV O 
, - PUNCT O 
Neurospora PROPN - B-GPE 
sitophila - VERB O 
, - PUNCT O 
and - CCONJ O 
Rhizopus PROPN - B-MEDICINE 
stolonifer - PROPN O 
was - VERB O 
evaluated - VERB O 
with - ADP O 
agar - ADJ O 
well - ADJ O 
diffusion - NOUN O 
and - CCONJ O 
agar - NOUN O 
dilution - NOUN O 
assays - NOUN O 
. - PUNCT O 

CotH - PROPN O 
was - VERB O 
detected - VERB O 
as - ADV O 
early - ADV O 
as - ADP O 
24 NUM - B-CARDINAL 
h - DET O 
postinfection - NOUN O 
in - ADP O 
plasma - NOUN O 
, - PUNCT O 
urine - NOUN O 
, - PUNCT O 
and - CCONJ O 
bronchoalveolar - ADJ O 
lavage - NOUN O 
( - PUNCT O 
BAL - PROPN O 
) - PUNCT O 
samples - NOUN O 
from - ADP O 
mice - NOUN O 
infected - VERB O 
intratracheally - ADV O 
with - ADP O 
Rhizopus PROPN - B-MEDICINE 
delemar - NOUN O 
, - PUNCT O 
Rhizopus PROPN - B-MEDICINE 
oryzae - NOUN O 
, - PUNCT O 
Mucor PROPN - B-ORG 
circinelloides - VERB O 
, - PUNCT O 
Lichtheimia PROPN - B-PRODUCT 
corymbifera - NOUN O 
, - PUNCT O 
or - CCONJ O 
Cunninghamella PROPN - B-ORG 
bertholletiae - VERB O 
but - CCONJ O 
not - ADV O 
from - ADP O 
samples - NOUN O 
taken - VERB O 
from - ADP O 
uninfected - ADJ O 
mice - NOUN O 
or - CCONJ O 
mice - NOUN O 
infected - VERB O 
with - ADP O 
Aspergillus PROPN - B-ORG 
fumigatus - NOUN O 
Detection - PROPN O 
of - ADP O 
CotH - PROPN O 
from - ADP O 
urine - NOUN O 
samples - NOUN O 
was - VERB O 
more - ADV O 
reliable - ADJ O 
than - ADP O 
from - ADP O 
plasma - NOUN O 
or - CCONJ O 
BAL - PROPN O 
fluid - ADJ O 
. - PUNCT O 

This - DET O 
work - NOUN O 
aimed - VERB O 
to - PART O 
improve - VERB O 
the - DET O 
enzymatic - ADJ O 
properties - NOUN O 
of - ADP O 
Rhizopus PROPN - B-MEDICINE 
oryzae - VERB O 
α - PUNCT O 
- - PUNCT O 
amylase - NOUN O 
by - ADP O 
site - NOUN O 
- - PUNCT O 
saturation - NOUN O 
mutagenesis - NOUN O 
of - ADP O 
histidine - NOUN O 
286 NUM - B-CARDINAL 
. - PUNCT O 

In - ADP O 
previous - ADJ O 
work - NOUN O 
, - PUNCT O 
we - PRON O 
proposed - VERB O 
a - DET O 
novel - NOUN O 
modified - VERB O 
one NUM - B-CARDINAL 
- - PUNCT O 
step - NOUN O 
fermentation - NOUN O 
fed - VERB O 
- - PUNCT O 
batch - NOUN O 
strategy - NOUN O 
to - PART O 
efficiently - ADV O 
generate - VERB O 
L - NOUN O 
- - PUNCT O 
lactic - ADJ O 
acid - NOUN O 
( - PUNCT O 
L - PROPN O 
- - PUNCT O 
LA - PROPN O 
) - PUNCT O 
using - VERB O 
Rhizopus PROPN - B-MEDICINE 
oryzae - NOUN O 
. - PUNCT O 

An - DET O 
optimized - VERB O 
fed - VERB O 
- - PUNCT O 
batch - NOUN O 
culture - NOUN O 
strategy - NOUN O 
integrated - VERB O 
with - ADP O 
a - DET O 
one NUM - B-CARDINAL 
- - PUNCT O 
step - NOUN O 
fermentation - NOUN O 
improves - VERB O 
L NOUN - B-ORG 
- - PUNCT O 
lactic - ADJ O 
acid - NOUN O 
production - NOUN O 
by - ADP O 
Rhizopus PROPN - B-MEDICINE 
oryzae - NOUN O 
. - PUNCT O 

An - DET O 
extracellular - ADJ O 
polysaccharide - NOUN O 
( - PUNCT O 
EPS1 - PROPN O 
- - PUNCT O 
1 - NUM O 
) - PUNCT O 
extracted - VERB O 
from - ADP O 
the - DET O 
fermentation - NOUN O 
broth - NOUN O 
of - ADP O 
Rhizopus PROPN - B-MEDICINE 
nigricans - NOUN O 
has - VERB O 
been - VERB O 
proved - VERB O 
to - PART O 
enhance - VERB O 
the - DET O 
immunity - NOUN O 
of - ADP O 
immunosuppressed - VERB O 
mice - NOUN O 
. - PUNCT O 

After - ADP O 
deeply - ADV O 
studying - VERB O 
the - DET O 
importance - NOUN O 
of - ADP O 
thermostability - NOUN O 
of - ADP O 
fungal - ADJ O 
α - NOUN O 
- - PUNCT O 
amylases - NOUN O 
applied - VERB O 
in - ADP O 
industrial - ADJ O 
production - NOUN O 
, - PUNCT O 
with - ADP O 
attempt - NOUN O 
to - PART O 
improve - VERB O 
the - DET O 
thermostability - NOUN O 
of - ADP O 
Rhizopus PROPN - B-MEDICINE 
oryzae - VERB O 
α - NOUN O 
- - PUNCT O 
amylase - NOUN O 
( - PUNCT O 
ROAmy PROPN - B-ORG 
) - PUNCT O 
, - PUNCT O 
single - ADJ O 
- - PUNCT O 
point - NOUN O 
mutations - NOUN O 
and - CCONJ O 
combined - VERB O 
mutations - NOUN O 
that - ADJ O 
based - VERB O 
on - ADP O 
analysis - NOUN O 
of - ADP O 
B - NOUN O 
- - PUNCT O 
factor - NOUN O 
values - NOUN O 
and - CCONJ O 
molecular - ADJ O 
dynamics - NOUN O 
simulations - NOUN O 
were - VERB O 
carried - VERB O 
out - PART O 
for - ADP O 
amino - ADJ O 
acid - NOUN O 
residues - NOUN O 
G128 - PROPN O 
, - PUNCT O 
K269 - PROPN O 
and - CCONJ O 
G393 - PROPN O 
of - ADP O 
ROAmy NUM - B-ORG 
by - ADP O 
overlapping - VERB O 
PCR PROPN - B-ORG 
. - PUNCT O 

[ - PUNCT O 
Improving - VERB O 
the - DET O 
thermostability - NOUN O 
of - ADP O 
α - NOUN O 
- - PUNCT O 
amylase - NOUN O 
from - ADP O 
Rhizopus PROPN - B-MEDICINE 
oryzae - NOUN O 
by - ADP O 
rational - ADJ O 
design]. - NOUN O 

In - ADP O 
this - DET O 
study - NOUN O 
the - DET O 
antifungal - ADJ O 
potential - NOUN O 
of - ADP O 
a - DET O 
phenolic - NOUN O 
extract - NOUN O 
obtained - VERB O 
from - ADP O 
rice - NOUN O 
bran - NOUN O 
fermented - VERB O 
with - ADP O 
Rhizopus PROPN - B-MEDICINE 
oryzae - VERB O 
CECT - PROPN O 
7560 NUM - B-CARDINAL 
and - CCONJ O 
its - ADJ O 
application - NOUN O 
in - ADP O 
the - DET O 
elaboration - NOUN O 
of - ADP O 
bread - NOUN O 
was - VERB O 
assessed - VERB O 
. - PUNCT O 

Antifungal - ADJ O 
effect - NOUN O 
of - ADP O 
phenolic - NOUN O 
extract - NOUN O 
of - ADP O 
fermented - ADJ O 
rice - NOUN O 
bran - NOUN O 
with - ADP O 
Rhizopus PROPN - B-MEDICINE 
oryzae - NOUN O 
and - CCONJ O 
its - ADJ O 
potential - ADJ O 
use - NOUN O 
in - ADP O 
loaf - ADJ O 
bread - NOUN O 
shelf - NOUN O 
life - NOUN O 
extension - NOUN O 
. - PUNCT O 

Rhizopus NOUN - B-MEDICINE 
oryzae - VERB O 
is - VERB O 
the - DET O 
most - ADV O 
prevalent - ADJ O 
causative - ADJ O 
agent - NOUN O 
of - ADP O 
mucormycosis - NOUN O 
, - PUNCT O 
an - DET O 
increasingly - ADV O 
reported - VERB O 
opportunistic - ADJ O 
fungal - ADJ O 
infection - NOUN O 
. - PUNCT O 

The - DET O 
aim - NOUN O 
of - ADP O 
this - DET O 
work - NOUN O 
was - VERB O 
to - PART O 
establish - VERB O 
if - ADP O 
the - DET O 
Rhizopus PROPN - B-MEDICINE 
oryzaeCYP51 - ADJ O 
genes - NOUN O 
are - VERB O 
uniquely - ADV O 
responsible - ADJ O 
for - ADP O 
intrinsic - ADJ O 
voriconazole - NOUN O 
and - CCONJ O 
fluconazole - ADJ O 
resistance - NOUN O 
in - ADP O 
these - DET O 
fungal - ADJ O 
pathogens - NOUN O 
. - PUNCT O 

Molecular PROPN - B-ORG 
Confirmation PROPN - I-ORG 
of ADP - I-ORG 
the DET - I-ORG 
Linkage PROPN - I-ORG 
between - ADP O 
the - DET O 
Rhizopus PROPN - B-MEDICINE 
oryzae - VERB O 
CYP51A - PROPN O 
Gene PROPN - B-PERSON 
Coding PROPN - I-PERSON 
Region PROPN - I-PERSON 
and - CCONJ O 
Its - ADJ O 
Intrinsic - PROPN O 
Voriconazole - PROPN O 
and - CCONJ O 
Fluconazole - PROPN O 
Resistance - PROPN O 
. - PUNCT O 

The - DET O 
isolate - NOUN O 
was - VERB O 
identified - VERB O 
as - ADP O 
Rhizopus PROPN - B-MEDICINE 
microspores - NOUN O 
by - ADP O 
ITS - ADJ O 
sequencing - NOUN O 
. - PUNCT O 

In - ADP O 
previous - ADJ O 
work - NOUN O 
, - PUNCT O 
we - PRON O 
proposed - VERB O 
a - DET O 
novel - NOUN O 
modified - VERB O 
one NUM - B-CARDINAL 
- - PUNCT O 
step - NOUN O 
fermentation - NOUN O 
fed - VERB O 
- - PUNCT O 
batch - NOUN O 
strategy - NOUN O 
to - PART O 
efficiently - ADV O 
generate - VERB O 
L - NOUN O 
- - PUNCT O 
lactic - ADJ O 
acid - NOUN O 
( - PUNCT O 
L - PROPN O 
- - PUNCT O 
LA - PROPN O 
) - PUNCT O 
using - VERB O 
Rhizopus PROPN - B-MEDICINE 
oryzae - NOUN O 
. - PUNCT O 

An - DET O 
optimized - VERB O 
fed - VERB O 
- - PUNCT O 
batch - NOUN O 
culture - NOUN O 
strategy - NOUN O 
integrated - VERB O 
with - ADP O 
a - DET O 
one NUM - B-CARDINAL 
- - PUNCT O 
step - NOUN O 
fermentation - NOUN O 
improves - VERB O 
L NOUN - B-ORG 
- - PUNCT O 
lactic - ADJ O 
acid - NOUN O 
production - NOUN O 
by - ADP O 
Rhizopus PROPN - B-MEDICINE 
oryzae - VERB O 

A - DET O 
silkworm - NOUN O 
infection - NOUN O 
assay - NOUN O 
with - ADP O 
the - DET O 
pathogenic - ADJ O 
fungus - NOUN O 
Rhizopus PROPN - B-MEDICINE 
oryzae - NOUN O 
was - VERB O 
established - VERB O 
. - PUNCT O 

Microbial - ADJ O 
culture - NOUN O 
broths - NOUN O 
were - VERB O 
screened - VERB O 
for - ADP O 
anti - ADJ O 
- - ADJ O 
Rhizopus ADJ - B-MEDICINE 
antibiotics - NOUN O 
using - VERB O 
this - DET O 
assay - NOUN O 
. - PUNCT O 

Polysaccharide - PROPN O 
( - PUNCT O 
EPS1 - PROPN O 
- - PUNCT O 
1 - NUM O 
) - PUNCT O 
extracted - VERB O 
from - ADP O 
fermentation - NOUN O 
liquor - NOUN O 
of - ADP O 
Rhizopus PROPN - B-MEDICINE 
nigricans - NOUN O 
possesses - VERB O 
antitumor - NOUN O 
and - CCONJ O 
immune - ADV O 
- - PUNCT O 
enhancing - VERB O 
activities - NOUN O 
. - PUNCT O 

Polysaccharide - VERB O 
from - ADP O 
Rhizopus PROPN - B-MEDICINE 
nigricans - NOUN O 
inhibits - VERB O 
the - DET O 
invasion - NOUN O 
and - CCONJ O 
metastasis - NOUN O 
of - ADP O 
colorectal - ADJ O 
cancer - NOUN O 
. - PUNCT O 

The - DET O 
lowest - ADJ O 
modal - ADJ O 
isavuconazole - NOUN O 
MIC PROPN - B-ORG 
values - NOUN O 
were - VERB O 
seen - VERB O 
for - ADP O 
Rhizopus PROPN - B-MEDICINE 
spp - NOUN O 
. - PUNCT O 

We - PRON O 
confirm - VERB O 
the - DET O 
potentially - ADV O 
useful - ADJ O 
activity - NOUN O 
of - ADP O 
isavuconazole - NOUN O 
against - ADP O 
species - NOUN O 
of - ADP O 
Rhizopus PROPN - B-MEDICINE 
as - ADP O 
determined - VERB O 
by - ADP O 
CLSI PROPN - B-ORG 
methods - NOUN O 
. - PUNCT O 

Although - ADP O 
glycerol - NOUN O 
contains - VERB O 
many - ADJ O 
types - NOUN O 
of - ADP O 
impurities - NOUN O 
, - PUNCT O 
it - PRON O 
can - VERB O 
be - VERB O 
used - VERB O 
as - ADP O 
a - DET O 
C - NOUN O 
- - PUNCT O 
source - NOUN O 
for - ADP O 
lactic - ADJ O 
acid - NOUN O 
production - NOUN O 
by - ADP O 
fungi - NOUN O 
, - PUNCT O 
such - ADJ O 
as - ADP O 
Rhizopus PROPN - B-MEDICINE 
microsporus - NOUN O 
. - PUNCT O 

Rhizopus NOUN - B-MEDICINE 
microsporus - NOUN O 
NBRC PROPN - B-PERSON 
32995 NUM - I-PERSON 
was - VERB O 
found - VERB O 
to - PART O 
hydrolyze - VERB O 
fructooligosaccharides - NOUN O 
( - PUNCT O 
FOS PROPN - B-ORG 
) - PUNCT O 
, - PUNCT O 
as - ADV O 
well - ADV O 
as - ADP O 
sucrose - NOUN O 
, - PUNCT O 
almost - ADV O 
completely - ADV O 
into - ADP O 
monosaccharides - NOUN O 
through - ADP O 
the - DET O 
production - NOUN O 
of - ADP O 
sufficient - ADJ O 
amounts - NOUN O 
of - ADP O 
organic - ADJ O 
acids - NOUN O 
, - PUNCT O 
indicating - VERB O 
that - ADP O 
the - DET O 
complete - ADJ O 
hydrolysis - NOUN O 
of - ADP O 
FOS PROPN - B-ORG 
was - VERB O 
caused - VERB O 
by - ADP O 
the - DET O 
secretion - NOUN O 
of - ADP O 
β - NOUN O 
- - PUNCT O 
fructofuranosidase - NOUN O 
from - ADP O 
fungal - ADJ O 
cells - NOUN O 
. - PUNCT O 

The - DET O 
total - ADJ O 
length - NOUN O 
of - ADP O 
the - DET O 
sucA - NOUN O 
gene - NOUN O 
was - VERB O 
1590 NUM - B-DATE 
bp - NOUN O 
, - PUNCT O 
and - CCONJ O 
the - DET O 
SucA PROPN - B-ORG 
protein - NOUN O 
of - ADP O 
R. PROPN - B-NORP 
microsporus - NOUN O 
NBRC PROPN - B-PERSON 
32995 NUM - I-PERSON 
belonged - VERB O 
to - PART O 
clade - VERB O 
VIa - NOUN O 
, - PUNCT O 
which - ADJ O 
also - ADV O 
contains - VERB O 
Rhizopus PROPN - B-MEDICINE 
delemar - NOUN O 
and - CCONJ O 
is - VERB O 
closely - ADV O 
related - VERB O 
to - ADP O 
Saccharomycotina PROPN - B-PERSON 
, - PUNCT O 
a - DET O 
subdivision - NOUN O 
of - ADP O 
the - DET O 
Ascomycota - PROPN O 
. - PUNCT O 

Identification - NOUN O 
of - ADP O 
sucA - NOUN O 
, - PUNCT O 
Encoding - VERB O 
β - PUNCT O 
- - PUNCT O 
Fructofuranosidase - PROPN O 
, - PUNCT O 
in - ADP O 
Rhizopus PROPN - B-MEDICINE 
microsporus - NOUN O 
. - PUNCT O 

A - DET O 
novel - ADJ O 
fermentation - NOUN O 
system - NOUN O 
was - VERB O 
employed - VERB O 
whereby - ADV O 
the - DET O 
mycelial - ADJ O 
mat - NOUN O 
of - ADP O 
Rhizopus PROPN - B-MEDICINE 
oryzae - NOUN O 
was - VERB O 
attached - VERB O 
to - ADP O 
a - DET O 
polypropylene - NOUN O 
tube - NOUN O 
. - PUNCT O 

This - DET O 
study - NOUN O 
is - VERB O 
dedicated - VERB O 
to - PART O 
efficiently - ADV O 
produce - VERB O 
Rhizopus NOUN - B-MEDICINE 
oryzae - NOUN O 
lipase - NOUN O 
( - PUNCT O 
ROL PROPN - B-ORG 
) - PUNCT O 
by - ADP O 
optimizing - VERB O 
the - DET O 
expression - NOUN O 
of - ADP O 
multiple - ADJ O 
expression - NOUN O 
- - PUNCT O 
related - VERB O 
helper - NOUN O 
proteins - NOUN O 
in - ADP O 
Pichia PROPN - B-GPE 
pastoris - NOUN O 
. - PUNCT O 

Efficient - PROPN O 
Heterologous - PROPN O 
Production - PROPN O 
of - ADP O 
Rhizopus PROPN - B-MEDICINE 
oryzae - VERB O 
Lipase - PROPN O 
via - ADP O 
Optimization - PROPN O 
of - ADP O 
Multiple - PROPN O 
Expression - PROPN O 
- - PUNCT O 
Related - VERB O 
Helper - PROPN O 
Proteins - PROPN O 
. - PUNCT O 

A - DET O 
punch - NOUN O 
biopsy - NOUN O 
of - ADP O 
the - DET O 
lesion - NOUN O 
revealed - VERB O 
fungal - ADJ O 
elements - NOUN O 
that - ADJ O 
were - VERB O 
later - ADV O 
identified - VERB O 
as - ADP O 
Rhizopus PROPN - B-MEDICINE 
spp - NOUN O 
. - PUNCT O 

In - ADP O 
this - DET O 
study - NOUN O 
, - PUNCT O 
we - PRON O 
report - VERB O 
the - DET O 
isolation - NOUN O 
, - PUNCT O 
purification - NOUN O 
and - CCONJ O 
chemical - NOUN O 
characterization - NOUN O 
of - ADP O 
CMHs - NOUN O 
from - ADP O 
Rhizopus PROPN - B-MEDICINE 
stolonifer - PROPN O 
and - CCONJ O 
R. PROPN - B-NORP 
microspores - NOUN O 
. - PUNCT O 

CMH VERB - B-ORG 
from - ADP O 
both - DET O 
Rhizopus PROPN - B-MEDICINE 
species - NOUN O 
inhibited - VERB O 
the - DET O 
growth - NOUN O 
of - ADP O 
Bacillus - PROPN O 
terrae - NOUN O 
, - PUNCT O 
Micrococcus PROPN - B-PERSON 
luteus - NOUN O 
( - PUNCT O 
M. PROPN - B-PERSON 
luteus - PROPN O 
) - PUNCT O 
and - CCONJ O 
Pseudomonas PROPN - B-GPE 
stutzeri - NOUN O 
( - PUNCT O 
P. - PROPN O 
stutzeri - NOUN O 
) - PUNCT O 
with - ADP O 
a - DET O 
MIC50 - PROPN O 
of - ADP O 
6.25 NUM - B-CARDINAL 
, - PUNCT O 
6.25 NUM - B-CARDINAL 
and - CCONJ O 
3.13 NUM - B-CARDINAL 
mg NOUN - B-ORG 
/ SYM - I-ORG 
mL PROPN - I-ORG 
, - PUNCT O 
respectively - ADV O 
. - PUNCT O 

The - DET O 
study - NOUN O 
assessed - VERB O 
the - DET O 
effectiveness - NOUN O 
of - ADP O 
hot - ADJ O 
- - PUNCT O 
air - NOUN O 
treatment - NOUN O 
( - PUNCT O 
45 NUM - B-CARDINAL 
° PROPN - B-ORG 
C PROPN - I-ORG 
, - PUNCT O 
4 NUM - B-CARDINAL 
h - NUM O 
) - PUNCT O 
and - CCONJ O 
antagonistic - ADJ O 
yeast - NOUN O 
( - PUNCT O 
Pichia - PROPN O 
guilliermondii - NOUN O 
at - ADP O 
108 NUM - B-CARDINAL 
CFU PROPN - B-ORG 
mL-1 - NOUN O 
) - PUNCT O 
alone - ADV O 
or - CCONJ O 
in - ADP O 
combination - NOUN O 
on - ADP O 
the - DET O 
two NUM - B-CARDINAL 
major - ADJ O 
postharvest - NOUN O 
diseases - NOUN O 
( - PUNCT O 
Rhizopus PROPN - B-MEDICINE 
stolonifer - PROPN O 
and - CCONJ O 
Penicillium - PROPN O 
expansum - NOUN O 
) - PUNCT O 
, - PUNCT O 
as - ADV O 
well - ADV O 
as - ADP O 
the - DET O 
quality - NOUN O 
and - CCONJ O 
antioxidant - NOUN O 
parameters - NOUN O 
in - ADP O 
harvested - VERB O 
peaches - NOUN O 
. - PUNCT O 

Overall - ADV O 
, - PUNCT O 
Rhizopus NOUN - B-MEDICINE 
arrhizus - PROPN O 
( - PUNCT O 
n - NOUN O 
= - SYM O 
124 NUM - B-CARDINAL 
, - PUNCT O 
51.9 NUM - B-PERCENT 
% NOUN - I-PERCENT 
) - PUNCT O 
was - VERB O 
the - DET O 
predominant - ADJ O 
agent - NOUN O 
identified - VERB O 
, - PUNCT O 
followed - VERB O 
by - ADP O 
Rhizopus PROPN - B-MEDICINE 
microsporus - NOUN O 
( - PUNCT O 
n - NOUN O 
= - SYM O 
30 - NUM O 
, - PUNCT O 
12.6 NUM - B-PERCENT 
% NOUN - I-PERCENT 
) - PUNCT O 
, - PUNCT O 
Apophysomyces - PROPN O 
variabilis - NOUN O 
( - PUNCT O 
n - NOUN O 
= - SYM O 
22 NUM - B-DATE 
, - PUNCT O 
9.2 NUM - B-PERCENT 
% NOUN - I-PERCENT 
) - PUNCT O 
and - CCONJ O 
Rhizopus PROPN - B-MEDICINE 
homothallicus - NOUN O 
( - PUNCT O 
n - NOUN O 
= - SYM O 
6 - NUM O 
, - PUNCT O 
2.5 NUM - B-PERCENT 
% NOUN - I-PERCENT 
) - PUNCT O 
. - PUNCT O 

Direct - ADJ O 
Utilization - PROPN O 
of - ADP O 
Non - PROPN O 
- - ADJ O 
pretreated - ADJ O 
Hydrolytic PROPN - B-ORG 
Liquid PROPN - I-ORG 
of ADP - I-ORG 
Dried PROPN - I-ORG 
Distiller PROPN - I-ORG 
's PART - I-ORG 
Grains - NOUN O 
with - ADP O 
Solubles - PROPN O 
for - ADP O 
Bio PROPN - B-ORG 
- PUNCT - I-ORG 
Ethanol PROPN - I-ORG 
by - ADP O 
Rhizopus PROPN - B-MEDICINE 
arrhizus - VERB O 
RH - PROPN O 
7 - NUM O 
- - PUNCT O 
13 - NUM O 
- - SYM O 
9 - NUM O 
. - PUNCT O 

The - DET O 
rhizosphere - NOUN O 
, - PUNCT O 
air - NOUN O 
, - PUNCT O 
and - CCONJ O 
phylloplane - NOUN O 
was - VERB O 
dominated - VERB O 
by - ADP O 
Rhizopus PROPN - B-MEDICINE 
stolonifer - PROPN O 
( - PUNCT O 
22.13 NUM - B-PERCENT 
% NOUN - I-PERCENT 
; - PUNCT O 
15.08 NUM - B-CARDINAL 
; - SYM O 
24.01 NUM - B-CARDINAL 
) - PUNCT O 
while - ADP O 
Aspergillus ADV - B-ORG 
niger - NOUN O 
( - PUNCT O 
12.63 NUM - B-PERCENT 
% NOUN - I-PERCENT 
) - PUNCT O 
was - VERB O 
the - DET O 
dominant - ADJ O 
flora - NOUN O 
of - ADP O 
non - ADJ O 
- - NOUN O 
rhizosphere - ADJ O 
. - PUNCT O 

Curvularia PROPN - B-PERSON 
lunata - NOUN O 
while - ADP O 
Rhizopus PROPN - B-MEDICINE 
stolonifer - VERB O 
, - PUNCT O 

In - ADP O 
phyllosphere - NOUN O 
, - PUNCT O 
the - DET O 
Chatuwa PROPN - B-ORG 
and - CCONJ O 
Jaruwa PROPN - B-LOC 
, - PUNCT O 
the - DET O 
winter NOUN - B-DATE 
generations - NOUN O 
were - VERB O 
mainly - ADV O 
dominated - VERB O 
by - ADP O 
Rhizopus PROPN - B-MEDICINE 
stolonifer - NOUN O 
. - PUNCT O 

The - DET O 
most - ADV O 
common - ADJ O 
agents - NOUN O 
isolated - VERB O 
were - VERB O 
Rhizopus PROPN - B-MEDICINE 
species - NOUN O 
( - PUNCT O 
75.9 NUM - B-PERCENT 
% NOUN - I-PERCENT 
, - PUNCT O 
R. PROPN - B-NORP 
arrhizus - VERB O 
[ - PUNCT O 
74.3 NUM - B-PERCENT 
% NOUN - I-PERCENT 
] - PUNCT O 
and - CCONJ O 
R. PROPN - B-NORP 
homothallicus - NOUN O 
[ - PUNCT O 
6.7 NUM - B-PERCENT 
% NOUN - I-PERCENT 
] - PUNCT O 
) - PUNCT O 

To - PART O 
improve - VERB O 
its - ADJ O 
composition - NOUN O 
, - PUNCT O 
okara - NOUN O 
was - VERB O 
fermented - VERB O 
using - VERB O 
a - DET O 
fungal - ADJ O 
monoculture - NOUN O 
of - ADP O 
Rhizopus PROPN - B-MEDICINE 
oligosporus - NOUN O 
( - PUNCT O 
RO - PROPN O 
) - PUNCT O 
, - PUNCT O 
and - CCONJ O 
a - DET O 
coculture - NOUN O 
of - ADP O 
R. PROPN - B-NORP 
oligosporus - NOUN O 
and - CCONJ O 
yeast - NOUN O 
Yarrowia PROPN - B-GPE 
lipolytica - NOUN O 
( - PUNCT O 
ROYL - PROPN O 
) - PUNCT O 
. - PUNCT O 

The - DET O 
effect - NOUN O 
of - ADP O 
temperature - NOUN O 
on - ADP O 
the - DET O 
mycelium - NOUN O 
growth - NOUN O 
kinetics - NOUN O 
of - ADP O 
four NUM - B-CARDINAL 
postharvest - ADJ O 
fungal - ADJ O 
isolates - NOUN O 
( - PUNCT O 
i.e. - X O 
, - PUNCT O 
Penicillium - PROPN O 
expansum - NOUN O 
, - PUNCT O 
Alternaria PROPN - B-PERSON 
alternata - NOUN O 
, - PUNCT O 
Botrytis PROPN - B-ORG 
cinerea - NOUN O 
and - CCONJ O 
Rhizopus PROPN - B-MEDICINE 
stolonifer - PROPN O 
) - PUNCT O 
was - VERB O 
assessed - VERB O 
. - PUNCT O 

The - DET O 
regional - ADJ O 
standard - NOUN O 
for - ADP O 
tempeh - NOUN O 
established - VERB O 
by - ADP O 
the DET - B-ORG 
Codex PROPN - I-ORG 
Alimentarius PROPN - I-ORG 
defines - VERB O 
the - DET O 
use - NOUN O 
of - ADP O 
Rhizopus PROPN - B-MEDICINE 
oligosporus - NOUN O 
, - PUNCT O 
R. PROPN - B-NORP 
oryzae - VERB O 
, - PUNCT O 
and/or - CCONJ O 
R. - PROPN O 
stolonifer - NOUN O 
as - ADP O 
soybean - NOUN O 
tempeh - NOUN O 
starters - NOUN O 
. - PUNCT O 

However - ADV O 
, - PUNCT O 
comparative - ADJ O 
studies - NOUN O 
on - ADP O 
the - DET O 
functions - NOUN O 
of - ADP O 
tempeh - NOUN O 
prepared - VERB O 
with - ADP O 
these - DET O 
Rhizopus PROPN - B-MEDICINE 
species - NOUN O 
are - VERB O 
scarce - ADJ O 
. - PUNCT O 

In - ADP O 
the - DET O 
present - ADJ O 
study - NOUN O 
, - PUNCT O 
we - PRON O 
examined - VERB O 
the - DET O 
effects - NOUN O 
of - ADP O 
dietary - ADJ O 
tempeh - NOUN O 
prepared - VERB O 
with - ADP O 
these - DET O 
three NUM - B-CARDINAL 
Rhizopus PROPN - B-MEDICINE 
species - NOUN O 
using - VERB O 
rats - NOUN O 
fed - VERB O 
with - ADP O 
a - DET O 
high - ADJ O 
- - PUNCT O 
fat - NOUN O 
diet - NOUN O 
. - PUNCT O 

Beneficial PROPN - B-ORG 
Effects PROPN - I-ORG 
of ADP - I-ORG 
Dietary PROPN - I-ORG 
Tempeh PROPN - I-ORG 
Prepared PROPN - I-ORG 
with - ADP O 
Rhizopus PROPN - B-MEDICINE 
stolonifer - NOUN O 
on - ADP O 
Liver PROPN - B-ORG 
Function PROPN - I-ORG 
in ADP - I-ORG 
Rats PROPN - I-ORG 
Fed PROPN - I-ORG 
with - ADP O 
a - DET O 
High - PROPN O 
- - PUNCT O 
Fat - PROPN O 
Diet - PROPN O 
. - PUNCT O 

During - ADP O 
our - ADJ O 
studies - NOUN O 
with - ADP O 
Piper - PROPN O 
essential - ADJ O 
oils - NOUN O 
, - PUNCT O 
we - PRON O 
evaluated - VERB O 
its - ADJ O 
activity - NOUN O 
against - ADP O 
Rhizopus PROPN - B-MEDICINE 
oryzae - NOUN O 
, - PUNCT O 
the - DET O 
main - ADJ O 
agent - NOUN O 
of - ADP O 
mucormycosis - NOUN O 
. - PUNCT O 

Characterization - NOUN O 
of - ADP O 
quinoa - NOUN O 
( - PUNCT O 
Chenopodium - PROPN O 
quinoa - NOUN O 
) - PUNCT O 
fermented - VERB O 
by - ADP O 
Rhizopus PROPN - B-MEDICINE 
oligosporus - NOUN O 
and - CCONJ O 
its - ADJ O 
bioactive - ADJ O 
properties - NOUN O 
. - PUNCT O 

Rhizopus NOUN - B-MEDICINE 
rot - PROPN O 
, - PUNCT O 
caused - VERB O 
by - ADP O 
Rhizopus PROPN - B-MEDICINE 
stolonifer - NOUN O 
, - PUNCT O 
is - VERB O 
one - NUM O 
of - ADP O 
the - DET O 
main - ADJ O 
postharvest - NOUN O 
diseases - NOUN O 
in - ADP O 
stone - NOUN O 
fruits - NOUN O 
, - PUNCT O 
but - CCONJ O 
there - ADV O 
is - VERB O 
little - ADV O 
known - ADJ O 
about - ADP O 
the - DET O 
processes - NOUN O 
of - ADP O 
disease - NOUN O 
development - NOUN O 
during - ADP O 
transport - NOUN O 
and - CCONJ O 
postharvest - NOUN O 
storage - NOUN O 
. - PUNCT O 

Rhizopus NOUN - B-MEDICINE 
rot - PROPN O 
development - NOUN O 
was - VERB O 
evaluated - VERB O 
using - VERB O 
two NUM - B-CARDINAL 
different - ADJ O 
fruit - NOUN O 
arrangements - NOUN O 
. - PUNCT O 

Influence - NOUN O 
of - ADP O 
rice - NOUN O 
straw - NOUN O 
- - PUNCT O 
derived - VERB O 
dissolved - VERB O 
organic - ADJ O 
matter - NOUN O 
on - ADP O 
lactic - ADJ O 
acid - NOUN O 
fermentation - NOUN O 
by - ADP O 
Rhizopus PROPN - B-MEDICINE 
oryzae - NOUN O 
. - PUNCT O 

Primary - ADJ O 
cutaneous - ADJ O 
mucormycosis - NOUN O 
is - VERB O 
an - DET O 
opportunistic - ADJ O 
fungal - ADJ O 
infection - NOUN O 
caused - VERB O 
by - ADP O 
the - DET O 
order - NOUN O 
Mucorales PROPN - B-GPE 
, - PUNCT O 
most - ADV O 
frequently - ADV O 
by - ADP O 
the - DET O 
Rhizopus PROPN - B-MEDICINE 
species - NOUN O 
. - PUNCT O 

, - PUNCT O 
Rhizopus PROPN - B-MEDICINE 
spp - NOUN O 
. - PUNCT O 

Although - ADP O 
increasing - VERB O 
the - DET O 
gene - NOUN O 
dosage - NOUN O 
is - VERB O 
a - DET O 
common - ADJ O 
strategy - NOUN O 
to - PART O 
improve - VERB O 
recombinant - ADJ O 
protein - NOUN O 
productivities - NOUN O 
, - PUNCT O 
P. PROPN - B-PERSON 
pastoris - NOUN O 
strains - VERB O 
harboring - VERB O 
more ADJ - B-CARDINAL 
than ADP - I-CARDINAL 
two NUM - I-CARDINAL 
copies - NOUN O 
of - ADP O 
a - DET O 
Rhizopus PROPN - B-MEDICINE 
oryzae - VERB O 
lipase - NOUN O 
gene - NOUN O 
( - PUNCT O 
ROL PROPN - B-ORG 
) - PUNCT O 
have - VERB O 
previously - ADV O 
shown - VERB O 
a - DET O 
decrease - NOUN O 
in - ADP O 
cell - NOUN O 
growth - NOUN O 
, - PUNCT O 
lipase - NOUN O 
production - NOUN O 
, - PUNCT O 
and - CCONJ O 
substrate - NOUN O 
consumption - NOUN O 
, - PUNCT O 
as - ADV O 
well - ADV O 
as - ADP O 
a - DET O 
significant - ADJ O 
transcriptional - ADJ O 
downregulation - NOUN O 
of - ADP O 
methanol - NOUN O 
metabolism - NOUN O 
. - PUNCT O 

A - DET O 
fermented - VERB O 
solid - ADJ O 
containing - VERB O 
lipases - NOUN O 
was - VERB O 
produced - VERB O 
by - ADP O 
solid - ADJ O 
- - PUNCT O 
state - NOUN O 
fermentation - NOUN O 
of - ADP O 
Rhizopus PROPN - B-MEDICINE 
microsporus - NOUN O 
on - ADP O 
sugarcane - NOUN O 
bagasse - NOUN O 
enriched - VERB O 
with - ADP O 
urea - NOUN O 
, - PUNCT O 
soybean - NOUN O 
oil - NOUN O 
, - PUNCT O 
and - CCONJ O 
a - DET O 
mineral - NOUN O 
solution - NOUN O 
. - PUNCT O 

Optimization - NOUN O 
of - ADP O 
biodiesel - NOUN O 
synthesis - NOUN O 
by - ADP O 
esterification - NOUN O 
using - VERB O 
a - DET O 
fermented - VERB O 
solid - NOUN O 
produced - VERB O 
by - ADP O 
Rhizopus PROPN - B-MEDICINE 
microsporus - NOUN O 
on - ADP O 
sugarcane - NOUN O 
bagasse - NOUN O 
. - PUNCT O 

Rhizopus NOUN - B-MEDICINE 
oryzae - VERB O 
lipase - NOUN O 
( - PUNCT O 
ROL PROPN - B-ORG 
) - PUNCT O 
is - VERB O 
an - DET O 
important - ADJ O 
industrial - ADJ O 
enzyme - ADJ O 
limited - VERB O 
in - ADP O 
application - NOUN O 
due - ADP O 
to - ADP O 
its - ADJ O 
low - ADJ O 
production - NOUN O 
in - ADP O 
native - ADJ O 
strains - NOUN O 
. - PUNCT O 

Here - ADV O 
we - PRON O 
present - VERB O 
the - DET O 
first ADJ - B-ORDINAL 
reported - VERB O 
case - NOUN O 
of - ADP O 
a - DET O 
noninvasive - ADJ O 
Rhizopus PROPN - B-MEDICINE 
fungal - ADJ O 
ball - NOUN O 
confined - VERB O 
to - ADP O 
the - DET O 
bladder - NOUN O 
of - ADP O 
a - DET O 
patient - NOUN O 
with - ADP O 
poorly - ADV O 
controlled - VERB O 
diabetes - NOUN O 
and - CCONJ O 
right - ADJ O 
flank - NOUN O 
pain - NOUN O 
. - PUNCT O 

During - ADP O 
cystoscopy - NOUN O 
to - PART O 
replace - VERB O 
a - DET O 
ureteral - ADJ O 
stent - NOUN O 
, - PUNCT O 
he - PRON O 
was - VERB O 
found - VERB O 
to - PART O 
harbor - VERB O 
a - DET O 
fungal - ADJ O 
ball - NOUN O 
in - ADP O 
the - DET O 
bladder - NOUN O 
that - ADJ O 
was - VERB O 
removed - VERB O 
and - CCONJ O 
grew - VERB O 
Rhizopus PROPN - B-MEDICINE 
in - ADP O 
culture - NOUN O 
. - PUNCT O 

Effects - NOUN O 
of - ADP O 
Tempeh - PROPN O 
Fermentation - PROPN O 
with - ADP O 
Lactobacillus - PROPN O 
plantarum - NOUN O 
and - CCONJ O 
Rhizopus NOUN - B-MEDICINE 
oligosporus - NOUN O 
on - ADP O 
Streptozotocin - PROPN O 
- - PUNCT O 
Induced - PROPN O 
Type - PROPN O 
II - PROPN O 
Diabetes - NOUN O 
Mellitus - PROPN O 
in - ADP O 
Rats - PROPN O 
. - PUNCT O 

This - DET O 
study - NOUN O 
aimed - VERB O 
to - PART O 
investigate - VERB O 
the - DET O 
antifungal - ADJ O 
mechanism - NOUN O 
of - ADP O 
carvacrol - NOUN O 
and - CCONJ O 
eugenol - NOUN O 
to - PART O 
inhibit - VERB O 
Rhizopus PROPN - B-MEDICINE 
stolonifer - NOUN O 
and - CCONJ O 
the - DET O 
control - NOUN O 
of - ADP O 
postharvest - NOUN O 
soft - ADJ O 
rot - NOUN O 
decay - NOUN O 
in - ADP O 
peaches - NOUN O 
. - PUNCT O 

Carvacrol - NOUN O 
and - CCONJ O 
eugenol - NOUN O 
effectively - ADV O 
inhibit - VERB O 
Rhizopus PROPN - B-MEDICINE 
stolonifer - NOUN O 
and - CCONJ O 
control - VERB O 
postharvest - NOUN O 
soft - ADJ O 
rot - NOUN O 
decay - NOUN O 
in - ADP O 
peaches - NOUN O 
. - PUNCT O 

Additionally - ADV O 
, - PUNCT O 
Mucor PROPN - B-ORG 
and - CCONJ O 
Rhizopus PROPN - B-MEDICINE 
spp - NOUN O 
. - PUNCT O 
are - VERB O 
utilized - VERB O 
in - ADP O 
the - DET O 
production - NOUN O 
of - ADP O 
traditional - ADJ O 
fermented - ADJ O 
foods - NOUN O 
including - VERB O 
mold - NOUN O 
ripened - VERB O 
cheeses - NOUN O 
and - CCONJ O 
fermented - ADJ O 
soy - NOUN O 
products - NOUN O 
. - PUNCT O 

; - PUNCT O 
molds - NOUN O 
: - PUNCT O 
Aspergillus - PROPN O 
spp.(N=7 - PROPN O 
) - PUNCT O 
; - PUNCT O 
Fusarium - NOUN O 
spp.(N=2 - PROPN O 
) - PUNCT O 
; - PUNCT O 
Rhizopus PROPN - B-MEDICINE 
oryzae(N=2)]. - NOUN O 

The - DET O 
brown - ADJ O 
rot - VERB O 
fungus - NOUN O 
Rhizopus PROPN - B-MEDICINE 
delemar - NOUN O 
F2 - PROPN O 
was - VERB O 
shown - VERB O 
to - PART O 
produce - VERB O 
extracellular - NOUN O 
thermostable - NOUN O 
and - CCONJ O 
multiple - ADJ O 
carbohydrase - NOUN O 
enzymes - NOUN O 
. - PUNCT O 

The - DET O 
potential - NOUN O 
of - ADP O 
Rhizopus PROPN - B-MEDICINE 
delemar - NOUN O 
F2 - NOUN O 
in - ADP O 
utilizing - VERB O 
apple - NOUN O 
pomace - NOUN O 
under - ADP O 
solid - ADJ O 
state - NOUN O 
fermentation - NOUN O 
( - PUNCT O 
SSF PROPN - B-ORG 
) - PUNCT O 
is - VERB O 
the - DET O 
purpose - NOUN O 
of - ADP O 
the - DET O 
study - NOUN O 
. - PUNCT O 

Utilization - NOUN O 
of - ADP O 
horticultural - ADJ O 
waste - NOUN O 
( - PUNCT O 
Apple PROPN - B-ORG 
Pomace PROPN - I-ORG 
) - PUNCT O 
for - ADP O 
multiple - ADJ O 
carbohydrase - NOUN O 
production - NOUN O 
from - ADP O 
Rhizopus PROPN - B-MEDICINE 
delemar - NOUN O 
F2 - NOUN O 
under - ADP O 
solid - ADJ O 
state - NOUN O 
fermentation - NOUN O 
. - PUNCT O 

Primary - ADJ O 
cutaneous - ADJ O 
Rhizopus PROPN - B-MEDICINE 
folliculitis - NOUN O 
in - ADP O 
an - DET O 
immunocompetent - ADJ O 
woman - NOUN O 
. - PUNCT O 

Due - ADP O 
to - ADP O 
Rhizopus PROPN - B-MEDICINE 
arrhizus - VERB O 
in - ADP O 
an - DET O 
8-Year NUM - B-CARDINAL 
- PUNCT - I-CARDINAL 
Old ADJ - I-CARDINAL 
Girl NOUN - I-CARDINAL 
. PUNCT - I-CARDINAL 

Therefore - ADV O 
, - PUNCT O 
the - DET O 
changes - NOUN O 
in - ADP O 
the - DET O 
structure - NOUN O 
of - ADP O 
Rhizopus PROPN - B-MEDICINE 
chinensis - NOUN O 
lipase - NOUN O 
( - PUNCT O 
RCL PROPN - B-ORG 
) - PUNCT O 
after - ADP O 
high - ADJ O 
hydrostatic - ADJ O 
pressure - NOUN O 
treatment - NOUN O 
were - VERB O 
investigated - VERB O 
. - PUNCT O 

The - DET O 
present - ADJ O 
study - NOUN O 
focused - VERB O 
on - ADP O 
the - DET O 
changes - NOUN O 
in - ADP O 
polyphenols - NOUN O 
, - PUNCT O 
antioxidant - NOUN O 
activities - NOUN O 
and - CCONJ O 
lipid - ADJ O 
compositions - NOUN O 
from - ADP O 
chokeberry - ADJ O 
pomace - NOUN O 
during - ADP O 
solid - ADJ O 
- - PUNCT O 
state - NOUN O 
fermentation - NOUN O 
( - PUNCT O 
SSF NOUN - B-ORG 
) - PUNCT O 
with - ADP O 
Aspergillus PROPN - B-ORG 
niger - NOUN O 
and - CCONJ O 
Rhizopus PROPN - B-MEDICINE 
oligosporus - NOUN O 
. - PUNCT O 

Liberation - NOUN O 
and - CCONJ O 
recovery - NOUN O 
of - ADP O 
phenolic - NOUN O 
antioxidants - NOUN O 
and - CCONJ O 
lipids - NOUN O 
in - ADP O 
chokeberry - NOUN O 
( - PUNCT O 
Aronia PROPN - B-GPE 
melanocarpa - NOUN O 
) - PUNCT O 
pomace - NOUN O 
by - ADP O 
solid - ADJ O 
- - PUNCT O 
state - NOUN O 
bioprocessing - NOUN O 
using - VERB O 
Aspergillus ADV - B-ORG 
niger - NOUN O 
and - CCONJ O 
Rhizopus PROPN - B-MEDICINE 
oligosporus - NOUN O 
strains - VERB O 

This - DET O 
study - NOUN O 
evaluated - VERB O 
the - DET O 
efficacy - NOUN O 
of - ADP O 
coatings - NOUN O 
comprising - VERB O 
gum - NOUN O 
arabic - NOUN O 
( - PUNCT O 
GA PROPN - B-ORG 
) - PUNCT O 
and - CCONJ O 
essential - ADJ O 
oils - NOUN O 
from - ADP O 
Origanum PROPN - B-GPE 
vulgare - VERB O 
L. PROPN - B-PERSON 
( - PUNCT O 
OVEO PROPN - B-ORG 
) - PUNCT O 
and - CCONJ O 
Rosmarinus PROPN - B-ORG 
officinalis - NOUN O 
L. PROPN - B-PERSON 
( - PUNCT O 
ROEO PROPN - B-ORG 
) - PUNCT O 
to - PART O 
control - VERB O 
Rhizopus PROPN - B-MEDICINE 
soft - ADJ O 
rot - NOUN O 
and - CCONJ O 
quality - NOUN O 
of - ADP O 
plums - NOUN O 
( - PUNCT O 
Prunus - PROPN O 
domestica - PROPN O 
L. PROPN - B-PERSON 
) - PUNCT O 
during - ADP O 
storage - NOUN O 
at - ADP O 
room - NOUN O 
( - PUNCT O 
25Â NUM - B-CARDINAL 
° - PROPN O 
C - NOUN O 
; - PUNCT O 
12 NUM - B-DATE 
days NOUN - I-DATE 
) - PUNCT O 
and - CCONJ O 
cold - ADJ O 
( - PUNCT O 
12Â - NUM O 
° PROPN - B-PERSON 
C PROPN - I-PERSON 
; - PUNCT O 
24 NUM - B-DATE 
days NOUN - I-DATE 
) - PUNCT O 
temperatures - NOUN O 
. - PUNCT O 

In - ADP O 
plums - NOUN O 
, - PUNCT O 
the - DET O 
reduction - NOUN O 
of - ADP O 
postharvest - ADJ O 
quality - NOUN O 
losses - NOUN O 
resulting - VERB O 
from - ADP O 
decay - NOUN O 
caused - VERB O 
by - ADP O 
Rhizopus PROPN - B-MEDICINE 
stolonifer - NOUN O 
contamination - NOUN O 
or - CCONJ O 
by - ADP O 
the - DET O 
ripening - NOUN O 
process - NOUN O 
is - VERB O 
a - DET O 
major - ADJ O 
goal - NOUN O 
of - ADP O 
postharvest - ADJ O 
technology - NOUN O 
, - PUNCT O 
which - ADJ O 
increase - VERB O 
attention - NOUN O 
to - PART O 
use - VERB O 
environmental - ADJ O 
friendly - ADJ O 
methods - NOUN O 
as - ADP O 
postharvest - ADJ O 
treatment - NOUN O 
of - ADP O 
fruit - NOUN O 
. - PUNCT O 

This - DET O 
study - NOUN O 
evaluated - VERB O 
coatings - NOUN O 
containing - VERB O 
reduced - VERB O 
amounts - NOUN O 
of - ADP O 
oregano - NOUN O 
and - CCONJ O 
rosemary - ADJ O 
essential - ADJ O 
oils - NOUN O 
in - ADP O 
combination - NOUN O 
as - ADP O 
postharvest - ADJ O 
treatment - NOUN O 
to - PART O 
control - VERB O 
Rhizopus PROPN - B-MEDICINE 
soft - ADJ O 
rot - NOUN O 
in - ADP O 
plums - NOUN O 
( - PUNCT O 
Prunus - PROPN O 
domestica - PROPN O 
) - PUNCT O 
, - PUNCT O 
as - ADV O 
well - ADV O 
as - ADP O 
their - ADJ O 
effects - NOUN O 
on - ADP O 
the - DET O 
quality - NOUN O 
attributes - NOUN O 
of - ADP O 
this - DET O 
fruit - NOUN O 
during - ADP O 
storage - NOUN O 
. - PUNCT O 

Control - NOUN O 
of - ADP O 
Rhizopus PROPN - B-MEDICINE 
soft - ADJ O 
rot - NOUN O 
and - CCONJ O 
quality - NOUN O 
responses - NOUN O 
in - ADP O 
plums - NOUN O 
( - PUNCT O 
Prunus PROPN - B-NORP 
domestica - PROPN O 
L. PROPN - B-PERSON 
) - PUNCT O 
coated - VERB O 
with - ADP O 
gum - NOUN O 
arabic - ADJ O 
, - PUNCT O 
oregano - NOUN O 
and - CCONJ O 
rosemary - ADJ O 
essential - ADJ O 
oils - NOUN O 

In - ADP O 
order - NOUN O 
to - PART O 
improve - VERB O 
the - DET O 
quality - NOUN O 
and - CCONJ O 
functionality - NOUN O 
of - ADP O 
Makgeolli PROPN - B-ORG 
, - PUNCT O 
the - DET O 
Rhizopus PROPN - B-MEDICINE 
oligosporus - NOUN O 
fermented - VERB O 
buckwheat - NOUN O 
containing - VERB O 
18.7 NUM - B-CARDINAL 
  - SPACE O 
mg - NOUN O 
/ - SYM O 
kg - NOUN O 
of - ADP O 
l - NOUN O 
- - PUNCT O 
carnitine - NOUN O 
were - VERB O 
utilized - VERB O 
to - PART O 
brew - VERB O 
l - NOUN O 
- - PUNCT O 
carnitine - NOUN O 
fortified - VERB O 
Makgeolli PROPN - B-ORG 
with - ADP O 
rice - NOUN O 
. - PUNCT O 

B. - NOUN O 
subtilis - NOUN O 
B9 - PROPN O 
- - PUNCT O 
5 - NUM O 
significantly - ADV O 
inhibited - VERB O 
mycelial - ADJ O 
growth - NOUN O 
and - CCONJ O 
spore - ADJ O 
germination - NOUN O 
of - ADP O 
Fusarium PROPN - B-ORG 
sambucinum - NOUN O 
and - CCONJ O 
Verticillium PROPN - B-ORG 
dahliae - NOUN O 
, - PUNCT O 
but - CCONJ O 
not - ADV O 
Rhizopus PROPN - B-MEDICINE 
stolonifer - NOUN O 
. - PUNCT O 

With - ADP O 
co - NOUN O 
- - NOUN O 
cultures - NOUN O 
of - ADP O 
the - DET O 
tolerant - ADJ O 
fungus - NOUN O 
Rhizopus PROPN - B-MEDICINE 
stolonifer - NOUN O 
, - PUNCT O 
B. - PROPN O 
subtilis - NOUN O 
produced - VERB O 
high - ADJ O 
amounts - NOUN O 
of - ADP O 
CLPs - PROPN O 
( - PUNCT O 
per - ADP O 
bacterial - ADJ O 
cell - NOUN O 
) - PUNCT O 
for - ADP O 
the - DET O 
duration - NOUN O 
of - ADP O 
the - DET O 
interaction - NOUN O 
. - PUNCT O 

Rhinocerebral - ADJ O 
mucormycosis - NOUN O 
caused - VERB O 
by - ADP O 
Rhizopus PROPN - B-MEDICINE 
arrhizus - PROPN O 
var - NOUN O 
. - PUNCT O 

Although - ADP O 
infections - NOUN O 
with - ADP O 
fungi - NOUN O 
, - PUNCT O 
such - ADJ O 
as - ADP O 
Rhizopus PROPN - B-MEDICINE 
species - NOUN O 
, - PUNCT O 
usually - ADV O 
occur - VERB O 
in - ADP O 
diabetics - NOUN O 
or - CCONJ O 
immunocompromised - VERB O 
patients - NOUN O 
, - PUNCT O 
they - PRON O 
can - VERB O 
also - ADV O 
rarely - ADV O 
affect - VERB O 
immunocompetent - ADJ O 
individuals - NOUN O 
. - PUNCT O 

We - PRON O 
present - VERB O 
a - DET O 
case - NOUN O 
of - ADP O 
disseminated - ADJ O 
infection - NOUN O 
with - ADP O 
multiple - ADJ O 
cold - ADJ O 
abscesses - NOUN O 
in - ADP O 
a - DET O 
13-year NUM - B-CARDINAL 
, - PUNCT O 
otherwise - ADV O 
healthy - ADJ O 
girl - NOUN O 
caused - VERB O 
by - ADP O 
Rhizopus PROPN - B-MEDICINE 
arrhizus - PROPN O 
. - PUNCT O 

Enhanced - VERB O 
vitamin - NOUN O 
B12 - PROPN O 
production - NOUN O 
in - ADP O 
an - DET O 
innovative - ADJ O 
lupin - NOUN O 
tempeh - NOUN O 
is - VERB O 
due - ADJ O 
to - ADP O 
synergic - ADJ O 
effects - NOUN O 
of - ADP O 
Rhizopus PROPN - B-MEDICINE 
and CCONJ - I-ORG 
Propionibacterium PROPN - I-ORG 
in - ADP O 
cofermentation - NOUN O 
. - PUNCT O 

Among - ADP O 
the - DET O 
recovered - VERB O 
isolates - NOUN O 
, - PUNCT O 
27 NUM - B-CARDINAL 
Rhizopus PROPN - B-MEDICINE 
arrhizus - NOUN O 
, - PUNCT O 
11 NUM - B-CARDINAL 
Mucor PROPN - B-ORG 
circinelloides - VERB O 
, - PUNCT O 
one NUM - B-CARDINAL 
Lichtheimia PROPN - B-NORP 
corymbifera - NOUN O 
, - PUNCT O 
one NUM - B-CARDINAL 
Rhizopus PROPN - B-MEDICINE 
microsporus - NOUN O 
and - CCONJ O 
one NUM - B-CARDINAL 
Cunninghamella PROPN - B-ORG 
bertholletiae - VERB O 
were - VERB O 
found - VERB O 
. - PUNCT O 

We - PRON O 
measured - VERB O 
the - DET O 
in - X O 
vitro - X O 
activity - NOUN O 
of - ADP O 
VT-1598 PROPN - B-ORG 
against - ADP O 
clinical - ADJ O 
isolates - NOUN O 
of - ADP O 
Candida PROPN - B-ORG 
and CCONJ - I-ORG 
Cryptococcus PROPN - I-ORG 
species - NOUN O 
, - PUNCT O 
endemic - NOUN O 
fungi - NOUN O 
, - PUNCT O 
including - VERB O 
Coccidioides PROPN - B-ORG 
, - PUNCT O 
Blastomyces PROPN - B-ORG 
and - CCONJ O 
Histoplasma PROPN - B-PERSON 
, - PUNCT O 
Aspergillus - PROPN O 
species - NOUN O 
and - CCONJ O 
Rhizopus PROPN - B-MEDICINE 
arrhizus - PROPN O 
. - PUNCT O 

Fungal - ADJ O 
- - PUNCT O 
specific - ADJ O 
Cyp51 PROPN - B-ORG 
inhibitor - NOUN O 
VT-1598 PROPN - B-ORG 
demonstrates - VERB O 
in - ADP O 
vitro - ADJ O 
activity - NOUN O 
against - ADP O 
Candida PROPN - B-GPE 
and - CCONJ O 
Cryptococcus - PROPN O 
species - NOUN O 
, - PUNCT O 
endemic - NOUN O 
fungi - NOUN O 
, - PUNCT O 
including - VERB O 
Coccidioides PROPN - B-NORP 
species - NOUN O 
, - PUNCT O 
Aspergillus PROPN - B-ORG 
species - NOUN O 
and - CCONJ O 
Rhizopus PROPN - B-MEDICINE 
arrhizus - PROPN O 
. - PUNCT O 

Coupled - ADJ O 
effects - NOUN O 
of - ADP O 
salt - NOUN O 
and - CCONJ O 
pressure - NOUN O 
on - ADP O 
catalytic - ADJ O 
ability - NOUN O 
of - ADP O 
Rhizopus PROPN - B-MEDICINE 
chinensis - NOUN O 
lipase - NOUN O 

niger - ADV O 
, - PUNCT O 
Mucor PROPN - B-ORG 
wutungkiao - NOUN O 
, - PUNCT O 
Penicillium PROPN - B-ORG 
funiculosum - NOUN O 
, - PUNCT O 
and - CCONJ O 
Rhizopus PROPN - B-MEDICINE 
oryzae - VERB O 
at - ADP O 
2.00 NUM - B-CARDINAL 
μL PROPN - B-ORG 
/ SYM - I-ORG 
mLair PROPN - I-ORG 
concentration - NOUN O 
, - PUNCT O 
respectively - ADV O 
. - PUNCT O 

We - PRON O 
searched - VERB O 
for - ADP O 
secreted - ADJ O 
or - CCONJ O 
membrane - ADJ O 
- - PUNCT O 
bound - VERB O 
proteins - NOUN O 
of - ADP O 
Rhizopus ADJ - B-MEDICINE 
oryzae - NOUN O 
, - PUNCT O 
which - ADJ O 
is - VERB O 
the - DET O 
most - ADV O 
common - ADJ O 
pathogen - NOUN O 
of - ADP O 
mucormycosis - NOUN O 
, - PUNCT O 
using - VERB O 
the - DET O 
method - NOUN O 
of - ADP O 
a - DET O 
signal - ADJ O 
sequence - NOUN O 
trap - NOUN O 
by - ADP O 
retrovirus - NOUN O 
- - PUNCT O 
mediated - VERB O 
expression - NOUN O 
( - PUNCT O 
SST PROPN - B-ORG 
- PUNCT - I-ORG 
REX PROPN - I-ORG 
) - PUNCT O 
. - PUNCT O 

Among - ADP O 
the - DET O 
identified - VERB O 
proteins - NOUN O 
, - PUNCT O 
a - DET O 
Rhizopus NOUN - B-MEDICINE 
- - PUNCT O 
specific - ADJ O 
antigen - NOUN O 
was - VERB O 
selected - VERB O 
as - ADP O 
a - DET O 
candidate - NOUN O 
, - PUNCT O 
and - CCONJ O 
efficacy - NOUN O 
of - ADP O 
this - DET O 
specific - ADJ O 
antigen - NOUN O 
was - VERB O 
evaluated - VERB O 
using - VERB O 
R. PROPN - B-NORP 
oryzae - NOUN O 
- - PUNCT O 
infected - VERB O 
mice - NOUN O 
. - PUNCT O 

In - ADP O 
this - DET O 
regard - NOUN O 
, - PUNCT O 
a - DET O 
correlation - NOUN O 
was - VERB O 
obtained - VERB O 
between - ADP O 
oxygen - NOUN O 
uptake - NOUN O 
rate - NOUN O 
( - PUNCT O 
OUR - PROPN O 
) - PUNCT O 
and - CCONJ O 
biomass - NOUN O 
concentration - NOUN O 
( - PUNCT O 
X - PROPN O 
) - PUNCT O 
of - ADP O 
Rhizopus PROPN - B-MEDICINE 
oryzae - VERB O 
MTCC - PROPN O 
1987 NUM - B-DATE 
, - PUNCT O 
during - ADP O 
phytase - NOUN O 
production - NOUN O 
, - PUNCT O 
in - ADP O 
an - DET O 
intermittently - ADV O 
mixed - ADJ O 
novel - NOUN O 
SSF NOUN - B-ORG 
bioreactor - NOUN O 
. - PUNCT O 

Advanced - PROPN O 
Effect - PROPN O 
of - ADP O 
Moringa - PROPN O 
oleifera - NOUN O 
Bioconversion - PROPN O 
by - ADP O 
Rhizopus PROPN - B-MEDICINE 
oligosporus - NOUN O 
on - ADP O 
the - DET O 
Treatment - PROPN O 
of - ADP O 
Atopic - PROPN O 
Dermatitis - NOUN O 
: - PUNCT O 
Preliminary - PROPN O 
Study - PROPN O 
. - PUNCT O 

Moreover - ADV O 
, - PUNCT O 
Pneumocystis PROPN - B-ORG 
, PUNCT - I-ORG 
Cryptococcus PROPN - I-ORG 
, PUNCT - I-ORG 
Fusarium PROPN - I-ORG 
and - CCONJ O 
Rhizopus PROPN - B-MEDICINE 
can - VERB O 
cause - VERB O 
devastating - ADJ O 
illnesses - NOUN O 
. - PUNCT O 

The - DET O 
study - NOUN O 
was - VERB O 
aimed - VERB O 
at - ADP O 
production - NOUN O 
of - ADP O 
different - ADJ O 
organic - ADJ O 
acids - NOUN O 
( - PUNCT O 
OA - PROPN O 
) - PUNCT O 
( - PUNCT O 
lactic - ADJ O 
, - PUNCT O 
fumaric - ADJ O 
, - PUNCT O 
or - CCONJ O 
succinic - ADJ O 
) - PUNCT O 
by - ADP O 
various - ADJ O 
microbial - ADJ O 
cells - NOUN O 
( - PUNCT O 
filamentous - ADJ O 
fungi - NOUN O 
Rhizopus NOUN - B-MEDICINE 
oryzae - NOUN O 
( - PUNCT O 
F-814 PROPN - B-ORG 
, - PUNCT O 
F-1127 - NOUN O 
) - PUNCT O 
and - CCONJ O 
bacteria - NOUN O 
Actinobacillus - PROPN O 
succinogenes - NOUN O 
B-10111 PROPN - B-PERSON 
) - PUNCT O 
immobilized - VERB O 
into - ADP O 
poly(vinyl - SYM O 
alcohol - NOUN O 
) - PUNCT O 

, - PUNCT O 
Rhizopus PROPN - B-MEDICINE 
spp - NOUN O 
. - PUNCT O 

Fungal - ADJ O 
isolates - NOUN O 
belonged - VERB O 
to - PART O 
genera - VERB O 
Aspergillus PROPN - B-PERSON 
, - PUNCT O 
Emericella PROPN - B-PERSON 
, - PUNCT O 
Rhizopus PROPN - B-MEDICINE 
, - PUNCT O 
Actinomucor PROPN - B-ORG 
and - CCONJ O 
Apophysomyces PROPN - B-GPE 
with - ADP O 
two NUM - B-CARDINAL 
undescribed - ADJ O 
species - NOUN O 
. - PUNCT O 

Aspergillus - ADV O 
variecolor - NOUN O 
, - PUNCT O 
Aspergillus - PROPN O 
quadrilinieatus - NOUN O 
, - PUNCT O 
Aspergillus - PROPN O 
tubingensis - NOUN O 
, - PUNCT O 
Rhizopus PROPN - B-MEDICINE 
oryzae - NOUN O 
, - PUNCT O 
Actinomucor PROPN - B-ORG 
elegans - NOUN O 
and - CCONJ O 
Apophysomyces - PROPN O 
variabilis - NOUN O 
were - VERB O 
firstly - ADV O 
detected - VERB O 
in - ADP O 
all - DET O 
sea - NOUN O 
turtle - NOUN O 
nests - NOUN O 
within - ADP O 
this - DET O 
study - NOUN O 
. - PUNCT O 

The - DET O 
lipase - NOUN O 
gene - NOUN O 
proRCL - PRON O 
from - ADP O 
Rhizopus PROPN - B-MEDICINE 
microsporus - NOUN O 
var - NOUN O 
. - PUNCT O 

chinensis - NOUN O 
( - PUNCT O 
also - ADV O 
Rhizopus PROPN - B-MEDICINE 
chinensis - NOUN O 
) - PUNCT O 

The - DET O 
present - ADJ O 
work - NOUN O 
was - VERB O 
designed - VERB O 
to - PART O 
investigate - VERB O 
the - DET O 
phenolic - NOUN O 
profiles - NOUN O 
, - PUNCT O 
DNA - NOUN O 
damage - NOUN O 
protection - NOUN O 
and - CCONJ O 
antiâinflammatory - ADJ O 
effects - NOUN O 
of - ADP O 
Tartary - PROPN O 
buckwheat - NOUN O 
fermented - VERB O 
by - ADP O 
Rhizopus PROPN - B-MEDICINE 
oryzae - VERB O 
40469 - NUM O 
, - PUNCT O 
Rhizopus PROPN - B-MEDICINE 
oryzae - VERB O 
40503 NUM - B-DATE 
and - CCONJ O 
Rhizopus PROPN - B-MEDICINE 
oligosporus - NOUN O 
3152 - NUM O 
. - PUNCT O 

Oats - PROPN O 
were - VERB O 
fermented - VERB O 
by - ADP O 
Lactobacillus PROPN - B-ORG 
plantarum - NOUN O 
B1 PROPN - B-DATE 
- PUNCT - I-DATE 
6 NUM - I-DATE 
, - PUNCT O 
Rhizopus PROPN - B-MEDICINE 
oryzae - NOUN O 
, - PUNCT O 
or - CCONJ O 
a - DET O 
combination - NOUN O 
of - ADP O 
L. PROPN - B-PERSON 
plantarum - NOUN O 
B1 PROPN - B-CARDINAL 
- - PUNCT O 
6 - NUM O 
and - CCONJ O 
R. PROPN - B-NORP 
oryzae - NOUN O 
. - PUNCT O 

Starter - NOUN O 
microbiota - NOUN O 
were - VERB O 
dominated - VERB O 
by - ADP O 
the - DET O 
Rhizopus PROPN - B-MEDICINE 
genus - NOUN O 
in - ADP O 
SZ5 PROPN - B-GPE 
, PUNCT - I-GPE 
LS6 PROPN - B-GPE 
, - PUNCT O 
NN8 PROPN - B-GPE 
, - PUNCT O 
QD9 PROPN - B-ORG 
, - PUNCT O 
DZ10 PROPN - B-ORG 
and - CCONJ O 
DZ11 - PROPN O 
, - PUNCT O 
indicating - VERB O 
its - ADJ O 
important - ADJ O 
role - NOUN O 
in - ADP O 
starch - ADJ O 
hydrolysis - NOUN O 
during - ADP O 
CSRW - PROPN O 
brewing - NOUN O 
. - PUNCT O 

A - DET O 
diagnosis - NOUN O 
of - ADP O 
pulmonary - ADJ O 
mucormycosis - NOUN O 
( - PUNCT O 
Rhizopus PROPN - B-MEDICINE 
microsporus - NOUN O 
) - PUNCT O 
was - VERB O 
made - VERB O 
based - VERB O 
on - ADP O 
microbiology - NOUN O 
results - NOUN O 
from - ADP O 
pleural - ADJ O 
aspirate - NOUN O 
, - PUNCT O 
and - CCONJ O 
patient - NOUN O 
was - VERB O 
treated - VERB O 
with - ADP O 
intravenous - ADJ O 
antifungals - NOUN O 
. - PUNCT O 

Bacteria - NOUN O 
such - ADJ O 
as - ADP O 
Lysobacter PROPN - B-ORG 
, PUNCT - I-ORG 
Spingomonas PROPN - I-ORG 
and CCONJ - I-ORG 
Haliangium PROPN - I-ORG 
of ADP - I-ORG 
Proteobacteria PROPN - I-ORG 
; - PUNCT O 
Actinomadura PROPN - B-GPE 
and - CCONJ O 
Lamia PROPN - B-GPE 
of - ADP O 
Actinobacteria PROPN - B-GPE 
; - PUNCT O 
and - CCONJ O 
unidentified - ADJ O 
Acidobacteria PROPN - B-GPE 
of - ADP O 
Acidobacteria PROPN - B-GPE 
as - ADV O 
well - ADV O 
as - ADP O 
fungi - ADV O 
such - ADJ O 
as - ADP O 
Talaromyces PROPN - B-GPE 
and - CCONJ O 
Fusarium - PROPN O 
of - ADP O 
Ascomycota - PROPN O 
and - CCONJ O 
Rhizopus PROPN - B-MEDICINE 
of - ADP O 
Zygomycota PROPN - B-GPE 
were - VERB O 
dominant - ADJ O 
in - ADP O 
the - DET O 
rhizosphere - NOUN O 
soil - NOUN O 
of - ADP O 
maize - NOUN O 
. - PUNCT O 

Our - ADJ O 
previous - ADJ O 
studies - NOUN O 
demonstrated - VERB O 
that - ADP O 
the - DET O 
N - NOUN O 
- - PUNCT O 
glycans - NOUN O 
in - ADP O 
Rhizopus NOUN - B-MEDICINE 
chinensis - NOUN O 
lipase - NOUN O 
( - PUNCT O 
RCL PROPN - B-ORG 
) - PUNCT O 
was - VERB O 
important - ADJ O 
for - ADP O 
its - ADJ O 
secretion - NOUN O 
. - PUNCT O 

In - ADP O 
order - NOUN O 
to - PART O 
improve - VERB O 
the - DET O 
secretion - NOUN O 
of - ADP O 
Rhizopus PROPN - B-MEDICINE 
oryzae - NOUN O 
lipase - NOUN O 
( - PUNCT O 
ROL PROPN - B-ORG 
) - PUNCT O 
under - ADP O 
the - DET O 
control - NOUN O 
of - ADP O 
the - DET O 
GAP PROPN - B-ORG 
promoter - NOUN O 
in - ADP O 
Komagataella PROPN - B-GPE 
phaffii - NOUN O 
, - PUNCT O 
two NUM - B-CARDINAL 
extra - ADJ O 
N - NOUN O 
- - PUNCT O 
glycosylation - NOUN O 
sites - NOUN O 
were - VERB O 
introduced - VERB O 
in - ADP O 
ROL PROPN - B-ORG 
according - VERB O 
to - ADP O 
the - DET O 
position - NOUN O 
of - ADP O 
the - DET O 
N NUM - B-ORG 
- - PUNCT O 
glycosylation - NOUN O 
sites - NOUN O 
of - ADP O 
RCL PROPN - B-ORG 
by - ADP O 
sequence - NOUN O 
alignment - NOUN O 
. - PUNCT O 

Finally - ADV O 
, - PUNCT O 
by - ADP O 
using - VERB O 
the - DET O 
fluorescent - ADJ O 
probe - NOUN O 
, - PUNCT O 
two NUM - B-CARDINAL 
target - NOUN O 
fungi - NOUN O 
were - VERB O 
isolated - VERB O 
and - CCONJ O 
identified - VERB O 
to - PART O 
be - VERB O 
Rhizopus PROPN - B-MEDICINE 
oryzae - NOUN O 
and - CCONJ O 
Mucor PROPN - B-ORG 
circinelloides - NOUN O 
by - ADP O 
molecular - ADJ O 
analysis - NOUN O 
, - PUNCT O 
and - CCONJ O 
they - PRON O 
exhibited - VERB O 
a - DET O 
robust - ADJ O 
capability - NOUN O 
for - ADP O 
regio- - NOUN O 
and - CCONJ O 
stereospecific - ADJ O 
O - NOUN O 
- - PUNCT O 
glycosylation - NOUN O 
. - PUNCT O 

Moreover - ADV O 
, - PUNCT O 
changes - NOUN O 
in - ADP O 
the - DET O 
functional - ADJ O 
levels - NOUN O 
were - VERB O 
monitored - VERB O 
, - PUNCT O 
and - CCONJ O 
metaproteomic - ADJ O 
analysis - NOUN O 
revealed - VERB O 
that - ADP O 
most - ADJ O 
of - ADP O 
the - DET O 
proteins - NOUN O 
were - VERB O 
mainly - ADV O 
expressed - VERB O 
by - ADP O 
members - NOUN O 
of - ADP O 
Rhizopus PROPN - B-MEDICINE 
, PUNCT - I-ORG 
Penicillium PROPN - I-ORG 
and CCONJ - I-ORG 
Geotrichum PROPN - I-ORG 
. - PUNCT O 

Soursop - PROPN O 
( - PUNCT O 
Annona PROPN - B-GPE 
muricata - NOUN O 
) - PUNCT O 
is - VERB O 
a - DET O 
tropical - ADJ O 
fruit - NOUN O 
that - ADJ O 
can - VERB O 
be - VERB O 
infected - VERB O 
by - ADP O 
Colletotrichum PROPN - B-NORP 
gloeosporioides - NOUN O 
and - CCONJ O 
Rhizopus PROPN - B-MEDICINE 
stolonifer - NOUN O 
. - PUNCT O 

In - ADP O 
this - DET O 
study - NOUN O 
, - PUNCT O 
Colletotrichum PROPN - B-NORP 
was - VERB O 
reactivated - VERB O 
and - CCONJ O 
Rhizopus PROPN - B-MEDICINE 
was - VERB O 
identified - VERB O 
using - VERB O 
morphological - ADJ O 
features - NOUN O 
and - CCONJ O 
molecular - ADJ O 
tools - NOUN O 
. - PUNCT O 

One NUM - B-CARDINAL 
steroid - NOUN O 
- - PUNCT O 
treated - VERB O 
patient - NOUN O 
with - ADP O 
diabetes - NOUN O 
died - VERB O 
6 NUM - B-DATE 
weeks NOUN - I-DATE 
after - ADP O 
biopsy - NOUN O 
, - PUNCT O 
with - ADP O 
invasive - ADJ O 
rhinoorbital - ADJ O 
Rhizopus PROPN - B-MEDICINE 
infection - NOUN O 
. - PUNCT O 

With - ADP O 
glutaraldehyde - NOUN O 
, - PUNCT O 
as - ADP O 
the - DET O 
coupling - VERB O 
agent - NOUN O 
, - PUNCT O 
the - DET O 
lipase - NOUN O 
from - ADP O 
Rhizopus PROPN - B-MEDICINE 
oryzae - NOUN O 
was - VERB O 
successfully - ADV O 
immobilized - VERB O 
onto - ADP O 
the - DET O 
amino - NOUN O 
- - PUNCT O 
functionalized - ADJ O 
magnetic - ADJ O 
nanoparticles - NOUN O 
. - PUNCT O 

In - ADP O 
this - DET O 
study - NOUN O 
, - PUNCT O 
we - PRON O 
aimed - VERB O 
to - PART O 
increase - VERB O 
the - DET O 
titer - NOUN O 
of - ADP O 
FA PROPN - B-ORG 
production - NOUN O 
by - ADP O 
using - VERB O 
an - DET O 
improved - ADJ O 
Rhizopus PROPN - B-MEDICINE 
oryzae - VERB O 
WHT5 - PROPN O 
, - PUNCT O 
which - ADJ O 
was - VERB O 
domesticated - VERB O 
to - PART O 
obtain - VERB O 
a - DET O 
furfural - ADJ O 
- - PUNCT O 
resistant - ADJ O 
strain - NOUN O 
in - ADP O 
corncob - NOUN O 
hydrolytes - NOUN O 
. - PUNCT O 

In - ADP O 
2009 NUM - B-DATE 
this - DET O 
tomb - NOUN O 
was - VERB O 
deteriorated - VERB O 
by - ADP O 
" - PUNCT O 
Aspergillus - ADV O 
niger - ADV O 
, - PUNCT O 
A. - NOUN O 
flavus - NOUN O 
, - PUNCT O 
Fusarium NOUN - B-PRODUCT 
moniliforme - NOUN O 
, - PUNCT O 
Alternaria PROPN - B-PERSON 
alternate - NOUN O 
, - PUNCT O 
Rhizopus NOUN - B-MEDICINE 
stolonifera - NOUN O 
, - PUNCT O 
Bacillus - NOUN O 
subtilis - NOUN O 
, - PUNCT O 
Bacillus - NOUN O 
cereus - NOUN O 
, - PUNCT O 
and - CCONJ O 
micrococcus - NOUN O 
iuteus - NOUN O 
. - PUNCT O 

Olanzapine PROPN - B-MEDICINE 
is - VERB O 
a - DET O 
second ADJ - B-ORDINAL 
- - PUNCT O 
generation - NOUN O 
anti - ADJ O 
- - ADJ O 
psychotic - ADJ O 
drug - NOUN O 
used - VERB O 
to - PART O 
prevent - VERB O 
neuroinflammation - NOUN O 
in - ADP O 
patients - NOUN O 
with - ADP O 
schizophrenia - NOUN O 
. - PUNCT O 

Olanzapine PROPN - B-MEDICINE 
medicated - VERB O 
rats - NOUN O 
experienced - VERB O 
weight - NOUN O 
gain - NOUN O 
and - CCONJ O 
adiposity - NOUN O 
, - PUNCT O 
as - ADV O 
well - ADV O 
as - ADP O 
the - DET O 
development - NOUN O 
of - ADP O 
hyperglycemia - NOUN O 
, - PUNCT O 
hyperinsulinemia - NOUN O 
, - PUNCT O 
insulin - NOUN O 
resistance - NOUN O 
, - PUNCT O 
hyperlipidemia - NOUN O 
, - PUNCT O 
and - CCONJ O 
inflammation - NOUN O 
. - PUNCT O 

Olanzapine PROPN - B-MEDICINE 
Induced - VERB O 
Dysmetabolic - PROPN O 
Changes - PROPN O 
Involving - PROPN O 
Tissue - PROPN O 
Chromium - PROPN O 
Mobilization - NOUN O 
in - ADP O 
Female - PROPN O 
Rats - PROPN O 
. - PUNCT O 

Olanzapine NOUN - B-MEDICINE 
pamoate - NOUN O 
is - VERB O 
one - NUM O 
of - ADP O 
the - DET O 
recently - ADV O 
approved - VERB O 
long - ADV O 
- - PUNCT O 
acting - VERB O 
depot - NOUN O 
psychotropic - ADJ O 
preparations - NOUN O 
that - ADJ O 
have - VERB O 
shown - VERB O 
its - ADJ O 
efficacy - NOUN O 
both - CCONJ O 
in - ADP O 
clinical - ADJ O 
trials - NOUN O 
and - CCONJ O 
in - ADP O 
clinical - ADJ O 
uses - NOUN O 
against - ADP O 
the - DET O 
illness - NOUN O 
. - PUNCT O 

Olanzapine NOUN - B-MEDICINE 
- - PUNCT O 
induced - VERB O 
weight - NOUN O 
gain - NOUN O 
and - CCONJ O 
fourteen NUM - B-CARDINAL 
genera - NOUN O 
of - ADP O 
intestinal - ADJ O 
bacteria - NOUN O 
, - PUNCT O 
were - VERB O 
not - ADV O 
influenced - VERB O 
by - ADP O 
sodium - NOUN O 
acetate - NOUN O 
intake - NOUN O 
. - PUNCT O 

A - DET O 
Case - NOUN O 
of - ADP O 
Schizophrenia - PROPN O 
With - ADP O 
Catatonia - PROPN O 
Resistant - PROPN O 
to - ADP O 
Lorazepam PROPN - B-PERSON 
and - CCONJ O 
Olanzapine PROPN - B-MEDICINE 
Monotherapy PROPN - I-PERSON 

Olanzapine NOUN - B-MEDICINE 
pamoate - NOUN O 
has - VERB O 
a - DET O 
higher - ADJ O 
cost - NOUN O 
of - ADP O 
treatment - NOUN O 
than - ADP O 
the - DET O 
oral - ADJ O 
form - NOUN O 
and - CCONJ O 
requires - VERB O 
administration - NOUN O 
in - ADP O 
a - DET O 
hospital - NOUN O 
setting - NOUN O 
( - PUNCT O 
unlike - ADP O 
other - ADJ O 
long - ADV O 
- - PUNCT O 
acting - VERB O 
antipsychotics - NOUN O 
) - PUNCT O 
, - PUNCT O 
and - CCONJ O 
the - DET O 
cost - NOUN O 
- - PUNCT O 
effectiveness - NOUN O 
of - ADP O 
this - DET O 
treatment - NOUN O 
may - VERB O 
be - VERB O 
questioned - VERB O 
. - PUNCT O 

Olanzapine NOUN - B-MEDICINE 
pamoate - VERB O 
significantly - ADV O 
reduced - VERB O 
the - DET O 
number - NOUN O 
of - ADP O 
hospitalizations - NOUN O 
compared - VERB O 
to - ADP O 
the - DET O 
previous - ADJ O 
management - NOUN O 
strategy - NOUN O 
( - PUNCT O 
1 NUM - B-CARDINAL 
less - ADJ O 
hospitalization - NOUN O 
, - PUNCT O 
P<0.001 PROPN - B-PERSON 
in - ADP O 
patients - NOUN O 
treated - VERB O 
more ADJ - B-DATE 
than ADP - I-DATE 
one NUM - I-DATE 
year NOUN - I-DATE 
and - CCONJ O 
in - ADP O 
the - DET O 
general - ADJ O 
cohort - NOUN O 
) - PUNCT O 
. - PUNCT O 

Olanzapine PROPN - B-MEDICINE 
is - VERB O 
a - DET O 
commonly - ADV O 
prescribed - VERB O 
antipsychotic - NOUN O 
available - ADJ O 
as - ADP O 
oral - ADJ O 
and - CCONJ O 
long - ADV O 
- - PUNCT O 
acting - VERB O 
injectable - ADJ O 
( - PUNCT O 
LAI PROPN - B-ORG 
) - PUNCT O 
formulations - NOUN O 
. - PUNCT O 

Olanzapine NOUN - B-MEDICINE 
concentrations - NOUN O 
and - CCONJ O 
doses - NOUN O 
from - ADP O 
8,288 NUM - B-CARDINAL 
patients - NOUN O 
( - PUNCT O 
21,378 NUM - B-QUANTITY 
measurements NOUN - I-QUANTITY 
) - PUNCT O 
were - VERB O 
included - VERB O 
. - PUNCT O 

Age - NOUN O 
Impacts - VERB O 
Olanzapine NOUN - B-MEDICINE 
Exposure - NOUN O 

Olanzapine PROPN - B-MEDICINE 
is - VERB O 
an - DET O 
atypical - ADJ O 
antipsychotic - NOUN O 
widely - ADV O 
used - VERB O 
in - ADP O 
the - DET O 
treatment - NOUN O 
of - ADP O 
schizophrenia - NOUN O 
and - CCONJ O 
bipolar - ADJ O 
disorder - NOUN O 
. - PUNCT O 

Olanzapine NOUN - B-MEDICINE 
treatment - NOUN O 
significantly - ADV O 
increased - VERB O 
fasting - NOUN O 
plasma - NOUN O 
insulin - NOUN O 
concentration - NOUN O 
, - PUNCT O 
the - DET O 
index - NOUN O 
of - ADP O 
the - DET O 
homeostasis - NOUN O 
model - NOUN O 
assessment - NOUN O 
of - ADP O 
insulin - NOUN O 
resistance - NOUN O 
( - PUNCT O 
HOMA PROPN - B-ORG 
- PUNCT - I-ORG 
IR PROPN - I-ORG 
) - PUNCT O 
, - PUNCT O 
and - CCONJ O 
hepatic - ADJ O 
triglyceride - NOUN O 
and - CCONJ O 
fatty - ADJ O 
droplet - NOUN O 
accumulation - NOUN O 
in - ADP O 
rats - NOUN O 
. - PUNCT O 

Olanzapine PROPN - B-MEDICINE 
Versus PROPN - I-GPE 
Placebo PROPN - I-GPE 
in - ADP O 
Adult PROPN - B-ORG 
Outpatients NOUN - I-ORG 
With ADP - I-ORG 
Anorexia PROPN - I-ORG 
Nervosa NOUN - I-ORG 
: - PUNCT O 
A - DET O 
Randomized VERB - B-ORG 
Clinical PROPN - I-ORG 
Trial PROPN - I-ORG 
. - PUNCT O 

Olanzapine NOUN - B-MEDICINE 
treatment - NOUN O 
( - PUNCT O 
mean - VERB O 
[ - PUNCT O 
standard - ADJ O 
deviation - NOUN O 
] - PUNCT O 
duration - NOUN O 
  - SPACE O 
= - PUNCT O 
  - SPACE O 
12.3 NUM - B-CARDINAL 
[ - PUNCT O 
7.6 NUM - B-DATE 
] PUNCT - I-DATE 
weeks NOUN - I-DATE 
) - PUNCT O 
was - VERB O 
associated - VERB O 
with - ADP O 
a - DET O 
significant - ADJ O 
decrease - NOUN O 
in - ADP O 
blood - NOUN O 
ghrelin - NOUN O 
levels - NOUN O 
with - ADP O 
a - DET O 
medium - ADJ O 
effect - NOUN O 
size - NOUN O 
( - PUNCT O 
SMD - PROPN O 
  - SPACE O 
= - SYM O 
  - SPACE O 
-0.48 - PUNCT O 
, - PUNCT O 
95 NUM - B-PERCENT 
% NOUN - I-PERCENT 
CI PROPN - B-ORG 
-0.88 - PROPN O 
to - ADP O 
-0.08 - PRON O 
, - PUNCT O 
p - X O 
  - SPACE O 
= - SYM O 
  - SPACE O 
0.018 NUM - B-CARDINAL 
) - PUNCT O 
. - PUNCT O 

Olanzapine PROPN - B-MEDICINE 
dose - NOUN O 
was - VERB O 
inversely - ADV O 
correlated - VERB O 
with - ADP O 
the - DET O 
drug - NOUN O 
efficacy - NOUN O 
( - PUNCT O 
p - VERB O 
  - SPACE O 

Olanzapine NOUN - B-MEDICINE 
treatment - NOUN O 
outcome - NOUN O 
is - VERB O 
also - ADV O 
affected - VERB O 
by - ADP O 
dose - NOUN O 
, - PUNCT O 
sex - NOUN O 
, - PUNCT O 
age - NOUN O 
and - CCONJ O 
CYP2D6 NOUN - B-PERSON 
metabolizer - NOUN O 
status - NOUN O 
. - PUNCT O 

Olanzapine NOUN - B-MEDICINE 
and - CCONJ O 
droperidol - ADJ O 
lead - NOUN O 
to - ADP O 
lower - ADJ O 
rates - NOUN O 
of - ADP O 
rescue - NOUN O 
sedation - NOUN O 
at - ADP O 
1 NUM - B-CARDINAL 
  - SPACE O 
h - NOUN O 
and - CCONJ O 
overall - ADV O 
, - PUNCT O 
compared - VERB O 
with - ADP O 
haloperidol - NOUN O 
. - PUNCT O 

Reference - PROPN O 
Brain - PROPN O 
and - CCONJ O 
Blood - PROPN O 
Concentrations - PROPN O 
of - ADP O 
Olanzapine PROPN - B-MEDICINE 
in - ADP O 
Postmortem - PROPN O 
Cases - PROPN O 
. - PUNCT O 

Olanzapine NOUN - B-MEDICINE 
- - PUNCT O 
induced - VERB O 
leucopaenia - NOUN O 
and - CCONJ O 
thrombocytopaenia - NOUN O 
in - ADP O 
an - DET O 
elderly - ADJ O 
patient - NOUN O 
: - PUNCT O 
a - DET O 
case - NOUN O 
report - NOUN O 
and - CCONJ O 
review - NOUN O 
of - ADP O 
the - DET O 
evidence - NOUN O 
. - PUNCT O 

Resurgence - NOUN O 
of - ADP O 
Eating - PROPN O 
Disorders - PROPN O 
with - ADP O 
Olanzapine PROPN - B-MEDICINE 
. - PUNCT O 

Atypical - PROPN O 
Antipsychotic - PROPN O 
Drug - PROPN O 
Olanzapine PROPN - B-MEDICINE 
Deregulates - VERB O 
Hepatic - PROPN O 
Lipid - PROPN O 
Metabolism - PROPN O 
and - CCONJ O 
Aortic - PROPN O 
Inflammation - PROPN O 
and - CCONJ O 
Aggravates - PROPN O 
Atherosclerosis - PROPN O 
. - PUNCT O 

CONCLUSION - NOUN O 
: - PUNCT O 
Olanzapine NOUN - B-MEDICINE 
, - PUNCT O 
haloperidol - NOUN O 
plus - CCONJ O 
promethazine - NOUN O 
or - CCONJ O 
droperidol - NOUN O 
are - VERB O 
most - ADV O 
effective - ADJ O 
and - CCONJ O 
safe - ADJ O 
for - ADP O 
use - NOUN O 
as - ADP O 
rapid - ADJ O 
tranquilisation - NOUN O 
. - PUNCT O 

Olanzapine NOUN - B-MEDICINE 
for - ADP O 
the - DET O 
prevention - NOUN O 
and - CCONJ O 
treatment - NOUN O 
of - ADP O 
cancer - NOUN O 
- - PUNCT O 
related - VERB O 
nausea - NOUN O 
and - CCONJ O 
vomiting - VERB O 
in - ADP O 
adults - NOUN O 
. - PUNCT O 

Call - VERB O 
for - ADP O 
" PUNCT - B-WORK_OF_ART 
High ADJ - I-WORK_OF_ART 
- PUNCT - I-WORK_OF_ART 
Dose PROPN - I-WORK_OF_ART 
" PUNCT - I-WORK_OF_ART 
Olanzapine PROPN - I-MEDICINE 
Research PROPN - I-WORK_OF_ART 
in ADP - I-WORK_OF_ART 
Treatment PROPN - I-WORK_OF_ART 
- PUNCT - I-WORK_OF_ART 
Resistant PROPN - I-WORK_OF_ART 
Psychosis PROPN - I-WORK_OF_ART 
. - PUNCT O 

Olanzapine NOUN - B-MEDICINE 
- - PUNCT O 
Induced - VERB O 
Fatal - PROPN O 
Ketoacidosis - PROPN O 
with - ADP O 
Pneumomediastinum PROPN - B-GPE 
and - CCONJ O 
Subcutaneous - PROPN O 
Emphysema - PROPN O 
. - PUNCT O 

Olanzapine PROPN - B-MEDICINE 
is - VERB O 
an - DET O 
atypical - ADJ O 
antipsychotic - ADJ O 
drug - NOUN O 
most - ADV O 
commonly - ADV O 
used - VERB O 
to - PART O 
manage - VERB O 
psychoses - NOUN O 
and - CCONJ O 
symptoms - NOUN O 
of - ADP O 
irritability - NOUN O 
and - CCONJ O 
aggressive - ADJ O 
behavior - NOUN O 
. - PUNCT O 

After - ADP O 
Acute - ADJ O 
Voluntary - PROPN O 
Poisoning - PROPN O 
With - ADP O 
a - DET O 
Huge - PROPN O 
Dose - PROPN O 
of - ADP O 
Oxcarbazepine - PROPN O 
and - CCONJ O 
Olanzapine PROPN - B-MEDICINE 
. - PUNCT O 

Olanzapine NOUN - B-MEDICINE 
for - ADP O 
the - DET O 
Prevention - PROPN O 
of - ADP O 
Chemotherapy - PROPN O 
- - PUNCT O 
Induced - VERB O 
Nausea - PROPN O 
and - CCONJ O 
Vomiting - NOUN O 
: - PUNCT O 

Olanzapine PROPN - B-MEDICINE 
is - VERB O 
an - DET O 
atypical - ADJ O 
antipsychotic - ADJ O 
that - ADJ O 
has - VERB O 
shown - VERB O 
efficacy - NOUN O 
for - ADP O 
the - DET O 
treatment - NOUN O 
of - ADP O 
nausea - NOUN O 
, - PUNCT O 
anxiety - NOUN O 
, - PUNCT O 
and - CCONJ O 
insomnia - NOUN O 
. - PUNCT O 

This - DET O 
study - NOUN O 
was - VERB O 
conducted - VERB O 
to - PART O 
evaluate - VERB O 
the - DET O 
efficacy - NOUN O 
of - ADP O 
olanzapine NOUN - B-MEDICINE 
( - PUNCT O 
5 NUM - B-CARDINAL 
  SPACE - I-CARDINAL 
mg - NOUN O 
) - PUNCT O 
combined - VERB O 
with - ADP O 
5-HT3 - ADJ O 
receptor - NOUN O 
antagonists - NOUN O 
and - CCONJ O 
dexamethasone - NOUN O 
for - ADP O 
the - DET O 
prevention - NOUN O 
of - ADP O 
chemotherapy - NOUN O 
- - PUNCT O 
induced - VERB O 
nausea - NOUN O 
and - CCONJ O 
vomiting - NOUN O 
( - PUNCT O 
CINV - PROPN O 
) - PUNCT O 
in - ADP O 
lung - NOUN O 
patients - NOUN O 
receiving - VERB O 
cisplatin - ADV O 
- - PUNCT O 
based - VERB O 
( - PUNCT O 
25 NUM - B-CARDINAL 
  SPACE - I-CARDINAL 
mg - NOUN O 
/ - SYM O 
m2 - ADJ O 
d1 - NOUN O 
- - SYM O 
3 - NUM O 
) - PUNCT O 
highly - ADV O 
emetogenic - ADJ O 
chemotherapy - NOUN O 
( - PUNCT O 
HEC).Olanzapine - PROPN O 
( - PUNCT O 
5 NUM - B-CARDINAL 
  SPACE - I-CARDINAL 
mg - PRON O 
) - PUNCT O 
was - VERB O 
administered - VERB O 
a DET - B-DATE 
day NOUN - I-DATE 
prior - ADV O 
to - ADP O 
cisplatin - ADJ O 
administration - NOUN O 
and - CCONJ O 
continued - VERB O 
on - ADP O 
days NOUN - B-DATE 
1 NUM - I-DATE 
to ADP - I-DATE 
5 NUM - I-DATE 
. - PUNCT O 

Olanzapine NOUN - B-MEDICINE 
plus - CCONJ O 
aprepitant - NOUN O 
, - PUNCT O 
palonosetron - NOUN O 
, - PUNCT O 
and - CCONJ O 
dexamethasone - VERB O 
for - ADP O 
nausea - NOUN O 
and - CCONJ O 
vomiting - NOUN O 
in - ADP O 
patients - NOUN O 
with - ADP O 
breast - NOUN O 
cancer - NOUN O 
receiving - VERB O 
anthracycline - NOUN O 
: - PUNCT O 
A - DET O 
retrospective - ADJ O 
study - NOUN O 
. - PUNCT O 

Brain - NOUN O 
Sub - PROPN O 
/ - SYM O 
Region - PROPN O 
- - PUNCT O 
Specific - PROPN O 
Effects - PROPN O 
of - ADP O 
Olanzapine PROPN - B-MEDICINE 
on - ADP O 
c - PROPN O 
- - PUNCT O 
Fos - PROPN O 
Expression - PROPN O 
of - ADP O 
Chronically - PROPN O 
Socially - PROPN O 
Isolated - PROPN O 
Rats - PROPN O 
. - PUNCT O 

Olanzapine PROPN - B-MEDICINE 
( - PUNCT O 
OLZ - PROPN O 
) - PUNCT O 
, - PUNCT O 
a - DET O 
drug - NOUN O 
for - ADP O 
the - DET O 
treatment - NOUN O 
of - ADP O 
schizophrenia - NOUN O 
, - PUNCT O 
presents - VERB O 
in - ADP O 
more ADJ - B-CARDINAL 
than ADP - I-CARDINAL 
60 NUM - I-CARDINAL 
crystal - NOUN O 
forms - NOUN O 
. - PUNCT O 

Olanzapine PROPN - B-MEDICINE 
significantly - ADV O 
increased - VERB O 
the - DET O 
phosphorylated - VERB O 
levels - NOUN O 
of - ADP O 
mTORC1 - NOUN O 
, - PUNCT O 
its - ADJ O 
downstream - ADJ O 
effectors - NOUN O 
, - PUNCT O 
and - CCONJ O 
its - ADJ O 
upstream - ADJ O 
activators - NOUN O 
. - PUNCT O 

Olanzapine PROPN - B-MEDICINE 
also - ADV O 
increased - VERB O 
dendritic - ADJ O 
outgrowth - NOUN O 
and - CCONJ O 
synaptic - ADJ O 
proteins - NOUN O 
levels - NOUN O 
; - PUNCT O 
all - DET O 
of - ADP O 
these - DET O 
effects - NOUN O 
were - VERB O 
blocked - VERB O 
by - ADP O 
rapamycin - NOUN O 
. - PUNCT O 

Olanzapine PROPN - B-MEDICINE 
, - PUNCT O 
a - DET O 
second ADJ - B-ORDINAL 
generation - NOUN O 
antipsychotic - ADJ O 
, - PUNCT O 
has - VERB O 
previously - ADV O 
been - VERB O 
associated - VERB O 
with - ADP O 
an - DET O 
increased - VERB O 
risk - NOUN O 
of - ADP O 
venous - ADJ O 
thromboembolism - NOUN O 
( - PUNCT O 
VTE - PROPN O 
) - PUNCT O 
. - PUNCT O 

Olanzapine NOUN - B-MEDICINE 
treatment - NOUN O 
reduced - VERB O 
RER PROPN - B-ORG 
in - ADP O 
the - DET O 
dark - ADJ O 
and - CCONJ O 
light - ADJ O 
phases - NOUN O 
( - PUNCT O 
most - ADV O 
consistently - ADV O 
in - ADP O 
the - DET O 
4-hours NUM - B-ORDINAL 
post - ADJ O 
- - ADJ O 
treatment - ADJ O 
) - PUNCT O 
, - PUNCT O 
while - ADP O 
ICV PROPN - B-ORG 
insulin - NOUN O 
reduced - VERB O 
average - ADJ O 
RER PROPN - B-ORG 
predominantly - ADV O 
in - ADP O 
the - DET O 
dark - ADJ O 
phase - NOUN O 
, - PUNCT O 
but - CCONJ O 
also - ADV O 
at - ADP O 
the - DET O 
end - NOUN O 
of - ADP O 
the - DET O 
light - ADJ O 
cycle - NOUN O 
. - PUNCT O 

Olanzapine NOUN - B-MEDICINE 
treatment - NOUN O 
, - PUNCT O 
alone - ADV O 
or - CCONJ O 
in - ADP O 
combination - NOUN O 
with - ADP O 
ICV - PROPN O 
- - PUNCT O 
insulin - NOUN O 
, - PUNCT O 
significantly - ADV O 
reduced - VERB O 
VCO2 - PROPN O 
at - ADP O 
regular - ADJ O 
intervals - NOUN O 
in - ADP O 
the - DET O 
dark - ADJ O 
phase - NOUN O 
( - PUNCT O 
specifically - ADV O 
3 NUM - B-CARDINAL 
  - SPACE O 
h - PRON O 
post - ADJ O 
- - ADJ O 
treatment - ADJ O 
) - PUNCT O 
, - PUNCT O 
while - ADP O 
VO2 PROPN - B-PERSON 
was - VERB O 
not - ADV O 
significantly - ADV O 
altered - VERB O 
by - ADP O 
either - DET O 
treatment - NOUN O 
. - PUNCT O 

Reply - VERB O 
to - ADP O 
: - PUNCT O 
Comment - VERB O 
on - ADP O 
: - PUNCT O 
Olanzapine NOUN - B-MEDICINE 
for - ADP O 
chemotherapy - NOUN O 
- - PUNCT O 
induced - VERB O 
nausea - NOUN O 
: - PUNCT O 
Lessons - NOUN O 
learned - VERB O 
from - ADP O 
child - NOUN O 
and - CCONJ O 
adolescent - NOUN O 
psychiatry - NOUN O 
. - PUNCT O 

Olanzapine PROPN - B-MEDICINE 
is - VERB O 
an - DET O 
atypical - ADJ O 
antipsychotic - ADJ O 
and - CCONJ O 
acts - NOUN O 
on - ADP O 
multiple - ADJ O 
receptors - NOUN O 
and - CCONJ O 
may - VERB O 
help - VERB O 
in - ADP O 
treating - VERB O 
vomiting - VERB O 
in - ADP O 
a - DET O 
patient - NOUN O 
with - ADP O 
advanced - ADJ O 
malignancy - NOUN O 
. - PUNCT O 

Olanzapine PROPN - B-MEDICINE 
in - ADP O 
the DET - B-ORG 
Treatment PROPN - I-ORG 
of ADP - I-ORG 
Refractory PROPN - I-ORG 
Nausea PROPN - I-ORG 
and CCONJ - I-ORG 
Vomiting PROPN - I-ORG 
in - ADP O 
Palliative - PROPN O 
Care - PROPN O 
Settings - PROPN O 
. - PUNCT O 

( - PUNCT O 
1)Olanzapine NUM - B-CARDINAL 
group - NOUN O 
had - VERB O 
higher - ADJ O 
incidence - NOUN O 
of - ADP O 
somnolence - NOUN O 
than - ADP O 
risperidone - NOUN O 
group - NOUN O 
( - PUNCT O 
OR=1.49 - PROPN O 
, - PUNCT O 

( - PUNCT O 
3 PUNCT - B-CARDINAL 
) - PUNCT O 
Olanzapine PROPN - B-MEDICINE 
group - NOUN O 
had - VERB O 
higher - ADJ O 
incidence - NOUN O 
of - ADP O 
extrapyramidal - ADJ O 
symptoms - NOUN O 
than - ADP O 
quetiapine - NOUN O 
group - NOUN O 
( - PUNCT O 
OR=11.10 PROPN - B-ORG 
, - PUNCT O 
95 NUM - B-PERCENT 
% NOUN - I-PERCENT 
CI - PROPN O 
[ - PUNCT O 
3.35 NUM - B-CARDINAL 
- - SYM O 
36.75 - NUM O 
] - PUNCT O 
, - PUNCT O 
P<0.000 - PROPN O 
1 NUM - B-CARDINAL 
) - PUNCT O 
, - PUNCT O 
while - ADP O 
for - ADP O 
somnolence - NOUN O 
, - PUNCT O 
sleep - NOUN O 
disturbances - NOUN O 
, - PUNCT O 
constipation - NOUN O 
, - PUNCT O 
agitation - NOUN O 
, - PUNCT O 
weight - NOUN O 
gain - NOUN O 
, - PUNCT O 
dizziness - NOUN O 
, - PUNCT O 
there - ADV O 
was - VERB O 
no - DET O 
significant - ADJ O 
difference - NOUN O 
. - PUNCT O 

Olanzapine NOUN - B-MEDICINE 
treatment - NOUN O 
increased - VERB O 
the - DET O 
food - NOUN O 
intake - NOUN O 
of - ADP O 
the - DET O 
mice - NOUN O 
as - ADV O 
well - ADV O 
as - ADP O 
their - ADJ O 
body - NOUN O 
weight - NOUN O 
. - PUNCT O 

Olanzapine ADV - B-MEDICINE 
long - ADV O 
- - PUNCT O 
acting - VERB O 
injection - NOUN O 
( - PUNCT O 
LAI PROPN - B-ORG 
; - PUNCT O 
adjusted - VERB O 
hazard - NOUN O 
ratio - NOUN O 
= - SYM O 
0.46 NUM - B-CARDINAL 
, - PUNCT O 
95 NUM - B-PERCENT 
% NOUN - I-PERCENT 
confidence - NOUN O 
interval - NOUN O 
= - SYM O 
0.36 NUM - B-CARDINAL 
- - SYM O 
0.61 - NUM O 
) - PUNCT O 
, - PUNCT O 
clozapine - NOUN O 
( - PUNCT O 
0.51 NUM - B-CARDINAL 
, - PUNCT O 
0.49 NUM - B-CARDINAL 
- - SYM O 
0.53 - NUM O 
) - PUNCT O 
, - PUNCT O 
and - CCONJ O 
paliperidone - ADJ O 
LAI PROPN - B-ORG 
( - PUNCT O 
0.51 NUM - B-CARDINAL 
, - PUNCT O 
0.40 NUM - B-CARDINAL 
- - SYM O 
0.66 - NUM O 
) - PUNCT O 
were - VERB O 
associated - VERB O 
with - ADP O 
the - DET O 
lowest - ADJ O 
risk - NOUN O 
of - ADP O 
psychiatric - ADJ O 
rehospitalization - NOUN O 
in - ADP O 
the - DET O 
prevalent - ADJ O 
cohort - NOUN O 
. - PUNCT O 

Olanzapine ADV - B-MEDICINE 
, - PUNCT O 
quetiapine - NOUN O 
, - PUNCT O 
risperidone - NOUN O 
, - PUNCT O 
aripiprazole - NOUN O 
, - PUNCT O 
and - CCONJ O 
ziprasidone - NOUN O 
are - VERB O 
the - DET O 
only - ADJ O 
AAs - NOUN O 
with - ADP O 
published - VERB O 
studies - NOUN O 
in - ADP O 
pain - NOUN O 
management - NOUN O 
. - PUNCT O 

Olanzapine PROPN - B-MEDICINE 
shows - VERB O 
preliminary - ADJ O 
and - CCONJ O 
consistent - ADJ O 
efficacy - NOUN O 
in - ADP O 
fibromyalgia - NOUN O 
and - CCONJ O 
headache - NOUN O 
/ - SYM O 
migraine - NOUN O 
, - PUNCT O 
although - ADP O 
only ADV - B-CARDINAL 
1 NUM - I-CARDINAL 
study - NOUN O 
was - VERB O 
a - DET O 
randomized - VERB O 
controlled - VERB O 
trial - NOUN O 
with - ADP O 
level - NOUN O 

A - DET O 
Systematic - PROPN O 
Review - PROPN O 
of - ADP O 
Atypical - PROPN O 
Antipsychotics - PROPN O 
in - ADP O 
Chronic - PROPN O 
Pain - PROPN O 
Management - NOUN O 
: - PUNCT O 
Olanzapine NOUN - B-MEDICINE 
Demonstrates - VERB O 
Potential - PROPN O 
in - ADP O 
Central - PROPN O 
Sensitization - PROPN O 
, - PUNCT O 
Fibromyalgia PROPN - B-ORG 
, - PUNCT O 
and - CCONJ O 
Headache PROPN - B-ORG 
/ SYM - I-ORG 
Migraine PROPN - I-ORG 
. - PUNCT O 

Butyl PROPN - B-ORG 
Methacrylate PROPN - I-ORG 
- PUNCT - I-ORG 
Co PROPN - I-ORG 
- PUNCT - I-ORG 
Ethylene PROPN - I-ORG 
Glycol PROPN - I-ORG 
Dimethacrylate PROPN - I-ORG 
Monolith PROPN - I-ORG 
for ADP - I-ORG 
Online PROPN - I-ORG 
in ADP - I-ORG 
- PUNCT - I-ORG 
Tube PROPN - I-ORG 
SPME PROPN - I-ORG 
- PUNCT - I-ORG 
UHPLC PROPN - I-ORG 
- PUNCT - I-ORG 
MS PROPN - I-ORG 
/ SYM - I-ORG 
MS PROPN - I-ORG 
to - PART O 
Determine VERB - B-ORG 
Chlopromazine PROPN - I-ORG 
, - PUNCT O 
Clozapine PROPN - B-ORG 
, - PUNCT O 
Quetiapine PROPN - B-GPE 
, - PUNCT O 
Olanzapine PROPN - B-MEDICINE 
, - PUNCT O 
and - CCONJ O 
Their ADJ - B-WORK_OF_ART 
Metabolites NOUN - I-WORK_OF_ART 
in ADP - I-WORK_OF_ART 
Plasma PROPN - I-WORK_OF_ART 
Samples PROPN - I-WORK_OF_ART 
. - PUNCT O 

Olanzapine PROPN - B-MEDICINE 
was - VERB O 
administered - VERB O 
daily ADV - B-DATE 
by - ADP O 
intraperitoneal - ADJ O 
route - NOUN O 
, - PUNCT O 
alone - ADV O 
or - CCONJ O 
in - ADP O 
combination - NOUN O 
with - ADP O 
CART PROPN - B-ORG 
( - PUNCT O 
intracerebroventricular - ADJ O 
) - PUNCT O 
for - ADP O 
a DET - B-DATE 
period NOUN - I-DATE 
of ADP - I-DATE 
two NUM - B-DATE 
weeks NOUN - I-DATE 
. - PUNCT O 

Olanzapine NOUN - B-MEDICINE 
administration - NOUN O 
resulted - VERB O 
in - ADP O 
a - DET O 
significant - ADJ O 
reduction - NOUN O 
in - ADP O 
CART PROPN - B-ORG 
immunoreactivity - NOUN O 
in - ADP O 
the - DET O 
hypothalamic - ADJ O 
arcuate - NOUN O 
, - PUNCT O 
paraventricular - ADJ O 
, - PUNCT O 
dorsomedial - ADJ O 
and - CCONJ O 
ventromedial - ADJ O 
nuclei - NOUN O 
. - PUNCT O 

The - DET O 
Development - PROPN O 
of - ADP O 
Quasi - PROPN O 
- - PUNCT O 
isothermal - PROPN O 
Calorimetry - PROPN O 
for - ADP O 
the - DET O 
Measurement - PROPN O 
of - ADP O 
Drug - PROPN O 
- - PUNCT O 
Polymer - PROPN O 
Miscibility - PROPN O 
and - CCONJ O 
Crystallization - PROPN O 
Kinetics - PROPN O 
: - PUNCT O 
Olanzapine NOUN - B-MEDICINE 
- - PUNCT O 
Loaded - VERB O 
PLGA - NOUN O 
Microparticles - PROPN O 
. - PUNCT O 

Olanzapine NOUN - B-MEDICINE 
administration - NOUN O 
largely - ADV O 
prevented - VERB O 
these - DET O 
changes - NOUN O 
. - PUNCT O 

Olanzapine PROPN - B-MEDICINE 
resulted - VERB O 
in - ADP O 
a - DET O 
greater - ADJ O 
proportion - NOUN O 
of - ADP O 
patients - NOUN O 
adequately - ADV O 
sedated - VERB O 
at - ADP O 
15 NUM - B-TIME 
minutes NOUN - I-TIME 
compared - VERB O 
with - ADP O 
haloperidol - NOUN O 
5 NUM - B-CARDINAL 
mg - PRON O 
( - PUNCT O 
difference - NOUN O 
20 NUM - B-PERCENT 
% NOUN - I-PERCENT 
; - PUNCT O 
95 NUM - B-PERCENT 
% NOUN - I-PERCENT 
CI PROPN - B-ORG 
10 NUM - B-PERCENT 
% NOUN - I-PERCENT 
to PART - I-PERCENT 
31 NUM - I-PERCENT 
% NOUN - I-PERCENT 
) - PUNCT O 
, - PUNCT O 
haloperidol - NOUN O 
10 NUM - B-QUANTITY 
mg NOUN - I-QUANTITY 
( - PUNCT O 
difference - NOUN O 
18 NUM - B-PERCENT 
% NOUN - I-PERCENT 
; - PUNCT O 
95 NUM - B-PERCENT 
% NOUN - I-PERCENT 
CI PROPN - B-ORG 
7 NUM - B-PERCENT 
% NOUN - I-PERCENT 
to PART - I-PERCENT 
29 NUM - I-PERCENT 
% NOUN - I-PERCENT 
) - PUNCT O 
, - PUNCT O 
and - CCONJ O 
ziprasidone - NOUN O 
( - PUNCT O 
difference - NOUN O 
8 NUM - B-PERCENT 
% NOUN - I-PERCENT 
; - PUNCT O 
95 NUM - B-PERCENT 
% NOUN - I-PERCENT 
CI PROPN - B-PERCENT 
-3 NOUN - I-PERCENT 
% NOUN - I-PERCENT 
to PART - I-PERCENT 
19 NUM - I-PERCENT 
% NOUN - I-PERCENT 
) - PUNCT O 
. - PUNCT O 

Olanzapine PROPN - B-MEDICINE 
provided - VERB O 
more - ADV O 
effective - ADJ O 
sedation - NOUN O 
than - ADP O 
haloperidol - NOUN O 
. - PUNCT O 

Olanzapine PROPN - B-MEDICINE 
had - VERB O 
the - DET O 
highest - ADJ O 
reported - VERB O 
proportion - NOUN O 
. - PUNCT O 

The - DET O 
objective - NOUN O 
of - ADP O 
this - DET O 
study - NOUN O 
is - VERB O 
to - PART O 
explore - VERB O 
the - DET O 
influence - NOUN O 
of - ADP O 
the - DET O 
most - ADV O 
commonly - ADV O 
used - VERB O 
antipsychotics - NOUN O 
in - ADP O 
this - DET O 
population - NOUN O 
( - PUNCT O 
Olanzapine PROPN - B-MEDICINE 
and - CCONJ O 
Risperidone - PROPN O 
) - PUNCT O 
on - ADP O 
physical - ADJ O 
activity - NOUN O 
and - CCONJ O 
the - DET O 
physical - ADJ O 
fitness - NOUN O 
of - ADP O 
people - NOUN O 
with - ADP O 
severe - ADJ O 
mental - ADJ O 
illness - NOUN O 
. - PUNCT O 

The - DET O 
doses - NOUN O 
of - ADP O 
Risperidone PROPN - B-PERSON 
and - CCONJ O 
Olanzapine PROPN - B-MEDICINE 
were - VERB O 
also - ADV O 
evaluated - VERB O 
in - ADP O 
all - DET O 
participants - NOUN O 
. - PUNCT O 

Regarding - VERB O 
physical - ADJ O 
fitness - NOUN O 
, - PUNCT O 
significant - ADJ O 
differences - NOUN O 
were - VERB O 
only - ADV O 
found - VERB O 
for - ADP O 
the - DET O 
consumption - NOUN O 
of - ADP O 
Risperidone PROPN - B-GPE 
, - PUNCT O 
with - ADP O 
better - ADJ O 
physical - ADJ O 
fitness - NOUN O 
levels - NOUN O 
seen - VERB O 
in - ADP O 
patients - NOUN O 
who - NOUN O 
did - VERB O 
not - ADV O 
consume - VERB O 
this - DET O 
medication - NOUN O 
; - PUNCT O 
on - ADP O 
the - DET O 
other - ADJ O 
hand - NOUN O 
, - PUNCT O 
for - ADP O 
the - DET O 
consumption - NOUN O 
of - ADP O 
Olanzapine PROPN - B-MEDICINE 
, - PUNCT O 
differences - NOUN O 
were - VERB O 
found - VERB O 
in - ADP O 
muscular - ADJ O 
strength - NOUN O 
, - PUNCT O 
balance - NOUN O 
and - CCONJ O 
aerobic - ADJ O 
condition - NOUN O 
with - ADP O 
better - ADJ O 
values - NOUN O 
in - ADP O 
non ADJ - B-NORP 
- ADJ - I-NORP 
Olanzapine ADJ - I-MEDICINE 
consumers - NOUN O 
compared - VERB O 
with - ADP O 
Olanzapine PROPN - B-MEDICINE 
consumers - NOUN O 
. - PUNCT O 

Economic - PROPN O 
Evaluation - PROPN O 
of - ADP O 
Midazolam PROPN - B-ORG 
- PUNCT - I-ORG 
Droperidol PROPN - I-ORG 
Combination PROPN - I-ORG 
, - PUNCT O 
Versus PROPN - B-PERSON 
Droperidol PROPN - I-PERSON 
or - CCONJ O 
Olanzapine PROPN - B-MEDICINE 
for - ADP O 
the - DET O 
Management - PROPN O 
of - ADP O 
Acute - PROPN O 
Agitation - PROPN O 
in - ADP O 
the - DET O 
Emergency - PROPN O 
Department - PROPN O 
: - PUNCT O 
A PROPN - B-ORG 
Within PROPN - I-ORG 
- PUNCT - I-ORG 
Trial PROPN - I-ORG 
Analysis PROPN - I-ORG 
. - PUNCT O 

The DET - B-ORG 
Comparison PROPN - I-ORG 
of ADP - I-ORG 
Olanzapine PROPN - I-MEDICINE 
and CCONJ - I-ORG 
Risperidone PROPN - I-ORG 
Treatment PROPN - I-ORG 
in ADP - I-ORG 
Male PROPN - I-ORG 
Schizophrenic PROPN - I-ORG 
Patients PROPN - I-ORG 
using - VERB O 
Positive - PROPN O 
and - CCONJ O 
Negative - PROPN O 
Syndromes - PROPN O 
Scale - PROPN O 
( - PUNCT O 
PANSS - PROPN O 
) - PUNCT O 
. - PUNCT O 

Olanzapine PROPN - B-MEDICINE 
may - VERB O 
be - VERB O 
cataractogenic - ADJ O 
via - ADP O 
its - ADJ O 
action - NOUN O 
as - ADP O 
a - DET O 
serotonin - ADJ O 
antagonist - NOUN O 
, - PUNCT O 
which - ADJ O 
results - VERB O 
in - ADP O 
reduced - ADJ O 
glucose - NOUN O 
responsiveness - NOUN O 
of - ADP O 
the - DET O 
pancreatic - ADJ O 
beta - NOUN O 
- - PUNCT O 
cells - NOUN O 
. - PUNCT O 

Olanzapine NOUN - B-MEDICINE 
- - PUNCT O 
induced - VERB O 
Cataract PROPN - B-ORG 
in - ADP O 
a - DET O 
Teenage PROPN - B-FAC 
Girl PROPN - I-FAC 
. - PUNCT O 

Olanzapine PROPN - B-MEDICINE 
has - VERB O 
rapidly - ADV O 
become - VERB O 
the - DET O 
first ADJ - B-ORDINAL 
choice - NOUN O 
of - ADP O 
intramuscular - ADJ O 
medication - NOUN O 
in - ADP O 
psychiatric - ADJ O 
emergency - NOUN O 
situations - NOUN O 
since - ADP O 
it - PRON O 
became - VERB O 
available - ADJ O 
in - ADP O 
Japan PROPN - B-GPE 
, - PUNCT O 
probably - ADV O 
due - ADP O 
to - ADP O 
the - DET O 
advantages - NOUN O 
in - ADP O 
both - DET O 
efficacy - NOUN O 
and - CCONJ O 
safety - NOUN O 
. - PUNCT O 

Comment - NOUN O 
on - ADP O 
: - PUNCT O 
Olanzapine NOUN - B-MEDICINE 
for - ADP O 
chemotherapy - NOUN O 
- - PUNCT O 
induced - VERB O 
nausea - NOUN O 
: - PUNCT O 
Lessons - NOUN O 
learned - VERB O 
from - ADP O 
child - NOUN O 
and - CCONJ O 
adolescent - NOUN O 
psychiatry - NOUN O 
. - PUNCT O 

In - ADP O 
case - NOUN O 
of - ADP O 
typical - ADJ O 
antipsychotics - NOUN O 
such - ADJ O 
as - ADP O 
Haloperidol PROPN - B-PRODUCT 
, - PUNCT O 
the - DET O 
c - NOUN O 
- - PUNCT O 
fos - NOUN O 
active - ADJ O 
cells - NOUN O 
were - VERB O 
predominantly - ADV O 
found - VERB O 
in - ADP O 
the - DET O 
striatum - NOUN O 
, - PUNCT O 
whereas - ADP O 
in - ADP O 
case - NOUN O 
of - ADP O 
the - DET O 
atypical - ADJ O 
antipsychotics - NOUN O 
( - PUNCT O 
Clozapine PROPN - B-WORK_OF_ART 
and CCONJ - I-WORK_OF_ART 
Olanzapine PROPN - I-MEDICINE 
) - PUNCT O 
, - PUNCT O 
c - NOUN O 
- - PUNCT O 
fos - NOUN O 
- - PUNCT O 
induced - VERB O 
cells - NOUN O 
were - VERB O 
more - ADV O 
numerous - ADJ O 
in - ADP O 
the - DET O 
cortical - ADJ O 
regions - NOUN O 
, - PUNCT O 
e.g. - ADJ O 
, - PUNCT O 
orbital - ADJ O 
cortex - NOUN O 
, - PUNCT O 
piriform - NOUN O 
cortex - NOUN O 
. - PUNCT O 

A - DET O 
Randomized VERB - B-ORG 
, PUNCT - I-ORG 
Double ADJ - I-ORG 
- PUNCT - I-ORG 
Blind ADJ - I-ORG 
, - PUNCT O 
Placebo PROPN - B-GPE 
- - PUNCT O 
Controlled - PROPN O 
Study - PROPN O 
of - ADP O 
the - DET O 
Safety - PROPN O 
and - CCONJ O 
Efficacy - PROPN O 
of - ADP O 
Olanzapine PROPN - B-MEDICINE 
for - ADP O 
the - DET O 
Prevention - PROPN O 
of - ADP O 
Chemotherapy - PROPN O 
- - PUNCT O 
Induced - VERB O 
Nausea - PROPN O 
and - CCONJ O 
Vomiting - PROPN O 
in - ADP O 
Patients - PROPN O 
Receiving - VERB O 
Moderately - PROPN O 
Emetogenic - PROPN O 
Chemotherapy - NOUN O 
: - PUNCT O 
Results - NOUN O 
of - ADP O 
the DET - B-LOC 
Korean PROPN - I-LOC 
South PROPN - I-LOC 
West PROPN - I-LOC 
Oncology PROPN - I-LOC 
Group PROPN - I-LOC 

Olanzapine PROPN - B-MEDICINE 
is - VERB O 
an - DET O 
effective - ADJ O 
antinausea - NOUN O 
agent - NOUN O 
, - PUNCT O 
but - CCONJ O 
sedation - NOUN O 
can - VERB O 
be - VERB O 
a - DET O 
problem - NOUN O 
. - PUNCT O 

Cyclosporine PROPN - B-ORG 
- PUNCT - I-ORG 
Olanzapine PROPN - I-MEDICINE 
Drug PROPN - I-ORG 
- PUNCT - I-ORG 
Drug PROPN - I-ORG 
Interaction PROPN - I-ORG 
. - PUNCT O 

Successful - ADJ O 
Treatment - PROPN O 
with - ADP O 
Olanzapine PROPN - B-MEDICINE 
of - ADP O 
Psychosis - PROPN O 
in - ADP O 
Dentatorubral - PROPN O 
- - PUNCT O 
pallidoluysian - PROPN O 
Atrophy - PROPN O 
: - PUNCT O 

Eryt PROPN - B-PERSON 
and - CCONJ O 
Olanzapine PROPN - B-MEDICINE 
reduced - VERB O 
MDA PROPN - B-ORG 
concentration - NOUN O 
in - ADP O 
ST PROPN - B-ORG 
when - ADV O 
compared - VERB O 
to - ADP O 
KET - PROPN O 
group - NOUN O 
. - PUNCT O 

A - DET O 
systematic - ADJ O 
search - NOUN O 
of - ADP O 
the - DET O 
literature - NOUN O 
published - VERB O 
before - ADP O 
April PROPN - B-DATE 
2018 NUM - I-DATE 
was - VERB O 
performed - VERB O 
on - ADP O 
PubMed PROPN - B-ORG 
using - VERB O 
the - DET O 
following - VERB O 
search - NOUN O 
strings - NOUN O 
: - PUNCT O 
" - PUNCT O 
Delirium PROPN - B-WORK_OF_ART 
" - PUNCT O 
and - CCONJ O 
" - PUNCT O 
Atypical - ADJ O 
antipsychotics - NOUN O 
" - PUNCT O 
, - PUNCT O 
" - PUNCT O 
Novel - ADJ O 
antipsychotics - NOUN O 
" - PUNCT O 
, - PUNCT O 
" - PUNCT O 
New - ADJ O 
antipsychotics - NOUN O 
" - PUNCT O 
, - PUNCT O 
" - PUNCT O 
Quetiapine PROPN - B-GPE 
" - PUNCT O 
, - PUNCT O 
" - PUNCT O 
Olanzapine PROPN - B-MEDICINE 
" - PUNCT O 
, - PUNCT O 
" - PUNCT O 
Aripiprazole PROPN - B-PRODUCT 
" - PUNCT O 
, - PUNCT O 
" - PUNCT O 
Risperidone - PROPN O 
" - PUNCT O 
, - PUNCT O 
" - PUNCT O 
Paliperidone - PROPN O 
" - PUNCT O 
, - PUNCT O 
" - PUNCT O 
Clozapine - PROPN O 
" - PUNCT O 
, - PUNCT O 
" - PUNCT O 
Asenapine PROPN - B-WORK_OF_ART 
" - PUNCT O 
, - PUNCT O 
" - PUNCT O 
Iloperidone - NOUN O 
" - PUNCT O 
, - PUNCT O 
" - PUNCT O 
Amisulpiride - PROPN O 
" - PUNCT O 
, - PUNCT O 
" - PUNCT O 
Ziprasidone PROPN - B-ORG 
" PUNCT - I-ORG 
, - PUNCT O 
" - PUNCT O 
Zotepine PROPN - B-WORK_OF_ART 
" - PUNCT O 
, - PUNCT O 
" - PUNCT O 
Sertindole - PROPN O 
" - PUNCT O 
, - PUNCT O 
" - PUNCT O 
Lurasidone - NOUN O 
" - PUNCT O 
or - CCONJ O 
" - PUNCT O 
Perospirone PROPN - B-WORK_OF_ART 
" - PUNCT O 
. - PUNCT O 

Exercise - NOUN O 
Protects - VERB O 
Against - ADP O 
Olanzapine PROPN - B-MEDICINE 
- - PUNCT O 
Induced - PROPN O 
Hyperglycemia - PROPN O 
in - ADP O 
Male - PROPN O 
C57BL/6J - PROPN O 
Mice - NOUN O 
. - PUNCT O 

Olanzapine PROPN - B-MEDICINE 
, - PUNCT O 
but - CCONJ O 
not - ADV O 
clozapine - ADJ O 
, - PUNCT O 
reduced - VERB O 
correct - ADJ O 
entries - NOUN O 
in - ADP O 
the - DET O 
T - PROPN O 
- - PUNCT O 
Maze - PROPN O 
test - NOUN O 
( - PUNCT O 
p - VERB O 
< - X O 
0.05 NUM - B-CARDINAL 
versus - ADP O 
Control PROPN - B-ORG 
) - PUNCT O 
while - ADP O 
liraglutide - NOUN O 
prevented - VERB O 
this - DET O 
deficit - NOUN O 
. - PUNCT O 

Olanzapine PROPN - B-MEDICINE 
significantly - ADV O 
decreased - VERB O 
voluntary - ADJ O 
locomotor - NOUN O 
activity - NOUN O 
and - CCONJ O 
liraglutide - NOUN O 
co - NOUN O 
- - NOUN O 
treatment - NOUN O 
partially - ADV O 
reversed - VERB O 
this - DET O 
effect - NOUN O 
. - PUNCT O 

Olanzapine NOUN - B-MEDICINE 
and - CCONJ O 
haloperidol - NOUN O 
for - ADP O 
the - DET O 
treatment - NOUN O 
of - ADP O 
acute - ADJ O 
symptoms - NOUN O 
of - ADP O 
mental - ADJ O 
disorders - NOUN O 
induced - VERB O 
by - ADP O 
amphetamine - ADJ O 
- - PUNCT O 
type - NOUN O 
stimulants - NOUN O 
: - PUNCT O 
A - DET O 
randomized - ADJ O 
controlled - VERB O 
trial - NOUN O 
. - PUNCT O 

We - PRON O 
describe - VERB O 
the - DET O 
case - NOUN O 
of - ADP O 
a - DET O 
70-year NUM - B-MONEY 
- PUNCT - I-MONEY 
old ADJ - I-MONEY 
Alzheimer - PROPN O 
patient - NOUN O 
who - NOUN O 
was - VERB O 
taking - VERB O 
olanzapine NOUN - B-MEDICINE 
for - ADP O 
2 NUM - B-DATE 
months NOUN - I-DATE 
for - ADP O 
the - DET O 
treatment - NOUN O 
of - ADP O 
depression - NOUN O 
, - PUNCT O 
and - CCONJ O 
developed - VERB O 
peripheral - ADJ O 
eosinophilia - NOUN O 
and - CCONJ O 
bilateral - ADJ O 
EPE.Olanzapine - PROPN O 
- - PUNCT O 
induced - VERB O 
peripheral - ADJ O 
eosinophilia - NOUN O 
and - CCONJ O 
eosinophilic - ADJ O 
pleural - ADJ O 
effusion - NOUN O 
was - VERB O 
diagnosed - VERB O 
. - PUNCT O 

Olanzapine PROPN - B-MEDICINE 
was - VERB O 
discontinued - VERB O 
, - PUNCT O 
and - CCONJ O 
repeated - VERB O 
drainage - NOUN O 
of - ADP O 
fluid - NOUN O 
from - ADP O 
the - DET O 
pleural - ADJ O 
cavity - NOUN O 
was - VERB O 
performed - VERB O 
. - PUNCT O 

Olanzapine PROPN - B-MEDICINE 
associated - VERB O 
palpebral - ADJ O 
edema - NOUN O 
: - PUNCT O 
An - DET O 
uncommon - ADJ O 
adverse - ADJ O 
effect - NOUN O 
of - ADP O 
a - DET O 
commonly - ADV O 
prescribed - VERB O 
drug - NOUN O 
. - PUNCT O 

Comparison - NOUN O 
of - ADP O 
the - DET O 
Effects - NOUN O 
of - ADP O 
Piroxicam - PROPN O 
and - CCONJ O 
Diclofenac PROPN - B-MEDICINE 
Sodium PROPN - I-MEDICINE 
as - ADP O 
Treatments PROPN - B-ORG 
for ADP - I-ORG 
Primary PROPN - I-ORG 
Dysmenorrhea PROPN - I-ORG 
. - PUNCT O 

Assessment - NOUN O 
of - ADP O 
the - DET O 
Effect - PROPN O 
of - ADP O 
3 - NUM O 
% - NOUN O 
Diclofenac NOUN - B-MEDICINE 
Sodium PROPN - I-MEDICINE 
on - ADP O 
Photodamaged - PROPN O 
Skin - PROPN O 
by - ADP O 
Means - PROPN O 
of - ADP O 
Reflectance - PROPN O 
Confocal - PROPN O 
Microscopy - PROPN O 
. - PUNCT O 

In - ADP O 
Vitro - PROPN O 
Evaluation - NOUN O 
of - ADP O 
2D - PROPN O 
- - PUNCT O 
Printed - VERB O 
Edible - PROPN O 
Films - NOUN O 
for - ADP O 
the - DET O 
Buccal - ADJ O 
Delivery - NOUN O 
of - ADP O 
Diclofenac PROPN - B-MEDICINE 
Sodium PROPN - I-MEDICINE 
. - PUNCT O 

The DET - B-ORG 
Influence NOUN - I-ORG 
of ADP - I-ORG 
Simulated PROPN - I-ORG 
Fasted PROPN - I-ORG 
Gastrointestinal PROPN - I-ORG 
pH X - I-ORG 
Profiles NOUN - I-ORG 
on ADP - I-ORG 
Diclofenac PROPN - I-ORG 
Sodium PROPN - I-ORG 
Dissolution PROPN - I-ORG 
in - ADP O 
a - DET O 
Glass PROPN - B-FAC 
- PUNCT - I-FAC 
Bead PROPN - I-FAC 
Flow PROPN - I-FAC 
- PUNCT - I-FAC 
Through PROPN - I-FAC 
System PROPN - I-FAC 
. - PUNCT O 

Lycopene PROPN - B-PERSON 
Attenuates VERB - I-PERSON 
Tulathromycin PROPN - I-PERSON 
and - CCONJ O 
Diclofenac PROPN - B-ORG 
Sodium PROPN - I-ORG 
- PUNCT - I-ORG 
Induced PROPN - I-ORG 
Cardiotoxicity PROPN - I-ORG 
in - ADP O 
Mice PROPN - B-GPE 
. - PUNCT O 

Diclofenac PROPN - B-MEDICINE 
Sodium PROPN - I-MEDICINE 
3 NUM - B-PERCENT 
% NOUN - I-PERCENT 
in - ADP O 

Investigation - PROPN O 
an - DET O 
Antifungal - PROPN O 
Activity - PROPN O 
of - ADP O 
Diclofenac PROPN - B-MEDICINE 
Sodium PROPN - I-MEDICINE 
against - ADP O 
Hyphae PROPN - B-ORG 
Formation PROPN - I-ORG 
in - ADP O 
Aspergillus - PROPN O 
Fumigatus - PROPN O 
with - ADP O 
Attention - PROPN O 
to - ADP O 
the - DET O 
Expression - PROPN O 
of - ADP O 
Ef-1 - PROPN O 
Gene - PROPN O 
. - PUNCT O 

Impact - NOUN O 
of - ADP O 
Diclofenac PROPN - B-MEDICINE 
Sodium PROPN - I-MEDICINE 
on - ADP O 
Tilmicosin PROPN - B-ORG 
- PUNCT - I-ORG 
Induced PROPN - I-ORG 
Acute PROPN - I-ORG 
Cardiotoxicity PROPN - I-ORG 
in - ADP O 
Rats - PROPN O 
( - PUNCT O 
Tilmicosin - PROPN O 
and - CCONJ O 
Diclofenac - PROPN O 
Cardiotoxicity - PROPN O 
) - PUNCT O 
. - PUNCT O 

Corrigendum - VERB O 
to - ADP O 
" - PUNCT O 
Topical PROPN - B-WORK_OF_ART 
Colchicine PROPN - I-WORK_OF_ART 
Gel PROPN - I-WORK_OF_ART 
versus ADP - I-WORK_OF_ART 
Diclofenac PROPN - B-MEDICINE 
Sodium PROPN - I-MEDICINE 
Gel - PROPN O 
for - ADP O 
the DET - B-WORK_OF_ART 
Treatment PROPN - I-WORK_OF_ART 
of ADP - I-WORK_OF_ART 
Actinic PROPN - I-WORK_OF_ART 
Keratoses PROPN - I-WORK_OF_ART 
: - PUNCT O 
A - DET O 
Randomized - VERB O 
, - PUNCT O 
Double - ADJ O 
- - PUNCT O 
Blind - ADJ O 
Study - PROPN O 
" - PUNCT O 
. - PUNCT O 

Pharmacological - ADJ O 
effects - NOUN O 
of - ADP O 
Vitamin PROPN - B-ORG 
C PROPN - I-ORG 
& CCONJ - I-ORG 
E PROPN - I-ORG 
on - ADP O 
Diclofenac PROPN - B-ORG 
Sodium PROPN - I-ORG 
intoxicated - VERB O 
Rats PROPN - B-ORG 
. - PUNCT O 

Diclofenac PROPN - B-ORG 
Sodium PROPN - I-ORG 
Bolus PROPN - I-ORG 
Injection PROPN - I-ORG 
( - PUNCT O 
Dyloject(TM - PROPN O 
) - PUNCT O 
) - PUNCT O 
: - PUNCT O 

Low - ADJ O 
- - PUNCT O 
Dose - NOUN O 
Intramuscular - PROPN O 
Diclofenac PROPN - B-MEDICINE 
Sodium PROPN - I-MEDICINE 
for - ADP O 
Fever PROPN - B-ORG 
Control PROPN - I-ORG 
in - ADP O 
Acute - PROPN O 
Brain - PROPN O 
Injury - PROPN O 
. - PUNCT O 

Topical - PROPN O 
Colchicine - PROPN O 
Gel - PROPN O 
versus - ADP O 
Diclofenac PROPN - B-MEDICINE 
Sodium PROPN - I-MEDICINE 
Gel - PROPN O 
for - ADP O 
the - DET O 
Treatment - PROPN O 
of - ADP O 
Actinic - PROPN O 
Keratoses - PROPN O 
: - PUNCT O 

Development - PROPN O 
of - ADP O 
Oral - PROPN O 
Dissolvable - PROPN O 
Films - PROPN O 
of - ADP O 
Diclofenac PROPN - B-MEDICINE 
Sodium PROPN - I-MEDICINE 
for - ADP O 
Osteoarthritis - PROPN O 
Using - PROPN O 
Albizia - PROPN O 
and - CCONJ O 
Khaya PROPN - B-ORG 
Gums PROPN - I-ORG 
as - ADP O 
Hydrophilic PROPN - B-ORG 
Film PROPN - I-ORG 
Formers PROPN - I-ORG 
. - PUNCT O 

Pre - ADJ O 
- - ADJ O 
Emptive - ADJ O 
Effect - PROPN O 
of - ADP O 
Dexamethasone - PROPN O 
and - CCONJ O 
Diclofenac PROPN - B-MEDICINE 
Sodium NOUN - I-MEDICINE 

Comparison - NOUN O 
of - ADP O 
the - DET O 
Effects - NOUN O 
of - ADP O 
Daily - PROPN O 
Single - PROPN O 
- - PUNCT O 
Dose - PROPN O 
Use - PROPN O 
of - ADP O 
Flurbiprofen PROPN - B-ORG 
, PUNCT - I-ORG 
Diclofenac PROPN - I-ORG 
Sodium PROPN - I-ORG 
, - PUNCT O 
and - CCONJ O 
Tenoxicam PROPN - B-ORG 
on ADP - I-ORG 
Postoperative PROPN - I-ORG 
Pain PROPN - I-ORG 
, PUNCT - I-ORG 
Swelling NOUN - I-ORG 
, - PUNCT O 
and - CCONJ O 
Trismus PROPN - B-PERSON 
: - PUNCT O 
A - DET O 
Randomized - VERB O 
Double - ADJ O 
- - PUNCT O 
Blind - PROPN O 
Study - PROPN O 
. - PUNCT O 

Comparison - NOUN O 
of - ADP O 
the DET - B-ORG 
Analgesic PROPN - I-ORG 
Effect PROPN - I-ORG 
of ADP - I-ORG 
Diclofenac PROPN - I-ORG 
Sodium PROPN - I-ORG 
- PUNCT - I-ORG 
Eudragit PROPN - I-ORG 
( - PUNCT O 
® - NOUN O 
) - PUNCT O 

Pharmacokinetic - ADJ O 
Study - PROPN O 
of - ADP O 
a - DET O 
Diclofenac NOUN - B-MEDICINE 
Sodium PROPN - I-MEDICINE 
Capsule - PROPN O 
Filled - VERB O 
with - ADP O 
Enteric - PROPN O 
- - PUNCT O 
coated - VERB O 
Pellets - PROPN O 
in - ADP O 
Healthy - PROPN O 
Chinese - ADJ O 
Volunteers - PROPN O 
by - ADP O 
Liquid ADJ - B-PERSON 
Chromatography PROPN - I-PERSON 
- PUNCT - I-PERSON 
electrospray NOUN - I-PERSON 
Ionization PROPN - B-ORG 
- - PUNCT O 
tandem - PROPN O 
Mass PROPN - B-ORG 
Spectrometry PROPN - I-ORG 
. - PUNCT O 

Preparation - PROPN O 
and - CCONJ O 
Evaluation - PROPN O 
of - ADP O 
Diclofenac PROPN - B-MEDICINE 
Sodium PROPN - I-MEDICINE 
Tablet - PROPN O 
Coated - VERB O 
with - ADP O 
Polyelectrolyte - PROPN O 
Multilayer - PROPN O 
Film - PROPN O 
Using - VERB O 
Hypromellose - PROPN O 
Acetate - PROPN O 
Succinate - PROPN O 
and - CCONJ O 
Polymethacrylates PROPN - B-LOC 
for - ADP O 
pH - PROPN O 
- - PUNCT O 
Dependent - PROPN O 
, - PUNCT O 
Modified PROPN - B-ORG 
Release PROPN - I-ORG 
Drug PROPN - I-ORG 
Delivery NOUN - I-ORG 
. - PUNCT O 

Antibacterial PROPN - B-ORG 
Effect PROPN - I-ORG 
of ADP - I-ORG 
Diclofenac PROPN - I-ORG 
Sodium PROPN - I-ORG 
on - ADP O 
Enterococcus PROPN - B-ORG 
faecalis - NOUN O 
. - PUNCT O 

Development - PROPN O 
and - CCONJ O 
Evaluation - PROPN O 
of - ADP O 
Diclofenac PROPN - B-MEDICINE 
Sodium PROPN - I-MEDICINE 
Loaded - ADJ O 
- - PUNCT O 
N - PROPN O 
- - PUNCT O 
Trimethyl - NOUN O 
Chitosan - PROPN O 
Nanoparticles - PROPN O 
for - ADP O 
Ophthalmic - PROPN O 
Use - NOUN O 
. - PUNCT O 

Nephroprotective - ADJ O 
Effect - PROPN O 
of - ADP O 
the - DET O 
Leaves - PROPN O 
of - ADP O 
Aloe - PROPN O 
barbadensis - NOUN O 
( - PUNCT O 
Aloe PROPN - B-PERSON 
Vera PROPN - I-PERSON 
) - PUNCT O 
against - ADP O 
Toxicity - PROPN O 
Induced - VERB O 
by - ADP O 
Diclofenac PROPN - B-MEDICINE 
Sodium PROPN - I-MEDICINE 
in - ADP O 
Albino PROPN - B-GPE 
Rabbits PROPN - I-GPE 
. - PUNCT O 

Bioavailability - PROPN O 
and - CCONJ O 
Tolerability PROPN - B-ORG 
of ADP - I-ORG 
Topical PROPN - I-ORG 
and CCONJ - I-ORG 
Oral PROPN - I-ORG 
Diclofenac PROPN - I-ORG 
Sodium PROPN - I-ORG 
Administration PROPN - I-ORG 
in - ADP O 
Healthy - PROPN O 
Ponies - NOUN O 

THE - DET O 
ADJUNCTIVE - PROPN O 
LAMICTAL PROPN - B-MEDICINE 
( - PUNCT O 
LAMOTRIGINE - PROPN O 
) - PUNCT O 

Influence - NOUN O 
of - ADP O 
the - DET O 
Vehicle - PROPN O 
and - CCONJ O 
Antibiotic PROPN - B-ORG 
Formulation PROPN - I-ORG 
on ADP - I-ORG 
Cytotoxicity PROPN - I-ORG 
of ADP - I-ORG 
Triple PROPN - I-ORG 
Antibiotic PROPN - I-ORG 
Paste PROPN - I-ORG 
. - PUNCT O 

Infection PROPN - B-ORG 
Control PROPN - I-ORG 
in - ADP O 
Teeth PROPN - B-GPE 
with - ADP O 
Apical PROPN - B-ORG 
Periodontitis PROPN - I-ORG 
Using - VERB O 
a - DET O 
Triple PROPN - B-MEDICINE 
Antibiotic PROPN - I-MEDICINE 
Solution - PROPN O 
or - CCONJ O 
Calcium - PROPN O 
Hydroxide - PROPN O 
with - ADP O 
Chlorhexidine - NOUN O 
: - PUNCT O 

A - DET O 
Review - NOUN O 
on - ADP O 
Triple PROPN - B-MEDICINE 
Antibiotic PROPN - I-MEDICINE 
Paste - PROPN O 
as - ADP O 
a - DET O 
Suitable - PROPN O 
Material - PROPN O 
Used - VERB O 
in - ADP O 
Regenerative - PROPN O 
Endodontics - PROPN O 
. - PUNCT O 

Efficacy - NOUN O 
of - ADP O 
Vancomycin PROPN - B-GPE 
- - PUNCT O 
based - VERB O 
Continuous PROPN - B-ORG 
Triple PROPN - I-ORG 
Antibiotic PROPN - I-ORG 
Irrigation PROPN - I-ORG 
in - ADP O 
Immediate PROPN - B-NORP 
, - PUNCT O 
Implant - PROPN O 
- - PUNCT O 
based - VERB O 
Breast PROPN - B-GPE 
Reconstruction PROPN - I-GPE 
. - PUNCT O 

Comparison NOUN - B-ORG 
of ADP - I-ORG 
Residual PROPN - I-ORG 
Triple PROPN - I-ORG 
Antibiotic PROPN - I-ORG 
Paste PROPN - I-ORG 
, - PUNCT O 
Propolis PROPN - B-GPE 
and - CCONJ O 
Calcium PROPN - B-ORG 
Hydroxide PROPN - I-ORG 
on ADP - I-ORG 
Root - PROPN O 
Canal - PROPN O 
Walls - PROPN O 
in - ADP O 
Natural - PROPN O 
Open - PROPN O 
Apex - PROPN O 
Teeth - NOUN O 
: - PUNCT O 

Novel - ADJ O 
Microdilution - NOUN O 
Method - PROPN O 
to - ADP O 
Assess PROPN - B-ORG 
Double ADJ - I-ORG 
and - CCONJ O 
Triple PROPN - B-ORG 
Antibiotic PROPN - I-ORG 
Combination PROPN - I-ORG 
Therapy PROPN - I-ORG 

Calcium - NOUN O 
hydroxide - NOUN O 
Ca(OH)2 - PROPN O 
, - PUNCT O 
Group - PROPN O 
3 NUM - B-CARDINAL 
: - SYM O 
2 NUM - B-PERCENT 
% NOUN - I-PERCENT 
CHX - NOUN O 
gel - NOUN O 
, - PUNCT O 
Group - NOUN O 
4 NUM - B-CARDINAL 
: - PUNCT O 
Triple ADJ - B-MEDICINE 
Antibiotic ADJ - I-MEDICINE 
Paste - PROPN O 
( - PUNCT O 
TAP PROPN - B-ORG 
) - PUNCT O 

Antimicrobial - ADJ O 
Effects - NOUN O 
of - ADP O 
Novel - PROPN O 
Triple ADJ - B-MEDICINE 
Antibiotic ADJ - I-MEDICINE 
Paste - PROPN O 
- - PUNCT O 
Mimic - PROPN O 
Scaffolds - PROPN O 
on - ADP O 
Actinomyces - PROPN O 
naeslundii - VERB O 
Biofilm - PROPN O 
. - PUNCT O 

Evaluation - NOUN O 
of - ADP O 
Antimicrobial - PROPN O 
Effects - NOUN O 
of - ADP O 
Different - PROPN O 
Concentrations - PROPN O 
of - ADP O 
Triple PROPN - B-MEDICINE 
Antibiotic PROPN - I-MEDICINE 
Paste - PROPN O 
on - ADP O 
Mature - PROPN O 
Biofilm - PROPN O 
of - ADP O 
Enterococcus - PROPN O 
faecalis - NOUN O 
. - PUNCT O 

A - DET O 
Comparison NOUN - B-ORG 
between - ADP O 
the - DET O 
Antimicrobial - PROPN O 
Effects - PROPN O 
of - ADP O 
Triple PROPN - B-MEDICINE 
Antibiotic PROPN - I-MEDICINE 
Paste - PROPN O 
and - CCONJ O 
Calcium PROPN - B-PERSON 
Hydroxide PROPN - I-PERSON 
Against - PROPN O 
Entrococcus PROPN - B-PERSON 
Faecalis PROPN - I-PERSON 
. - PUNCT O 

Human - PROPN O 
APC PROPN - B-ORG 
were - VERB O 
tested - VERB O 
for - ADP O 
in - ADP O 
vitro - X O 
cytotoxicity - NOUN O 
of - ADP O 
modified - VERB O 
Triple - PROPN O 
Antibiotic PROPN - B-PERSON 
Paste PROPN - I-PERSON 
( - PUNCT O 
mTAP - PROPN O 
- - PUNCT O 
Ciprofloxacin - PROPN O 
, - PUNCT O 
Metronidazole PROPN - B-PERSON 
and - CCONJ O 
Cefaclor - PROPN O 
at - ADP O 
1:1:1 NUM - B-CARDINAL 
) - PUNCT O 
and - CCONJ O 
of - ADP O 
a - DET O 
paste - NOUN O 
of - ADP O 
Ciprofloxacin PROPN - B-ORG 
, - PUNCT O 
Metronidazole PROPN - B-PRODUCT 
and - CCONJ O 
Calcium PROPN - B-ORG 
hydroxide - NOUN O 
( - PUNCT O 
CMC - PROPN O 
- - PUNCT O 
1:1:2 - NUM O 
) - PUNCT O 
and - CCONJ O 
modified - VERB O 
CMC PROPN - B-ORG 
( - PUNCT O 
mCMC - PROPN O 
- - PUNCT O 
2:2:1 - NUM O 
) - PUNCT O 
by - ADP O 
using - VERB O 
MTT PROPN - B-ORG 
assay - NOUN O 
. - PUNCT O 

Dual - ADJ O 
versus - ADP O 
Triple PROPN - B-ORG 
Antibiotics PROPN - I-ORG 
Regimen PROPN - I-ORG 
in ADP - I-ORG 
Children PROPN - I-ORG 
with ADP - I-ORG 
Perforated PROPN - I-ORG 
Acute PROPN - I-ORG 
Appendicitis PROPN - I-ORG 
. - PUNCT O 

The - DET O 
Use - PROPN O 
of - ADP O 
Antidotes - PROPN O 
for - ADP O 
Calcium PROPN - B-MEDICINE 
Gluconate PROPN - I-MEDICINE 
Extravasation - PROPN O 
: - PUNCT O 
An - DET O 
Experimental - ADJ O 
Study - PROPN O 
in - ADP O 
Mice PROPN - B-GPE 
. - PUNCT O 

With - ADP O 
Calcium PROPN - B-MEDICINE 
Gluconate PROPN - I-MEDICINE 
: - PUNCT O 

A - DET O 
Double - PROPN O 
- - PUNCT O 
Blind - PROPN O 
, - PUNCT O 
Active PROPN - B-ORG 
- PUNCT - I-ORG 
Controlled VERB - I-ORG 
Clinical PROPN - I-ORG 
Trial PROPN - I-ORG 
of ADP - I-ORG 
Sodium PROPN - I-ORG 
Bicarbonate PROPN - I-ORG 
and CCONJ - I-ORG 
Calcium PROPN - B-MEDICINE 
Gluconate PROPN - I-MEDICINE 
in - ADP O 
the DET - B-ORG 
Treatment PROPN - I-ORG 
of ADP - I-ORG 
Bilateral PROPN - I-ORG 
Osteoarthritis PROPN - I-ORG 
of ADP - I-ORG 
the DET - I-ORG 
Knee PROPN - I-ORG 
. - PUNCT O 

Results - NOUN O 
from - ADP O 
a - DET O 
Natural - PROPN O 
Experiment - PROPN O 
Created - VERB O 
by - ADP O 
a - DET O 
Calcium PROPN - B-MEDICINE 
Gluconate PROPN - I-MEDICINE 
Shortage - PROPN O 
. - PUNCT O 

Physical PROPN - B-ORG 
Compatibility PROPN - I-ORG 
of ADP - I-ORG 
Sodium PROPN - I-ORG 
Glycerophosphate PROPN - I-ORG 
and CCONJ - I-ORG 
Calcium PROPN - B-ORG 
Gluconate PROPN - I-ORG 
in ADP - I-ORG 
Pediatric PROPN - I-ORG 
Parenteral PROPN - I-ORG 
Nutrition PROPN - I-ORG 
Solutions PROPN - I-ORG 
. - PUNCT O 

The - DET O 
study - NOUN O 
objective - NOUN O 
was - VERB O 
to - PART O 
reduce - VERB O 
aluminum - NOUN O 
( - PUNCT O 
Al PROPN - B-PERSON 
) - PUNCT O 
in - ADP O 
Calcium PROPN - B-ORG 
Gluconate PROPN - I-ORG 
Injection PROPN - I-ORG 
, - PUNCT O 
US PROPN - B-ORG 
Pharmacopeia PROPN - I-ORG 
( - PUNCT O 
USP PROPN - B-ORG 
) - PUNCT O 
used - VERB O 
in - ADP O 
the - DET O 
preparation - NOUN O 
of - ADP O 
parenteral - ADJ O 
nutrition - NOUN O 
( - PUNCT O 
PN - PROPN O 
) - PUNCT O 
solutions - NOUN O 
. - PUNCT O 

A - DET O 
flow - NOUN O 
- - PUNCT O 
through - PART O 
filter - NOUN O 
containing - VERB O 
an - DET O 
immobilized - ADJ O 
chelator - NOUN O 
that - ADJ O 
complexes - VERB O 
Al PROPN - B-ORG 
from ADP - I-ORG 
Calcium PROPN - B-ORG 
Gluconate PROPN - I-ORG 
Injection PROPN - I-ORG 
, - PUNCT O 
USP PROPN - B-ORG 
as - ADP O 
it - PRON O 
flows - VERB O 
through - ADP O 
the - DET O 
filter - NOUN O 
was - VERB O 
designed - VERB O 
, - PUNCT O 
refined - VERB O 
by - ADP O 
design - NOUN O 
modifications - NOUN O 
, - PUNCT O 
and - CCONJ O 
extensively - ADV O 
tested - VERB O 
. - PUNCT O 

When - ADV O 
a - DET O 
small - ADJ O 
- - PUNCT O 
volume - NOUN O 
parenteral - ADJ O 
vial - NOUN O 
containing - VERB O 
100 NUM - B-CARDINAL 
mL - NOUN O 
of - ADP O 
Calcium PROPN - B-ORG 
Gluconate PROPN - I-ORG 
Injection PROPN - I-ORG 
, - PUNCT O 
USP PROPN - B-ORG 
is - VERB O 
connected - VERB O 
on - ADP O 
the - DET O 
inlet - NOUN O 
side - NOUN O 
of - ADP O 
the - DET O 
filter - NOUN O 
, - PUNCT O 
and - CCONJ O 
the - DET O 
outlet - ADJ O 
side - NOUN O 
is - VERB O 
connected - VERB O 
to - ADP O 
an - DET O 
evacuated - VERB O 
receiving - VERB O 
vial - NOUN O 
, - PUNCT O 
the - DET O 
filtered - ADJ O 
solution - NOUN O 
is - VERB O 
drawn - VERB O 
into - ADP O 
the - DET O 
receiving - VERB O 
vial - NOUN O 
. - PUNCT O 

This - DET O 
constitutes - VERB O 
a - DET O 
complete - ADJ O 
system - NOUN O 
to - PART O 
remove - VERB O 
Al PROPN - B-ORG 
from ADP - I-ORG 
Calcium PROPN - B-ORG 
Gluconate PROPN - I-ORG 
Injection PROPN - I-ORG 
, - PUNCT O 
USP.The - PROPN O 
extent - NOUN O 
of - ADP O 
Al PROPN - B-PERSON 
removal - NOUN O 
is - VERB O 
flow - NOUN O 
rate - NOUN O 
dependent - ADJ O 
. - PUNCT O 

Given - VERB O 
that - ADP O 
Calcium PROPN - B-ORG 
Gluconate PROPN - I-ORG 
Injection PROPN - I-ORG 
, - PUNCT O 
USP PROPN - B-ORG 
provides - VERB O 
85 NUM - B-PERCENT 
% NOUN - I-PERCENT 
of - ADP O 
the - DET O 
Al - PROPN O 
in - ADP O 
neonatal - ADJ O 
PN - PROPN O 
solutions - NOUN O 
, - PUNCT O 
removal - NOUN O 
of - ADP O 
85 NUM - B-PERCENT 
% NOUN - I-PERCENT 
of - ADP O 
the - DET O 
Al - PROPN O 
from - ADP O 
this - DET O 
source - NOUN O 
was - VERB O 
calculated - VERB O 
to - PART O 
reduce - VERB O 
Al PROPN - B-PERSON 
delivered - VERB O 
to - ADP O 
most - ADJ O 
neonates - NOUN O 
to - PART O 
< - X O 
5 NUM - B-TIME 
mcg NOUN - I-TIME 
/ SYM - I-TIME 
kg NOUN - I-TIME 
/ - SYM O 
day - NOUN O 
. - PUNCT O 

A - DET O 
Filtration - PROPN O 
System - PROPN O 
That - ADJ O 
Greatly - ADV O 
Reduces - VERB O 
Aluminum - PROPN O 
in - ADP O 
Calcium PROPN - B-ORG 
Gluconate PROPN - I-ORG 
Injection PROPN - I-ORG 
, - PUNCT O 

Effects - NOUN O 
of - ADP O 
Calcium PROPN - B-ORG 
Gluconate PROPN - I-ORG 
, - PUNCT O 
a - DET O 
Water - PROPN O 
Soluble - PROPN O 
Calcium - PROPN O 
Salt - PROPN O 
on - ADP O 
the - DET O 
Collagen - PROPN O 
- - PUNCT O 
Induced - VERB O 
DBA/1J - PROPN O 
Mice - NOUN O 
Rheumatoid - PROPN O 
Arthritis - PROPN O 
. - PUNCT O 

Ondansetron PROPN - B-MEDICINE 
could - VERB O 
also - ADV O 
significantly - ADV O 
reduce - VERB O 
the - DET O 
frequency - NOUN O 
requirement - NOUN O 
of - ADP O 
fentanyl - NOUN O 
at - ADP O 
20 NUM - B-QUANTITY 
min NOUN - I-QUANTITY 
( - PUNCT O 
Dose NOUN - B-PERSON 
3 NUM - B-CARDINAL 
) - PUNCT O 
in - ADP O 
general - ADJ O 
anesthesia - NOUN O 
. - PUNCT O 

Effects - NOUN O 
of - ADP O 
Intraoperative PROPN - B-ORG 
Dexamethasone PROPN - I-ORG 
and - CCONJ O 
Ondansetron PROPN - B-MEDICINE 
on - ADP O 
Postoperative PROPN - B-ORG 
Nausea PROPN - I-ORG 
and CCONJ - I-ORG 
Vomiting PROPN - I-ORG 
in - ADP O 
Microvascular - PROPN O 
Decompression - PROPN O 
Surgery - PROPN O 
: - PUNCT O 
A - DET O 
Randomized - VERB O 
Controlled - PROPN O 
Study - PROPN O 
. - PUNCT O 

Ondansetron PROPN - B-MEDICINE 
is - VERB O 
one - NUM O 
of - ADP O 
the - DET O 
most - ADV O 
widely - ADV O 
used - VERB O 
drugs - NOUN O 
in - ADP O 
the - DET O 
prophylaxis - NOUN O 
of - ADP O 
PONV - PROPN O 
and - CCONJ O 
is - VERB O 
extensively - ADV O 
metabolized - VERB O 
in - ADP O 
humans - NOUN O 
. - PUNCT O 

This - DET O 
is - VERB O 
the - DET O 
first ADJ - B-ORDINAL 
reported - VERB O 
fluorescence - NOUN O 
study - NOUN O 
of - ADP O 
Ondansetron PROPN - B-MEDICINE 
in - ADP O 
Triton PROPN - B-GPE 
X - NOUN O 
100 NUM - B-CARDINAL 
system - NOUN O 
. - PUNCT O 

Ondansetron PROPN - B-MEDICINE 
- - PUNCT O 
a - DET O 
promising - ADJ O 
adjunctive - ADJ O 
treatment - NOUN O 
for - ADP O 
persistent - ADJ O 
schizophrenia - NOUN O 
. - PUNCT O 

Aromatherapy NOUN - B-ORG 
Versus PROPN - I-ORG 
Oral PROPN - I-ORG 
Ondansetron PROPN - I-MEDICINE 
for - ADP O 
Antiemetic - PROPN O 
Therapy - PROPN O 

PharmGKB - NOUN O 
summary - NOUN O 
: - PUNCT O 
Ondansetron NOUN - B-MEDICINE 
and - CCONJ O 
tropisetron - ADJ O 
pathways - NOUN O 
, - PUNCT O 
pharmacokinetics - NOUN O 
and - CCONJ O 
pharmacodynamics - NOUN O 
. - PUNCT O 

Ondansetron PROPN - B-MEDICINE 
dispensing - VERB O 
during - ADP O 
the - DET O 
first ADJ - B-ORDINAL 
trimester - NOUN O 
, - PUNCT O 
the - DET O 
period - NOUN O 
of - ADP O 
organogenesis - NOUN O 
. - PUNCT O 

A - DET O 
Comparison PROPN - B-ORG 
of ADP - I-ORG 
Metoclopramide PROPN - I-ORG 
and - CCONJ O 
Ondansetron PROPN - B-MEDICINE 
Efficacy PROPN - I-PERSON 
for - ADP O 
the DET - B-ORG 
Prevention PROPN - I-ORG 
of ADP - I-ORG 
Nausea PROPN - I-ORG 
and CCONJ - I-ORG 
Vomiting NOUN - I-ORG 

Investigation - NOUN O 
of - ADP O 
Ondansetron PROPN - B-MEDICINE 
, - PUNCT O 
Haloperidol PROPN - B-PERSON 
, - PUNCT O 
and - CCONJ O 
Dexmedetomidine PROPN - B-PERSON 
Efficacy PROPN - I-PERSON 
for - ADP O 
Prevention - PROPN O 
of - ADP O 
Postoperative - PROPN O 
Nausea - PROPN O 
and - CCONJ O 
Vomiting - PROPN O 

Ondansetron NOUN - B-MEDICINE 
or - CCONJ O 
promethazine - NOUN O 
: - PUNCT O 

Ondansetron PROPN - B-MEDICINE 
caused - VERB O 
concentration - NOUN O 
dependent - ADJ O 
bradycardia - NOUN O 
and - CCONJ O 
arrhythmia - NOUN O 
. - PUNCT O 

Oral - PROPN O 
Ondansetron PROPN - B-MEDICINE 
Offers - VERB O 
Effective - PROPN O 
Antidiarrheal - PROPN O 
Activity - PROPN O 
for - ADP O 
Carcinoid - PROPN O 
Syndrome - PROPN O 
Refractory - PROPN O 
to - ADP O 
Somatostatin PROPN - B-PERSON 
Analogs PROPN - I-PERSON 
. - PUNCT O 

Effect - NOUN O 
of - ADP O 
the DET - B-ORG 
Dexamethasone PROPN - I-ORG 
- PUNCT - I-ORG 
Ondansetron PROPN - I-MEDICINE 
Combination PROPN - I-ORG 
Versus PROPN - I-ORG 
Dexamethasone PROPN - I-ORG 
- PUNCT - I-ORG 
Aprepitant PROPN - I-ORG 
Combination PROPN - I-ORG 
to ADP - I-ORG 
Prevent VERB - I-ORG 
Postoperative PROPN - I-ORG 
Nausea PROPN - I-ORG 
and CCONJ - I-ORG 
Vomiting PROPN - I-ORG 
. - PUNCT O 

Ondansetron PROPN - B-MEDICINE 
use - NOUN O 
was - VERB O 
not - ADV O 
associated - VERB O 
with - ADP O 
an - DET O 
increased - VERB O 
risk - NOUN O 
for - ADP O 
most - ADJ O 
of - ADP O 
the - DET O 
51 NUM - B-CARDINAL 
defect - NOUN O 
groups - NOUN O 
analyzed - VERB O 
. - PUNCT O 

Assessing - VERB O 
the - DET O 
Efficacy - PROPN O 
of - ADP O 
Maropitant PROPN - B-GPE 
Versus PROPN - I-GPE 
Ondansetron PROPN - B-MEDICINE 
in - ADP O 
the DET - B-ORG 
Treatment PROPN - I-ORG 
of ADP - I-ORG 
Dogs PROPN - I-ORG 
with ADP - I-ORG 
Parvoviral PROPN - I-ORG 
Enteritis PROPN - I-ORG 
. - PUNCT O 

Ondansetron PROPN - B-MEDICINE 
appears - VERB O 
to - PART O 
have - VERB O 
benefit - NOUN O 
in - ADP O 
improving - VERB O 
positive - ADJ O 
symptoms - NOUN O 
of - ADP O 
psychosis - NOUN O 
in - ADP O 
individuals - NOUN O 
with - ADP O 
Parkinson - PROPN O 
's - PART O 
disease - NOUN O 
, - PUNCT O 
but - CCONJ O 
RCTs - NOUN O 
are - VERB O 
needed - VERB O 
before - ADP O 
routine - ADJ O 
use - NOUN O 
is - VERB O 
recommended - VERB O 
. - PUNCT O 

Oral - PROPN O 
Ondansetron PROPN - B-MEDICINE 
to - ADP O 
Reduce - VERB O 
Intravenous - PROPN O 
Fluid - PROPN O 
Rehydration - PROPN O 
: - PUNCT O 
Context PROPN - B-PERSON 
Matters PROPN - I-PERSON 
. - PUNCT O 

Comment - NOUN O 
on - ADP O 
: - PUNCT O 
Ondansetron PROPN - B-MEDICINE 
in - ADP O 
Pregnancy PROPN - B-GPE 
and - CCONJ O 
the DET - B-WORK_OF_ART 
Risk PROPN - I-WORK_OF_ART 
of ADP - I-WORK_OF_ART 
Congenital ADJ - I-WORK_OF_ART 
Malformations NOUN - I-WORK_OF_ART 
: - PUNCT O 
A - PROPN O 
Systematic - PROPN O 
Review - PROPN O 
. - PUNCT O 

Ondansetron PROPN - B-MEDICINE 
( - PUNCT O 
0.01 NUM - B-CARDINAL 
  - SPACE O 
mg - NOUN O 
/ - SYM O 
kg - NOUN O 
, - PUNCT O 
0.1 NUM - B-CARDINAL 
  - SPACE O 
mg - NOUN O 
/ - SYM O 
kg - NOUN O 
or - CCONJ O 
vehicle - NOUN O 
) - PUNCT O 
was - VERB O 
administered - VERB O 
before - ADP O 
the DET - B-TIME 
hour NOUN - I-TIME 
of - ADP O 
consumption - NOUN O 
in - ADP O 
the - DET O 
initial - ADJ O 
phase - NOUN O 
( - PUNCT O 
days - NOUN O 
1 - NUM O 
, - PUNCT O 
2 NUM - B-CARDINAL 
, - PUNCT O 
3 NUM - B-DATE 
) - PUNCT O 
of - ADP O 
the - DET O 
procedure - NOUN O 
, - PUNCT O 
and - CCONJ O 
after - ADP O 
prolonged - ADJ O 
alcohol - NOUN O 
intake - NOUN O 
( - PUNCT O 
days - NOUN O 
11 NUM - B-DATE 
, - PUNCT O 
12 NUM - B-DATE 
, - PUNCT O 
13 NUM - B-DATE 
) - PUNCT O 
. - PUNCT O 

Ondansetron PROPN - B-MEDICINE 
in - ADP O 
Pregnancy PROPN - B-GPE 
and - CCONJ O 
the DET - B-WORK_OF_ART 
Risk PROPN - I-WORK_OF_ART 
of ADP - I-WORK_OF_ART 
Congenital ADJ - I-WORK_OF_ART 
Malformations NOUN - I-WORK_OF_ART 
: - PUNCT O 
A - PROPN O 
Systematic - PROPN O 
Review - PROPN O 
. - PUNCT O 

Ondansetron PROPN - B-MEDICINE 
8 NUM - B-CARDINAL 
mg - NOUN O 
and - CCONJ O 
4 NUM - B-CARDINAL 
mg - PRON O 
with - ADP O 
normal - ADJ O 
saline - NOUN O 
against - ADP O 
post - ADJ O 
- - ADJ O 
operative - ADJ O 
headache - NOUN O 
and - CCONJ O 
nausea - NOUN O 
/ - SYM O 
vomiting - NOUN O 
after - ADP O 
spinal - ADJ O 
anesthesia - NOUN O 
: - PUNCT O 
a - DET O 
randomized - VERB O 
double - ADJ O 
- - PUNCT O 
blind - ADJ O 
trial - NOUN O 
. - PUNCT O 

[ - PUNCT O 
Adding - VERB O 
Ondansetron PROPN - B-MEDICINE 
in - ADP O 
Morphine PROPN - B-ORG 
Intravenous PROPN - I-ORG 
Analgesia PROPN - I-ORG 
Pump PROPN - B-ORG 
for ADP - I-ORG 
Prevention PROPN - I-ORG 
of ADP - I-ORG 
Postoperative PROPN - I-ORG 
Nausea PROPN - I-ORG 
and CCONJ - I-ORG 
Vomiting PROPN - I-ORG 
in - ADP O 
Women]. PROPN - B-GPE 

Association - NOUN O 
of - ADP O 
anti - ADJ O 
- - ADJ O 
emetic - ADJ O 
efficacy - NOUN O 
of - ADP O 
Ondansetron PROPN - B-MEDICINE 
with - ADP O 
18792A - PROPN O 
> - X O 
G - NOUN O 
polymorphism - NOUN O 
in - ADP O 
a - DET O 
drug - NOUN O 
target - NOUN O 
gene - NOUN O 
5-HT3B - NUM O 
in - ADP O 
Pakistani ADJ - B-NORP 
population - NOUN O 
. - PUNCT O 

Ondansetron PROPN - B-MEDICINE 
, - PUNCT O 
an - DET O 
antiemetic - NOUN O 
is - VERB O 
a - DET O 
serotonin - ADJ O 
receptor - NOUN O 
antagonist - NOUN O 
. - PUNCT O 

Ondansetron PROPN - B-MEDICINE 
hydrochloride - NOUN O 
( - PUNCT O 
OND PROPN - B-ORG 
) - PUNCT O 
is - VERB O 
commonly - ADV O 
used - VERB O 
for - ADP O 
management - NOUN O 
of - ADP O 
postoperative - NOUN O 
and - CCONJ O 
chemotherapeutic - NOUN O 
- - PUNCT O 
induced - VERB O 
nausea - NOUN O 
and - CCONJ O 
vomiting - NOUN O 
. - PUNCT O 

Transdermal ADJ - B-ORG 
Delivery NOUN - I-ORG 
of - ADP O 
Ondansetron PROPN - B-MEDICINE 
Hydrochloride PROPN - I-ORG 
via ADP - I-ORG 
Bilosomal PROPN - I-ORG 
Systems PROPN - I-ORG 
: - PUNCT O 

Ondansetron PROPN - B-MEDICINE 
blocks - VERB O 
wild - ADJ O 
- - PUNCT O 
type - NOUN O 
and - CCONJ O 
p - NOUN O 
. - PUNCT O 

Effect - NOUN O 
of - ADP O 
Intravenous - PROPN O 
Ondansetron PROPN - B-MEDICINE 
on - ADP O 
the DET - B-ORG 
QT PROPN - I-ORG 
Interval PROPN - I-ORG 
of ADP - I-ORG 
Patients PROPN - I-ORG 
' PART - I-ORG 
Electrocardiograms NOUN - I-ORG 
. - PUNCT O 

Aromatherapy NOUN - B-ORG 
Versus PROPN - I-ORG 
Oral PROPN - I-ORG 
Ondansetron PROPN - I-MEDICINE 
for - ADP O 
  - SPACE O 
Antiemetic - PROPN O 
Therapy - PROPN O 

Ondansetron PROPN - B-MEDICINE 
hydrochloride - NOUN O 
OR=7.12 - PROPN O 
( - PUNCT O 
95 NUM - B-PERCENT 
% NOUN - I-PERCENT 
CI - PROPN O 
, - PUNCT O 
1.59 NUM - B-CARDINAL 
– - NOUN O 
31.9 NUM - B-CARDINAL 
) - PUNCT O 
resulted - VERB O 
in - ADP O 
the - DET O 
highest - ADJ O 
odds - NOUN O 
of - ADP O 
pneumothorax - NOUN O 
. - PUNCT O 

Ondansetron PROPN - B-MEDICINE 
may - VERB O 
be - VERB O 
prescribed - VERB O 
if - ADP O 
needed - VERB O 
to - PART O 
prevent - VERB O 
vomiting - NOUN O 
and - CCONJ O 
improve - VERB O 
tolerance - NOUN O 
of - ADP O 
oral - ADJ O 
rehydration - NOUN O 
solutions - NOUN O 
. - PUNCT O 

Sodium - NOUN O 
Dodecyl - PROPN O 
Sulphate - PROPN O 
- - PUNCT O 
Supported - PROPN O 
Nanocomposite - PROPN O 
as - ADP O 
Drug - PROPN O 
Carrier - PROPN O 
System - PROPN O 
for - ADP O 
Controlled - PROPN O 
Delivery - PROPN O 
of - ADP O 
Ondansetron PROPN - B-MEDICINE 
. - PUNCT O 

Ondansetron PROPN - B-MEDICINE 
minskar - ADJ O 
kräkningar - NOUN O 
hos - PRON O 
barn - NOUN O 

Ondansetron PROPN - B-MEDICINE 
Prescription PROPN - I-ORG 
for ADP - I-ORG 
Home PROPN - I-ORG 
Use PROPN - I-ORG 
in - ADP O 
a DET - B-ORG 
Pediatric PROPN - I-ORG 
Emergency PROPN - I-ORG 
Department PROPN - I-ORG 
. - PUNCT O 

A - DET O 
Comparison PROPN - B-ORG 
of ADP - I-ORG 
Fosaprepitant PROPN - I-ORG 
and - CCONJ O 
Ondansetron PROPN - B-MEDICINE 
for - ADP O 
Preventing - VERB O 
Postoperative - ADJ O 
Nausea - PROPN O 
and - CCONJ O 
Vomiting - PROPN O 
in - ADP O 
Moderate - PROPN O 
to - ADP O 
High - ADJ O 
Risk - NOUN O 
Patients - NOUN O 
: - PUNCT O 
A - DET O 
Retrospective - PROPN O 
Database - PROPN O 
Analysis - PROPN O 
. - PUNCT O 

Ondansetron PROPN - B-MEDICINE 
has - VERB O 
been - VERB O 
reported - VERB O 
to - PART O 
reduce - VERB O 
the - DET O 
incidence - NOUN O 
of - ADP O 
SAIH - PROPN O 
in - ADP O 
patients - NOUN O 
undergoing - VERB O 
cesarean - ADJ O 
section - NOUN O 
. - PUNCT O 

Prophylactic - PROPN O 
Effects - PROPN O 
of - ADP O 
Ephedrine - PROPN O 
, - PUNCT O 
Ondansetron PROPN - B-MEDICINE 
and - CCONJ O 
Ringer PROPN - B-PERSON 
on - ADP O 
Hemodynamic - PROPN O 
Changes - PROPN O 
during - ADP O 
Cesarean - PROPN O 
Section - PROPN O 
under - ADP O 
Spinal PROPN - B-PERSON 
Anesthesia PROPN - I-PERSON 
- - PUNCT O 
a - DET O 
randomized - VERB O 
clinical - ADJ O 
trial - NOUN O 
. - PUNCT O 

Furthermore - ADV O 
, - PUNCT O 
ondansetron NOUN - B-MEDICINE 
reduced - VERB O 
diarrhea - NOUN O 
episodes - NOUN O 
, - PUNCT O 
most - ADV O 
pronounced - VERB O 
in - ADP O 
children - NOUN O 
that - ADJ O 
had - VERB O 
been - VERB O 
sick - ADJ O 
for - ADP O 
more ADJ - B-DATE 
than ADP - I-DATE 
3 NUM - I-DATE 
days NOUN - I-DATE 
before - ADP O 
treatment - NOUN O 
( - PUNCT O 
p - VERB O 
= - SYM O 
0.028).Ondansetron - NUM O 
may - VERB O 
be - VERB O 
a - DET O 
beneficial - ADJ O 
treatment - NOUN O 
for - ADP O 
children - NOUN O 
with - ADP O 
rotavirus - NOUN O 
gastroenteritis - NOUN O 
. - PUNCT O 

Use - PROPN O 
of - ADP O 
Prophylactic PROPN - B-GPE 
Ondansetron PROPN - I-MEDICINE 
with - ADP O 
Intravenous PROPN - B-ORG 
Opioids PROPN - I-ORG 
in ADP - I-ORG 
Emergency PROPN - I-ORG 
Department PROPN - I-ORG 
Patients PROPN - I-ORG 
: - PUNCT O 
A - DET O 
Prospective - ADJ O 
Observational - PROPN O 
Pilot - PROPN O 
Study - PROPN O 
. - PUNCT O 

Severe - ADJ O 
Proarrhythmic - PROPN O 
Potential - PROPN O 
of - ADP O 
the - DET O 
Antiemetic - PROPN O 
Agents - PROPN O 
Ondansetron PROPN - B-MEDICINE 
and - CCONJ O 
Domperidone NOUN - B-PERSON 
. - PUNCT O 

Prevention - PROPN O 
of - ADP O 
Shivering - PROPN O 
during - ADP O 
Spinal PROPN - B-LAW 
Anesthesia PROPN - I-LAW 
: PUNCT - I-LAW 
Comparison NOUN - I-LAW 
between - ADP O 
Tramadol PROPN - B-GPE 
, - PUNCT O 
Ketamine PROPN - B-GPE 
and - CCONJ O 
Ondansetron PROPN - B-MEDICINE 
. - PUNCT O 

Ondansetron PROPN - B-MEDICINE 
does - VERB O 
not - ADV O 
prevent - VERB O 
physical - ADJ O 
dependence - NOUN O 
in - ADP O 
patients - NOUN O 
taking - VERB O 
opioid - ADJ O 
medications - NOUN O 
chronically - ADV O 
for - ADP O 
pain - NOUN O 
control - NOUN O 
. - PUNCT O 

Ondansetron PROPN - B-MEDICINE 
was - VERB O 
administered - VERB O 
subcutaneously - ADV O 
at - ADP O 
a - DET O 
dose - NOUN O 
of - ADP O 
3 NUM - B-CARDINAL 
  - SPACE O 
mg - NOUN O 
/ - SYM O 
kg - NOUN O 
. - PUNCT O 

The - DET O 
5-HT3 - PROPN O 
Receptor - PROPN O 
Antagonist - PROPN O 
Ondansetron PROPN - B-MEDICINE 
Attenuates - VERB O 
Pancreatic - PROPN O 
Injury - PROPN O 
in - ADP O 
Cerulein PROPN - B-GPE 
- PUNCT - I-GPE 
Induced PROPN - I-GPE 
Acute - PROPN O 
Pancreatitis - PROPN O 
Model - PROPN O 
. - PUNCT O 

Ondansetron PROPN - B-MEDICINE 
Does - VERB O 
Not - ADV O 
Reduce - VERB O 
Withdrawal - PROPN O 
in - ADP O 
Patients PROPN - B-ORG 
With ADP - I-ORG 
Physical PROPN - I-ORG 
Dependence PROPN - I-ORG 
on - ADP O 
Chronic - PROPN O 
Opioid - PROPN O 
Therapy - PROPN O 
. - PUNCT O 

Oral - ADJ O 
fluid - NOUN O 
intake - NOUN O 
after - ADP O 
receiving - VERB O 
medication - NOUN O 
was - VERB O 
statistically - ADV O 
better - ADJ O 
with - ADP O 
Ondansetronwhile PROPN - B-PERSON 
also - ADV O 
having - VERB O 
less - ADJ O 
side - NOUN O 
effects - NOUN O 
compared - VERB O 
to - ADP O 
the - DET O 
other - ADJ O 
two NUM - B-CARDINAL 
agents - NOUN O 
. - PUNCT O 

Ondansetron PROPN - B-MEDICINE 
, - PUNCT O 
an - DET O 
Htr3 PROPN - B-GPE 
antagonist - NOUN O 
, - PUNCT O 
decreased - VERB O 
Kv PROPN - B-PERSON 
currents - NOUN O 
in - ADP O 
WT PROPN - B-ORG 
- PUNCT - I-ORG 
LP PROPN - I-ORG 
mice - NOUN O 
, - PUNCT O 
but - CCONJ O 
not - ADV O 
in - ADP O 
WT PROPN - B-ORG 
- PUNCT - I-ORG 
NP PROPN - I-ORG 
mice - NOUN O 
. - PUNCT O 

Ondansetron PROPN - B-MEDICINE 
has - VERB O 
proven - VERB O 
to - PART O 
be - VERB O 
a - DET O 
safe - ADJ O 
and - CCONJ O 
effective - ADJ O 
adjunct - NOUN O 
in - ADP O 
children - NOUN O 
with - ADP O 
vomiting - VERB O 
. - PUNCT O 

Ondansetron NOUN - B-MEDICINE 
and - CCONJ O 
maropitant - NOUN O 
reduced - VERB O 
overall - ADV O 
the - DET O 
area - NOUN O 
under - ADP O 
the - DET O 
curve - NOUN O 
of - ADP O 
nausea - NOUN O 
behaviour - NOUN O 
score - NOUN O 
by - ADP O 
90 NUM - B-PERCENT 
% NOUN - I-PERCENT 
and - CCONJ O 
25 NUM - B-PERCENT 
% NOUN - I-PERCENT 
, - PUNCT O 
respectively - ADV O 
. - PUNCT O 

Arrhythmic PROPN - B-PERSON 
Side PROPN - I-PERSON 
of - ADP O 
Ondansetron PROPN - B-MEDICINE 
Alongside - PROPN O 
Antiemetic - PROPN O 
Effect - PROPN O 
. - PUNCT O 

Co - NOUN O 
- - NOUN O 
administration - NOUN O 
of - ADP O 
Cyclosporin PROPN - B-ORG 
A PROPN - I-ORG 
and - CCONJ O 
Ondansetron PROPN - B-MEDICINE 
decreases - VERB O 
transient - ADJ O 
local - ADJ O 
cerebral - ADJ O 
ischemic - ADJ O 
injury - NOUN O 
in - ADP O 
the - DET O 
mouse - NOUN O 
. - PUNCT O 

Effect - NOUN O 
of - ADP O 
Ondansetron PROPN - B-MEDICINE 
on - ADP O 
Prevention - PROPN O 
of - ADP O 
Ventilator - PROPN O 
Associated - PROPN O 
Pneumonia - PROPN O 
in - ADP O 
Intensive PROPN - B-ORG 
Care PROPN - I-ORG 
Unit PROPN - I-ORG 
Patients PROPN - I-ORG 
in - ADP O 
Kashani PROPN - B-ORG 
Hospital PROPN - I-ORG 
in - ADP O 
2013 NUM - B-DATE 
. - PUNCT O 

Ondansetron NOUN - B-MEDICINE 
for - ADP O 
neuraxial - ADJ O 
morphine - NOUN O 
- - PUNCT O 
induced - VERB O 
pruritus - NOUN O 
: - PUNCT O 

Thirty NUM - B-CARDINAL 
drugs - NOUN O 
were - VERB O 
involved - VERB O 
in - ADP O 
the - DET O 
pharmaceutical - ADJ O 
interventions - NOUN O 
, - PUNCT O 
Carboplatin PROPN - B-GPE 
and - CCONJ O 
Ondansetron PROPN - B-MEDICINE 
being - VERB O 
the - DET O 
most - ADV O 
frequent - ADJ O 
. - PUNCT O 

Comparison - NOUN O 
of - ADP O 
Antiemetic - PROPN O 
Effectiveness - PROPN O 
of - ADP O 
Palonosetron - PROPN O 
Versus PROPN - B-PERSON 
Ondansetron PROPN - I-MEDICINE 
in - ADP O 
Patients PROPN - B-GPE 
on - ADP O 
Cancer - PROPN O 
Chemotherapy PROPN - B-PERSON 
: - PUNCT O 
A - DET O 
Prospective - ADJ O 
Observational - PROPN O 
Study - PROPN O 
in - ADP O 
South PROPN - B-NORP 
Indians PROPN - I-NORP 
. - PUNCT O 

The DET - B-LAW 
Comparative PROPN - I-LAW 
Study PROPN - I-LAW 
of ADP - I-LAW 
Ondansetron PROPN - I-MEDICINE 
and CCONJ - I-LAW 
Metoclopramide PROPN - I-LAW 
Effects PROPN - I-LAW 
in ADP - I-LAW 
Reducing VERB - I-LAW 
Nausea PROPN - I-LAW 
and CCONJ - I-LAW 
Vomiting PROPN - I-LAW 
After ADP - I-LAW 
Laparoscopic PROPN - I-LAW 
Cholecystectomy PROPN - I-LAW 
. - PUNCT O 

Ondansetron PROPN - B-MEDICINE 
has - VERB O 

 - SPACE O 
been - VERB O 
studied - VERB O 
in - ADP O 
the - DET O 
attenuation - NOUN O 
of - ADP O 
spinal - ADJ O 
anesthesia– - NOUN O 

 - SPACE O 
induced - VERB O 
hypotension - NOUN O 
( - PUNCT O 
SIH - PROPN O 
) - PUNCT O 
and - CCONJ O 
bradycardia - NOUN O 
because - ADP O 
of - ADP O 

 - SPACE O 
its - ADJ O 
antagonistic - ADJ O 
effect - NOUN O 
on - ADP O 
the - DET O 
Bezold - PROPN O 
- - PUNCT O 
Jarisch - PROPN O 
reflex - NOUN O 
. - PUNCT O 

Heparin PROPN - B-MEDICINE 
Sodium NOUN - I-MEDICINE 
Combined - VERB O 
with - ADP O 
Magnesium - PROPN O 
Sulfate - PROPN O 
in - ADP O 
the DET - B-ORG 
Treatment PROPN - I-ORG 
of ADP - I-ORG 
Patients PROPN - I-ORG 
with - ADP O 
Severe - PROPN O 
Preeclampsia - PROPN O 
. - PUNCT O 

A - DET O 
Biopolymer - PROPN O 
Heparin PROPN - B-MEDICINE 
Sodium PROPN - I-MEDICINE 
Interlayer - PROPN O 
Anchoring - PROPN O 
TiO2 - PROPN O 
and - CCONJ O 
MAPbI3 - PROPN O 
Enhances - PROPN O 
Trap - PROPN O 
Passivation - PROPN O 
and - CCONJ O 
Device - PROPN O 
Stability - PROPN O 
in - ADP O 
Perovskite - PROPN O 
Solar - PROPN O 
Cells - PROPN O 
. - PUNCT O 

Comparison NOUN - B-ORG 
on ADP - I-ORG 
Anticoagulation PROPN - I-ORG 
and CCONJ - I-ORG 
Antiplatelet PROPN - I-ORG 
Aggregation PROPN - I-ORG 
Effects PROPN - I-ORG 
of ADP - I-ORG 
Puerarin PROPN - I-ORG 
with - ADP O 
Heparin PROPN - B-PERSON 
Sodium PROPN - I-PERSON 
and - CCONJ O 
Tirofiban PROPN - B-PERSON 
Hydrochloride PROPN - I-PERSON 
: - PUNCT O 

Porcine - NOUN O 
samples - NOUN O 
met - VERB O 
the - DET O 
current - ADJ O 
criteria - NOUN O 
as - ADP O 
laid - VERB O 
out - PART O 
in - ADP O 
the - DET O 
USP PROPN - B-ORG 
Heparin PROPN - B-MEDICINE 
Sodium PROPN - I-MEDICINE 
monograph - NOUN O 
. - PUNCT O 

Turgor - PROPN O 
Pressure - PROPN O 
Effects - NOUN O 
on - ADP O 
Textural - PROPN O 
Behavior - PROPN O 
of - ADP O 
Honeydew PROPN - B-MEDICINE 
Melon PROPN - I-MEDICINE 

Endovascular - PROPN O 
Denervation - PROPN O 
: - PUNCT O 
A - DET O 
New - PROPN O 
Approach - PROPN O 
for - ADP O 
Cancer - PROPN O 
Pain PROPN - B-MEDICINE 
Relief PROPN - I-MEDICINE 
? - PUNCT O 

Improved PROPN - B-PERSON 
Morphine PROPN - I-PERSON 
- PUNCT - I-PERSON 
Loaded VERB - I-PERSON 
Hydrogels NOUN - B-ORG 
for ADP - I-ORG 
Wound PROPN - I-ORG 
- PUNCT - I-ORG 
Related VERB - I-ORG 
Pain PROPN - I-ORG 
Relief PROPN - I-ORG 
. - PUNCT O 

Prehospital PROPN - B-ORG 
Analgesic PROPN - I-ORG 
Administration PROPN - I-ORG 
by - ADP O 
Parents - NOUN O 
for - ADP O 
Pain PROPN - B-MEDICINE 
Relief PROPN - I-MEDICINE 
in - ADP O 
Children - PROPN O 
. - PUNCT O 

A - DET O 
Phenomenological - ADJ O 
Study - PROPN O 
of - ADP O 
Pain PROPN - B-MEDICINE 
Relief PROPN - I-MEDICINE 
by - ADP O 
Cannabis - PROPN O 
. - PUNCT O 

Solving - VERB O 
the - DET O 
Global - PROPN O 
Crisis - PROPN O 
in - ADP O 
Access - NOUN O 
to - ADP O 
Pain PROPN - B-MEDICINE 
Relief NOUN - I-MEDICINE 
: - PUNCT O 
Lessons - NOUN O 
From - ADP O 
Country - PROPN O 
Actions - PROPN O 
. - PUNCT O 

Cancer - PROPN O 
Pain PROPN - B-MEDICINE 
Relief NOUN - I-MEDICINE 

Addressing - VERB O 
the DET - B-ORG 
Clinical PROPN - I-ORG 
Need PROPN - I-ORG 
for ADP - I-ORG 
Novel PROPN - I-ORG 
Nonopioid PROPN - I-ORG 
Pain PROPN - I-ORG 
Relief PROPN - I-ORG 
Therapies PROPN - I-ORG 
for ADP - I-ORG 
Cancer PROPN - I-ORG 
Patients PROPN - I-ORG 
. - PUNCT O 

Tanezumab - ADJ O 
: - PUNCT O 
Finally - ADV O 
a - DET O 
Monoclonal - PROPN O 
Antibody - PROPN O 
for - ADP O 
Pain PROPN - B-MEDICINE 
Relief PROPN - I-MEDICINE 
. - PUNCT O 

Two NUM - B-CARDINAL 
- - PUNCT O 
Point - PROPN O 
Discrimination - PROPN O 
Predicts - PROPN O 
Pain PROPN - B-MEDICINE 
Relief PROPN - I-MEDICINE 
after - ADP O 
Lower - PROPN O 
Limb - PROPN O 
Nerve - PROPN O 
Decompression - PROPN O 
for - ADP O 
Painful - ADJ O 
Diabetic - PROPN O 
Peripheral - PROPN O 
Neuropathy - PROPN O 
. - PUNCT O 

Reply - NOUN O 
: - PUNCT O 
Two NUM - B-CARDINAL 
- - PUNCT O 
Point - PROPN O 
Discrimination - PROPN O 
Predicts - PROPN O 
Pain PROPN - B-MEDICINE 
Relief PROPN - I-MEDICINE 
after - ADP O 
Lower - PROPN O 
Limb - PROPN O 
Nerve - PROPN O 
Decompression - PROPN O 
for - ADP O 
Painful - ADJ O 
Diabetic - PROPN O 
Peripheral - PROPN O 
Neuropathy - PROPN O 
. - PUNCT O 

Optimal - PROPN O 
Laser - PROPN O 
Phototherapy - PROPN O 
Parameters - NOUN O 
for - ADP O 
Pain PROPN - B-MEDICINE 
Relief PROPN - I-MEDICINE 
. - PUNCT O 

Non - ADJ O 
- - ADJ O 
pharmacologic - ADJ O 
Measures - NOUN O 
for - ADP O 
Pain PROPN - B-MEDICINE 
Relief PROPN - I-MEDICINE 
in - ADP O 
Preterm - PROPN O 
Neonates - PROPN O 
. - PUNCT O 

Brain PROPN - B-ORG 
Dynamics PROPN - I-ORG 
and CCONJ - I-ORG 
Temporal PROPN - I-ORG 
Summation PROPN - I-ORG 
of ADP - I-ORG 
Pain PROPN - I-ORG 
Predicts PROPN - I-ORG 
Neuropathic PROPN - I-ORG 
Pain PROPN - I-ORG 
Relief PROPN - I-ORG 
from - ADP O 
Ketamine PROPN - B-ORG 
Infusion PROPN - I-ORG 
. - PUNCT O 

Efficacy - NOUN O 
of - ADP O 
Intraperitoneal PROPN - B-ORG 
Bupivacaine PROPN - I-ORG 
on ADP - I-ORG 
Pain PROPN - B-MEDICINE 
Relief NOUN - I-MEDICINE 

NF PROPN - B-GPE 
- - PUNCT O 
KappaB - NOUN O 
Pathway - NOUN O 
Is - VERB O 
Involved - VERB O 
in - ADP O 
Bone - PROPN O 
Marrow - PROPN O 
Stromal - PROPN O 
Cell - PROPN O 
- - PUNCT O 
Produced - VERB O 
Pain PROPN - B-MEDICINE 
Relief PROPN - I-MEDICINE 
. - PUNCT O 

The - DET O 
Efficacy - NOUN O 
of - ADP O 
Lidocaine - PROPN O 
Spray - PROPN O 
in - ADP O 
Pain PROPN - B-MEDICINE 
Relief PROPN - I-MEDICINE 
during - ADP O 
Outpatient - PROPN O 
- - PUNCT O 
Based - VERB O 
Endometrial - PROPN O 
Sampling - NOUN O 
: - PUNCT O 

Comparison - NOUN O 
of - ADP O 
the - DET O 
Effects - NOUN O 
of - ADP O 
Epidural - PROPN O 
Analgesia - PROPN O 
and - CCONJ O 
Patient - PROPN O 
- - PUNCT O 
controlled - VERB O 
Intravenous PROPN - B-ORG 
Analgesia PROPN - I-ORG 
on - ADP O 
Postoperative - PROPN O 
Pain PROPN - B-MEDICINE 
Relief PROPN - I-MEDICINE 
and - CCONJ O 
Recovery - PROPN O 
After - ADP O 
Laparoscopic - PROPN O 
Gastrectomy - PROPN O 
for - ADP O 
Gastric - PROPN O 
Cancer - PROPN O 
. - PUNCT O 

Effectiveness - NOUN O 
of - ADP O 
Sucrose - PROPN O 
Used - VERB O 
Routinely - ADV O 
for - ADP O 
Pain PROPN - B-MEDICINE 
Relief PROPN - I-MEDICINE 
and - CCONJ O 
Neonatal - PROPN O 
Clinical - PROPN O 
Risk - PROPN O 
in - ADP O 
Preterm - PROPN O 
Infants - PROPN O 
: - PUNCT O 
A - DET O 
Nonrandomized - PROPN O 
Study - PROPN O 
. - PUNCT O 

Role - NOUN O 
of - ADP O 
Heparin PROPN - B-ORG 
Irrigation PROPN - I-ORG 
in - ADP O 
the - DET O 
Management - PROPN O 
of - ADP O 
Superficial - PROPN O 
Burns - PROPN O 
with - ADP O 
Special - PROPN O 
Reference - PROPN O 
to - ADP O 
Pain PROPN - B-MEDICINE 
Relief PROPN - I-MEDICINE 
and - CCONJ O 
Wound PROPN - B-PERSON 
Healing PROPN - I-PERSON 
: - PUNCT O 
A PROPN - B-WORK_OF_ART 
Pilot PROPN - I-WORK_OF_ART 
Study PROPN - I-WORK_OF_ART 
. - PUNCT O 

Potential ADJ - B-ORG 
Uses NOUN - I-ORG 
of ADP - I-ORG 
Isolated PROPN - I-ORG 
Toxin PROPN - I-ORG 
Peptides PROPN - I-ORG 
in - ADP O 
Neuropathic - PROPN O 
Pain PROPN - B-MEDICINE 
Relief PROPN - I-MEDICINE 
: - PUNCT O 
A - PROPN O 
Literature - PROPN O 
Review - PROPN O 
. - PUNCT O 

Sustainability - NOUN O 
of - ADP O 
Pain PROPN - B-MEDICINE 
Relief PROPN - I-MEDICINE 

Acupuncture - VERB O 
and - CCONJ O 
Sham - PROPN O 
Acupuncture - PROPN O 
for - ADP O 
Pain PROPN - B-MEDICINE 
Relief PROPN - I-MEDICINE 
- - PUNCT O 
Reply - PROPN O 
. - PUNCT O 

Effects - NOUN O 
of - ADP O 
Pranoprofen PROPN - B-ORG 
on - ADP O 
Aqueous - PROPN O 
Humor - PROPN O 
Monocyte - PROPN O 
Chemoattractant - PROPN O 
Protein-1 - PROPN O 
Level - PROPN O 
and - CCONJ O 
Pain PROPN - B-MEDICINE 
Relief PROPN - I-MEDICINE 

Pethidine - PROPN O 
in - ADP O 
Low - PROPN O 
Doses - PROPN O 
versus - ADP O 
Dipyrone - NOUN O 
for - ADP O 
Pain PROPN - B-MEDICINE 
Relief PROPN - I-MEDICINE 
in - ADP O 
Labor - PROPN O 
: - PUNCT O 
A - DET O 
Randomized - VERB O 
Controlled - PROPN O 
Trial - PROPN O 
. - PUNCT O 

Selective - ADJ O 
L4 - NOUN O 
Dorsal - PROPN O 
Root - PROPN O 
Ganglion - PROPN O 
Stimulation - PROPN O 
Evokes - PROPN O 
Pain PROPN - B-MEDICINE 
Relief PROPN - I-MEDICINE 
and - CCONJ O 
Changes - PROPN O 
of - ADP O 
Inflammatory - PROPN O 
Markers - PROPN O 
: - PUNCT O 
Part - NOUN O 
I - NOUN O 
Profiling - NOUN O 
of - ADP O 
Saliva - PROPN O 
and - CCONJ O 
Serum - PROPN O 
Molecular - PROPN O 
Patterns - PROPN O 
. - PUNCT O 

Ring PROPN - B-PERSON 
Block PROPN - I-PERSON 
of - ADP O 
the - DET O 
Penis - PROPN O 
: - PUNCT O 
A - PROPN O 
Proven - VERB O 
Addition - NOUN O 
to - ADP O 
Multimodal - PROPN O 
Pain PROPN - B-MEDICINE 
Relief PROPN - I-MEDICINE 
for - ADP O 
Newborn - PROPN O 
Circumcision - PROPN O 
. - PUNCT O 

Following - VERB O 
Esophagectomy - NOUN O 
for - ADP O 
Acute - PROPN O 
Postoperative - PROPN O 
Pain PROPN - B-MEDICINE 
Relief PROPN - I-MEDICINE 
in - ADP O 
the DET - B-ORG 
Postanesthesia PROPN - I-ORG 
Care PROPN - I-ORG 
Unit PROPN - I-ORG 
. - PUNCT O 

Use - PROPN O 
of - ADP O 
Mindfulness PROPN - B-ORG 
or CCONJ - I-ORG 
Self PROPN - I-ORG 
- PUNCT - I-ORG 
Hypnosis NOUN - I-ORG 
Provides VERB - I-ORG 
Immediate - PROPN O 
Pain PROPN - B-MEDICINE 
Relief PROPN - I-MEDICINE 
to - ADP O 
Hospitalized - PROPN O 
Patients - PROPN O 
. - PUNCT O 

The DET - B-ORG 
Effect PROPN - I-ORG 
of ADP - I-ORG 
Pain PROPN - I-ORG 
Relief PROPN - I-ORG 
on ADP - I-ORG 
Daily PROPN - I-ORG 
Physical PROPN - I-ORG 
Activity PROPN - I-ORG 
: - PUNCT O 
in - ADP O 
- - PUNCT O 
Home - NOUN O 
Objective - PROPN O 
Physical - PROPN O 
Activity - PROPN O 
Assessment - PROPN O 
in - ADP O 
Chronic - PROPN O 
Low - PROPN O 
Back - PROPN O 
Pain - NOUN O 
Patients - PROPN O 
after - ADP O 
Paravertebral - PROPN O 
Spinal - PROPN O 
Block - PROPN O 

What - NOUN O 
Is - VERB O 
the - DET O 
Role - NOUN O 
of - ADP O 
the - DET O 
Placebo - PROPN O 
Effect - PROPN O 
for - ADP O 
Pain PROPN - B-MEDICINE 
Relief PROPN - I-MEDICINE 
in - ADP O 
Neurorehabilitation - PROPN O 
? - PUNCT O 

Opiate ADJ - B-ORG 
- PUNCT - I-ORG 
Free ADJ - I-ORG 
Pain PROPN - I-ORG 
Therapy PROPN - I-ORG 
Using VERB - I-ORG 
Carbamazepine - PROPN O 
- - PUNCT O 
Loaded - VERB O 
Microparticles - PROPN O 
Provides - VERB O 
Up - ADP O 
to - ADP O 
2 - NUM O 
Weeks - NOUN O 
of - ADP O 
Pain PROPN - B-MEDICINE 
Relief PROPN - I-MEDICINE 
in - ADP O 
a - DET O 
Neuropathic PROPN - B-PRODUCT 
Pain PROPN - I-PRODUCT 
Model PROPN - I-PRODUCT 
. - PUNCT O 

Efficacy - NOUN O 
of - ADP O 
Bilateral PROPN - B-ORG 
Transversus PROPN - I-ORG 
Abdominis PROPN - I-ORG 
Plane PROPN - I-ORG 
and - CCONJ O 
Ilioinguinal PROPN - B-ORG 
- PUNCT - I-ORG 
Iliohypogastric PROPN - I-ORG 
Nerve PROPN - I-ORG 
Blocks NOUN - I-ORG 
for - ADP O 
Postcaesarean - ADJ O 
Delivery - PROPN O 
Pain PROPN - B-MEDICINE 
Relief PROPN - I-MEDICINE 
under - ADP O 
Spinal PROPN - B-PERSON 
Anesthesia PROPN - I-PERSON 
. - PUNCT O 

Levofloxacin PROPN - B-MEDICINE 
, - PUNCT O 
a - DET O 
fluoroquinolone - NOUN O 
, - PUNCT O 
is - VERB O 
used - VERB O 
therapeutically - ADV O 
in - ADP O 
numerous - ADJ O 
countries - NOUN O 
; - PUNCT O 
however - ADV O 
, - PUNCT O 
it - PRON O 
can - VERB O 
cause - VERB O 
an - DET O 
increase - NOUN O 
in - ADP O 
liver - NOUN O 
function - NOUN O 
tests - NOUN O 
and - CCONJ O 
liver - NOUN O 
dysfunction - NOUN O 
. - PUNCT O 

The - DET O 
current - ADJ O 
study - NOUN O 
was - VERB O 
designed - VERB O 
to - PART O 
determine - VERB O 
the - DET O 
effect - NOUN O 
of - ADP O 
Levofloxacin PROPN - B-MEDICINE 
( - PUNCT O 
40 NUM - B-CARDINAL 
  - SPACE O 
mg - PROPN O 
/ - SYM O 
kg - VERB O 
body - NOUN O 
weight - NOUN O 
( - PUNCT O 
b.wt - NOUN O 
. - PUNCT O 
) - PUNCT O 

M. - PROPN O 
oleifera - NOUN O 
leaf - NOUN O 
extract - NOUN O 
was - VERB O 
found - VERB O 
to - PART O 
improve - VERB O 
the - DET O 
hepatic - ADJ O 
dysfunction - NOUN O 
induced - VERB O 
by - ADP O 
Levofloxacin PROPN - B-MEDICINE 
by - ADP O 
recovering - VERB O 
liver - NOUN O 
enzymatic - ADJ O 
activities - NOUN O 
( - PUNCT O 
alanine - NOUN O 
aminotransferase - NOUN O 
[ - PUNCT O 
ALT PROPN - B-ORG 
] - PUNCT O 
, - PUNCT O 
aspartate - NOUN O 
aminotransferase - NOUN O 
[ - PUNCT O 
AST - PROPN O 
] - PUNCT O 
and - CCONJ O 
gamma - NOUN O 
- - PUNCT O 
glutamyl - NOUN O 
transferase - NOUN O 
[ - PUNCT O 
GGT PROPN - B-ORG 
] - PUNCT O 
) - PUNCT O 
to - ADP O 
normal - ADJ O 
levels - NOUN O 
. - PUNCT O 

Additionally - ADV O 
, - PUNCT O 
its - ADJ O 
presence - NOUN O 
attenuated - VERB O 
the - DET O 
downregulation - NOUN O 
of - ADP O 
IL-1 - PROPN O 
induced - VERB O 
by - ADP O 
Levofloxacin PROPN - B-MEDICINE 
alone - ADV O 
from - ADP O 
hepatic - ADJ O 
tissue - NOUN O 
. - PUNCT O 

It - PRON O 
can - VERB O 
be - VERB O 
concluded - VERB O 
that - ADP O 
M. PROPN - B-ORG 
oleifera - NOUN O 
extract - NOUN O 
can - VERB O 
help - VERB O 
reduce - VERB O 
the - DET O 
side - NOUN O 
effects - NOUN O 
caused - VERB O 
by - ADP O 
Levofloxacin PROPN - B-MEDICINE 
administration - NOUN O 
. - PUNCT O 

Levofloxacin PROPN - B-MEDICINE 
- - PUNCT O 
associated - VERB O 
encephalopathy - ADJ O 
with - ADP O 
psychotic - ADJ O 
features - NOUN O 
is - VERB O 
a - DET O 
rare - ADJ O 
adverse - ADJ O 
event - NOUN O 
. - PUNCT O 

Levofloxacin NOUN - B-MEDICINE 
- - PUNCT O 
associated - VERB O 
Encephalopathy PROPN - B-GPE 
with - ADP O 
Severe - PROPN O 
Hyperventilation - PROPN O 
. - PUNCT O 

Levofloxacin PROPN - B-MEDICINE 
( - PUNCT O 
LVFX PROPN - B-ORG 
) - PUNCT O 
, - PUNCT O 
a - DET O 
broad - ADJ O 
- - PUNCT O 
spectrum - NOUN O 
antibacterial - ADJ O 
agent - NOUN O 
from - ADP O 
the - DET O 
fluoroquinolone - ADJ O 
family - NOUN O 
, - PUNCT O 
is - VERB O 
universally - ADV O 
prescribed - VERB O 
with - ADP O 
antipyretics - NOUN O 
, - PUNCT O 
including - VERB O 
paracetamol - NOUN O 
( - PUNCT O 
APAP PROPN - B-ORG 
) - PUNCT O 
analogs - VERB O 
. - PUNCT O 

Levofloxacin PROPN - B-MEDICINE 
, - PUNCT O 
pefloxacin - NOUN O 
, - PUNCT O 
ciprofloxacin - NOUN O 
and - CCONJ O 
moxifloxacin - NOUN O 
are - VERB O 
four NUM - B-CARDINAL 
fluoroquinolones - NOUN O 
used - VERB O 
in - ADP O 
the - DET O 
treatment - NOUN O 
of - ADP O 
serious - ADJ O 
bacterial - ADJ O 
infections - NOUN O 
. - PUNCT O 

AbstractBackgroundLevofloxacin - NOUN O 
given - VERB O 
at - ADP O 
a - DET O 
standard - ADJ O 
dose - NOUN O 
of - ADP O 
500 NUM - B-CARDINAL 
mg - NOUN O 
daily ADV - B-DATE 
is - VERB O 
recommended - VERB O 
for - ADP O 
antibacterial - ADJ O 
prophylaxis - NOUN O 
in - ADP O 
patients - NOUN O 
receiving - VERB O 
myelosuppressive - ADJ O 
chemotherapy - NOUN O 
. - PUNCT O 

Levofloxacin PROPN - B-MEDICINE 
AUC PROPN - B-ORG 
was - VERB O 
estimated - VERB O 
from - ADP O 
CrCL PROPN - B-ORG 
using - VERB O 
the - DET O 
method - NOUN O 
of - ADP O 
Pai PROPN - B-PERSON 
et PROPN - I-PERSON 
al PROPN - I-PERSON 
. - PUNCT O 

Infectious - ADJ O 
Outcomes - PROPN O 
of - ADP O 
Levofloxacin PROPN - B-MEDICINE 
Prophylaxis - PROPN O 
in - ADP O 
Obese PROPN - B-NORP 
vs. - ADP O 
Non ADJ - B-PERSON 
- ADJ - I-PERSON 
obese ADJ - I-PERSON 
Patients - PROPN O 
with - ADP O 
Hematologic - PROPN O 
Malignancies - PROPN O 
. - PUNCT O 

Population PROPN - B-ORG 
Pharmacokinetic PROPN - I-ORG 
Analysis PROPN - I-ORG 
of ADP - I-ORG 
Ciprofloxacin - PROPN O 
and - CCONJ O 
Levofloxacin PROPN - B-MEDICINE 
in - ADP O 
Critically - ADV O 
Ill - PROPN O 
Trauma - PROPN O 
, - PUNCT O 
Surgical - PROPN O 
, - PUNCT O 
and - CCONJ O 
Burn PROPN - B-ORG 
Patients PROPN - I-ORG 
. - PUNCT O 

Levofloxacin NOUN - B-MEDICINE 
prophylaxis - NOUN O 
was - VERB O 
standard - ADJ O 
of - ADP O 
care - NOUN O 
for - ADP O 
patients - NOUN O 
undergoing - VERB O 
autologous - ADJ O 
SCT PROPN - B-ORG 
or - CCONJ O 
induction - NOUN O 
chemotherapy - NOUN O 
for - ADP O 
acute - ADJ O 
myeloid - ADJ O 
leukemia - NOUN O 
( - PUNCT O 
AML PROPN - B-ORG 
) - PUNCT O 
. - PUNCT O 

Levofloxacin PROPN - B-MEDICINE 
( - PUNCT O 
Reference - PROPN O 
) - PUNCT O 
was - VERB O 
tested - VERB O 
against - ADP O 
E.coli - PROPN O 
standard - NOUN O 
( - PUNCT O 
American PROPN - B-ORG 
Type PROPN - I-ORG 
Culture PROPN - I-ORG 
Collection PROPN - I-ORG 
) - PUNCT O 
( - PUNCT O 
ATCC=25922 NOUN - B-NORP 
) - PUNCT O 
with - ADP O 
( - PUNCT O 
MIC90 PROPN - B-GPE 
; - PUNCT O 
0.03μg PROPN - B-ORG 
/ SYM - I-ORG 
ml NOUN - I-ORG 
) - PUNCT O 
and - CCONJ O 
compared - VERB O 
with - ADP O 
different - ADJ O 
eleven NUM - B-CARDINAL 
brands - NOUN O 
of - ADP O 
levofloxacin NOUN - B-MEDICINE 
tablets - NOUN O 
250 NUM - B-QUANTITY 
mg NOUN - I-QUANTITY 
( - PUNCT O 
MIC90 PROPN - B-GPE 
; - PUNCT O 
0.5μg NOUN - B-CARDINAL 
/ - SYM O 
ml - PROPN O 
-16.0μg - PUNCT O 
/ - SYM O 
ml - PROPN O 
) - PUNCT O 
. - PUNCT O 

Levofloxacin PROPN - B-MEDICINE 
( - PUNCT O 
Reference - PROPN O 
) - PUNCT O 
sensitivity - NOUN O 
against - ADP O 
S. - PROPN O 
aureus - NOUN O 
standard - NOUN O 
( - PUNCT O 
ATCC=25923 - PROPN O 
) - PUNCT O 
is - VERB O 
( - PUNCT O 
MIC90 PROPN - B-GPE 
; - PUNCT O 
0.12μg PROPN - B-ORG 
/ SYM - I-ORG 
ml NOUN - I-ORG 
) - PUNCT O 
and - CCONJ O 
similarly - ADV O 
when - ADV O 
it - PRON O 
was - VERB O 
compared - VERB O 
with - ADP O 
same - ADJ O 
levofloxacin NOUN - B-MEDICINE 
tablets - NOUN O 
( - PUNCT O 
MIC90 PROPN - B-GPE 
; - PUNCT O 
0.5 NUM - B-CARDINAL 
- - PUNCT O 
16.0μg - NUM O 
/ - SYM O 
ml - PROPN O 
) - PUNCT O 
. - PUNCT O 

Oral - ADJ O 
Step - NOUN O 
Down - ADV O 
Therapy - NOUN O 
With - ADP O 
Levofloxacin PROPN - B-MEDICINE 
for - ADP O 
Low - PROPN O 
- - PUNCT O 
Risk - NOUN O 
Febrile - PROPN O 
Neutropenia - PROPN O 
in - ADP O 
Children - PROPN O 
. - PUNCT O 

Optimized VERB - B-ORG 
Preparation PROPN - I-ORG 
of ADP - I-ORG 
Levofloxacin PROPN - I-MEDICINE 
Loaded PROPN - I-ORG 
Polymeric PROPN - I-ORG 
Nanoparticles PROPN - I-ORG 
. - PUNCT O 

Levofloxacin PROPN - B-MEDICINE 
is - VERB O 
used - VERB O 
for - ADP O 
the - DET O 
treatment - NOUN O 
of - ADP O 
multidrug - NOUN O 
- - PUNCT O 
resistant - ADJ O 
tuberculosis - NOUN O 
; - PUNCT O 
however - ADV O 
the - DET O 
optimal - NOUN O 
dose - NOUN O 
is - VERB O 
unknown - ADJ O 
. - PUNCT O 

Levofloxacin NOUN - B-MEDICINE 
- - PUNCT O 
resistant - ADJ O 
isolates - NOUN O 
underwent - VERB O 
whole - ADV O 
- - PUNCT O 
genome - ADJ O 
sequencing - NOUN O 
. - PUNCT O 

Levofloxacin PROPN - B-MEDICINE 
Pharmacokinetics PROPN - I-ORG 
/ SYM - I-ORG 
Pharmacodynamics PROPN - I-ORG 
, - PUNCT O 
Dosing - NOUN O 
, - PUNCT O 
Susceptibility - PROPN O 
Breakpoints - PROPN O 
, - PUNCT O 
and - CCONJ O 
Artificial PROPN - B-ORG 
Intelligence PROPN - I-ORG 
in - ADP O 
the DET - B-ORG 
Treatment PROPN - I-ORG 
of ADP - I-ORG 
Multidrug PROPN - I-ORG 
- - PUNCT O 
resistant - ADJ O 
Tuberculosis NOUN - B-ORG 
. - PUNCT O 

Levofloxacin PROPN - B-MEDICINE 
, - PUNCT O 
a - DET O 
third ADJ - B-ORDINAL 
- - PUNCT O 
generation - NOUN O 
fluoroquinolone - NOUN O 
antibiotic - NOUN O 
, - PUNCT O 
is - VERB O 
rarely - ADV O 
associated - VERB O 
with - ADP O 
neurotoxicity - NOUN O 
. - PUNCT O 

Colonization - NOUN O 
With - ADP O 
Levofloxacin PROPN - B-MEDICINE 
- - PUNCT O 
resistant - ADJ O 
Extended - ADJ O 
- - PUNCT O 
spectrum - PROPN O 
β - ADJ O 
- - PUNCT O 
Lactamase - NOUN O 
- - PUNCT O 
producing - VERB O 
Enterobacteriaceae - PROPN O 
and - CCONJ O 
Risk - PROPN O 
of - ADP O 
Bacteremia - PROPN O 
in - ADP O 
Hematopoietic - PROPN O 
Stem - PROPN O 
Cell - PROPN O 
Transplant - NOUN O 
Recipients - PROPN O 
. - PUNCT O 

Levofloxacin PROPN - B-MEDICINE 
was - VERB O 
discontinued - VERB O 
and - CCONJ O 
the - DET O 
symptoms - NOUN O 
resolved - VERB O 
. - PUNCT O 

A - DET O 
Case - PROPN O 
Report - PROPN O 
of - ADP O 
Anticoagulation - PROPN O 
Management - PROPN O 
in - ADP O 
Acquired - PROPN O 
Hemophilia - PROPN O 
Associated - VERB O 
With - ADP O 
Levofloxacin PROPN - B-MEDICINE 
. - PUNCT O 

P - NOUN O 
- - PUNCT O 
ValueAminoglycosides - PROPN O 
Amikacin66 - PROPN O 
% - NOUN O 
( - PUNCT O 
8)86 NUM - B-PERCENT 
% NOUN - I-PERCENT 
( - PUNCT O 
16)55 NUM - B-PERCENT 
% NOUN - I-PERCENT 
( - PUNCT O 
4)<0.001 - NUM O 
Gentamicin21 NOUN - B-PERCENT 
% NOUN - I-PERCENT 
( - PUNCT O 
2)31 NUM - B-PERCENT 
% NOUN - I-PERCENT 
( - PUNCT O 
4)21 NUM - B-PERCENT 
% NOUN - I-PERCENT 
( - PUNCT O 
2)<0.001 - NUM O 
Tobramycin15 NUM - B-PERCENT 
% NOUN - I-PERCENT 
( - PUNCT O 
2)18 NUM - B-PERCENT 
% NOUN - I-PERCENT 
( - PUNCT O 
4)14 NUM - B-PERCENT 
% NOUN - I-PERCENT 
( - PUNCT O 
1)0.063Cyclines - NUM O 
Minocycline–16 - PROPN O 
% - NOUN O 
( - PUNCT O 
4)1 NUM - B-PERCENT 
% NOUN - I-PERCENT 
( - PUNCT O 
1)<0.001 - NUM O 
Tigecycline43 - NOUN O 
% - NOUN O 
( - PUNCT O 
1)84 NUM - B-PERCENT 
% NOUN - I-PERCENT 
( - PUNCT O 
2)43 NUM - B-PERCENT 
% NOUN - I-PERCENT 
( - PUNCT O 
1)<0.001Fluoroquinolones - PROPN O 
Levofloxacin6 - PROPN O 
% - NOUN O 
( - PUNCT O 
0.5)15 NUM - B-PERCENT 
% NOUN - I-PERCENT 
( - PUNCT O 
2)6 NUM - B-PERCENT 
% NOUN - I-PERCENT 
( - PUNCT O 
0.5)0.001 - NUM O 
P - NOUN O 
< - NOUN O 
0.05 NUM - B-CARDINAL 
are - VERB O 
significant - ADJ O 
and - CCONJ O 
indicate - VERB O 
differences - NOUN O 
between - ADP O 
CLSI PROPN - B-ORG 
/ SYM - I-ORG 
FDA PROPN - I-ORG 
and - CCONJ O 
USCAST PROPN - B-ORG 
susceptibility - NOUN O 
. - PUNCT O 

Levofloxacin PROPN - B-MEDICINE 
, - PUNCT O 
a - DET O 
fluoroquinolone - NOUN O 
, - PUNCT O 
is - VERB O 
an - DET O 
isomer - NOUN O 
of - ADP O 
ofloxacin - NOUN O 
with - ADP O 
an - DET O 
extensive - ADJ O 
spectrum - NOUN O 
of - ADP O 
antimicrobial - ADJ O 
efficacy - NOUN O 
. - PUNCT O 

Effect - NOUN O 
of - ADP O 
Levofloxacin PROPN - B-MEDICINE 
Prophylaxis PROPN - I-ORG 
on ADP - I-ORG 
Bacteremia - PROPN O 
in - ADP O 
Children - PROPN O 
With - ADP O 
Acute - PROPN O 
Leukemia - PROPN O 
or - CCONJ O 
Undergoing - PROPN O 
Hematopoietic - PROPN O 
Stem - PROPN O 
Cell - PROPN O 
Transplantation - NOUN O 
: - PUNCT O 
A - DET O 
Randomized - VERB O 
Clinical - PROPN O 
Trial - PROPN O 
. - PUNCT O 

Spinal - ADJ O 
Cord - PROPN O 
Neuromodulation - PROPN O 
Therapy - PROPN O 
for - ADP O 
Levofloxacin PROPN - B-MEDICINE 
- PUNCT - I-ORG 
Reinduced PROPN - I-ORG 
Complex PROPN - I-ORG 
Regional PROPN - I-ORG 
Pain PROPN - I-ORG 
Syndrome PROPN - I-ORG 
and CCONJ - I-ORG 
Neurotoxicity PROPN - I-ORG 
: - PUNCT O 

Efficacy - NOUN O 
of - ADP O 
standard - ADJ O 
triple - ADJ O 
therapy - NOUN O 
versus - ADP O 
Levofloxacin PROPN - B-MEDICINE 
based - VERB O 
alternate - ADJ O 
therapy - NOUN O 
against - ADP O 
Helicobacter PROPN - B-ORG 
pylori - NOUN O 
infection - NOUN O 
. - PUNCT O 

Microarray - ADV O 
- - PUNCT O 
Based - VERB O 
Detection - PROPN O 
and - CCONJ O 
Clinical - PROPN O 
Evaluation - PROPN O 
for - ADP O 
Helicobacter - PROPN O 
pylori - NOUN O 
Resistance - NOUN O 
to - ADP O 
Clarithromycin - PROPN O 
or - CCONJ O 
Levofloxacin PROPN - B-MEDICINE 
and - CCONJ O 
the - DET O 
Genotype PROPN - B-PERSON 
of - ADP O 
CYP2C19 - PROPN O 
in - ADP O 
1083 NUM - B-DATE 
Patients - NOUN O 
. - PUNCT O 

Levofloxacin PROPN - B-MEDICINE 
and - CCONJ O 
moxifloxacin - NOUN O 
were - VERB O 
associated - VERB O 
with - ADP O 
a - DET O 
lower - ADJ O 
risk - NOUN O 
of - ADP O 
heart - NOUN O 
failure - NOUN O 
. - PUNCT O 

Levofloxacin PROPN - B-MEDICINE 
and - CCONJ O 
ciprofloxacin - VERB O 
still - ADV O 
remain - VERB O 
the - DET O 
commonest - ADJ O 
fluoroquinolones - NOUN O 
prescribed - VERB O 
for - ADP O 
UTIs - NOUN O 
in - ADP O 
many - ADJ O 
settings - NOUN O 
. - PUNCT O 

Who - NOUN O 
Receive - VERB O 
Prophylactic - PROPN O 
Levofloxacin PROPN - B-MEDICINE 
. - PUNCT O 

High - ADJ O 
- - PUNCT O 
Performance - NOUN O 
Photocatalytic - PROPN O 
Hydrogen - PROPN O 
Production - PROPN O 
and - CCONJ O 
Degradation - PROPN O 
of - ADP O 
Levofloxacin PROPN - B-MEDICINE 
by - ADP O 

An - DET O 
Unusual - PROPN O 
Case - NOUN O 
of - ADP O 
Levofloxacin PROPN - B-MEDICINE 
Pill - PROPN O 
Aspiration - NOUN O 
Causing - VERB O 
Respiratory - PROPN O 
Failure - PROPN O 
. - PUNCT O 

Levofloxacin PROPN - B-MEDICINE 
resistance - NOUN O 
increased - VERB O 
between ADP - B-DATE 
2000 NUM - I-DATE 
and CCONJ - I-DATE 
2016 NUM - I-DATE 
( - PUNCT O 
P<0.001 PROPN - B-PERSON 
) - PUNCT O 
, - PUNCT O 
but - CCONJ O 
resistance - NOUN O 
to - ADP O 
other - ADJ O 
antimicrobials - NOUN O 
did - VERB O 
not - ADV O 
change - VERB O 
over - ADP O 
time - NOUN O 
. - PUNCT O 

Levofloxacin PROPN - B-MEDICINE 
loaded - ADJ O 
samples - NOUN O 
also - ADV O 
presented - VERB O 
bacteria - NOUN O 
growth - NOUN O 
inhibition - NOUN O 
ability - NOUN O 
, - PUNCT O 
proving - VERB O 
that - DET O 
antibiotic - NOUN O 
was - VERB O 
not - ADV O 
degraded - VERB O 
during - ADP O 
the - DET O 
fabrication - NOUN O 
process - NOUN O 
and - CCONJ O 
its - ADJ O 
bactericidal - NOUN O 
efficacy - NOUN O 
was - VERB O 
preserved - VERB O 
. - PUNCT O 

Resistance - NOUN O 
( - PUNCT O 
R - PROPN O 
) - PUNCT O 
Trends - NOUN O 
in - ADP O 
Gram - PROPN O 
- - PUNCT O 
Negative - PROPN O 
Bacilli - PROPN O 
( - PUNCT O 
GNB PROPN - B-ORG 
) - PUNCT O 
to - ADP O 
Fluoroquinolones PROPN - B-ORG 
( PUNCT - I-ORG 
FQ PROPN - I-ORG 
) - PUNCT O 
, - PUNCT O 
[ - PUNCT O 
Ciprofloxacin PROPN - B-ORG 
( - PUNCT O 
CIP - PROPN O 
) - PUNCT O 
, - PUNCT O 
Levofloxacin PROPN - B-MEDICINE 
( - PUNCT O 
LEV PROPN - B-ORG 
) - PUNCT O 
, - PUNCT O 
Moxifloxacin PROPN - B-ORG 
( - PUNCT O 
MOX PROPN - B-ORG 
) - PUNCT O 
] - PUNCT O 
, - PUNCT O 
Trimethoprim - PROPN O 
– - PROPN O 
Sulfamethoxazole - PROPN O 
( - PUNCT O 
TMP PROPN - B-ORG 
/ SYM - I-ORG 
SMX PROPN - I-ORG 
) - PUNCT O 
and - CCONJ O 
Nitrofurantoin PROPN - B-ORG 
( - PUNCT O 
NFT PROPN - B-ORG 
) - PUNCT O 
over - ADP O 
a - DET O 
7-Year NUM - B-CARDINAL 
Period - NOUN O 
: - PUNCT O 
Pre- - PROPN O 
and - CCONJ O 
Post - PROPN O 
- - PROPN O 
Implementation - PROPN O 
of - ADP O 
FQ - PROPN O 
Restriction - PROPN O 
at - ADP O 
a - DET O 
Tertiary PROPN - B-ORG 
Care PROPN - I-ORG 
Veterans PROPN - I-ORG 
Affairs PROPN - I-ORG 
Medical PROPN - I-ORG 
Center PROPN - I-ORG 
( - PUNCT O 
VAMC - PROPN O 
) - PUNCT O 
. - PUNCT O 

Levofloxacin PROPN - B-MEDICINE 
was - VERB O 
most - ADV O 
commonly - ADV O 
requested - VERB O 
( - PUNCT O 
36.76 NUM - B-PERCENT 
% NOUN - I-PERCENT 
, - PUNCT O 
1,297 NUM - B-CARDINAL 
of - ADP O 
3,528 NUM - B-CARDINAL 
) - PUNCT O 
, - PUNCT O 
followed - VERB O 
by - ADP O 
meropenem - NOUN O 
, - PUNCT O 
caspofungin - NOUN O 
, - PUNCT O 
and - CCONJ O 
fluconazole - NOUN O 
. - PUNCT O 

Benzyl NOUN - B-PERSON 
penicillin - NOUN O 
, - PUNCT O 
Ampicillin PROPN - B-PERSON 
, - PUNCT O 
Cefotaxime - PROPN O 
, - PUNCT O 
Ceftriaxone - PROPN O 
, - PUNCT O 
Levofloxacin PROPN - B-MEDICINE 
, - PUNCT O 
Erythromycin PROPN - B-ORG 
, - PUNCT O 
Clindamycin PROPN - B-ORG 
, PUNCT - I-ORG 
Linezolid PROPN - I-ORG 
, - PUNCT O 
Vancomycin PROPN - B-ORG 
, - PUNCT O 
Tetracycline PROPN - B-PERSON 
and - CCONJ O 
Cotrimoxazole PROPN - B-GPE 
, - PUNCT O 
Olea PROPN - B-GPE 
europaea - NOUN O 
leaf - NOUN O 
extracts - NOUN O 
and - CCONJ O 
essential - ADJ O 
oil - NOUN O 
were - VERB O 
tested - VERB O 
against - ADP O 
GBS - PROPN O 
isolates - NOUN O 
from - ADP O 
South PROPN - B-GPE 
Africa PROPN - I-GPE 
and - CCONJ O 
Namibia PROPN - B-GPE 
. - PUNCT O 

Levofloxacin PROPN - B-MEDICINE 
, - PUNCT O 
which - ADJ O 
A. NOUN - B-PERSON 
  SPACE - I-PERSON 
actinomycetemcomitans - NOUN O 
is - VERB O 
usually - ADV O 
susceptible - ADJ O 
to - PART O 
, - PUNCT O 
can - VERB O 
be - VERB O 
an - DET O 
effective - ADJ O 
alternative - ADJ O 
oral - ADJ O 
antimicrobial - ADJ O 
agent - NOUN O 
in - ADP O 
such - ADJ O 
cases - NOUN O 
. - PUNCT O 

Tizanidine NOUN - B-MEDICINE 
exerts - NOUN O 
anti - ADJ O 
- - ADJ O 
nociceptive - ADJ O 
effects - NOUN O 
in - ADP O 
spared - VERB O 
nerve - NOUN O 
injury - NOUN O 
model - NOUN O 
of - ADP O 
neuropathic - ADJ O 
pain - NOUN O 
through - ADP O 
inhibition - NOUN O 
of - ADP O 
TLR4/NF PROPN - B-GPE 
- PUNCT - I-GPE 
κB PROPN - I-GPE 
pathway - NOUN O 
. - PUNCT O 

Co - PROPN O 
- - NOUN O 
Prescription - NOUN O 
of - ADP O 
Strong - PROPN O 
CYP1A2 - PROPN O 
Inhibitors - PROPN O 
and - CCONJ O 
the - DET O 
Risk - PROPN O 
of - ADP O 
Tizanidine PROPN - B-MEDICINE 
- - PUNCT O 
Associated - VERB O 
Hypotension - PROPN O 
: - PUNCT O 
A - DET O 
Retrospective - PROPN O 
Cohort - PROPN O 
Study - PROPN O 
. - PUNCT O 

Tizanidine PROPN - B-MEDICINE 
is - VERB O 
an - DET O 
alpha-2 - ADJ O 
agonist - NOUN O 
. - PUNCT O 

Comparison - PROPN O 
the - DET O 
Effects - NOUN O 
of - ADP O 
Oral - PROPN O 
Tizanidine PROPN - B-MEDICINE 
and - CCONJ O 
Tramadol PROPN - B-GPE 
on - ADP O 
Intra- - PROPN O 
and - CCONJ O 
Post PROPN - B-ORG 
- - ADJ O 
operative - ADJ O 
Shivering - PROPN O 
in - ADP O 
Patients - PROPN O 
Underwent - PROPN O 
Spinal - PROPN O 
Anesthesia - PROPN O 
. - PUNCT O 

Tizanidine NOUN - B-MEDICINE 
is - VERB O 
not - ADV O 
effective - ADJ O 
treating - NOUN O 
EPMS ADV - B-ORG 
. - PUNCT O 

Clinically PROPN - B-PERSON 
Significant ADJ - I-PERSON 
Bradycardia PROPN - I-PERSON 
From - ADP O 
Tizanidine PROPN - B-MEDICINE 
. - PUNCT O 

Tizanidine ADJ - B-MEDICINE 
withdrawal - NOUN O 
syndrome - NOUN O 
is - VERB O 
caused - VERB O 
by - ADP O 
adrenergic - ADJ O 
discharge - NOUN O 
due - ADP O 
to - ADP O 
its - ADJ O 
α2-agonist - ADJ O 
mechanism - NOUN O 
and - CCONJ O 
is - VERB O 
characterized - VERB O 
by - ADP O 
hypertension - NOUN O 
, - PUNCT O 
reflex - ADJ O 
tachycardia - NOUN O 
, - PUNCT O 
hypertonicity - NOUN O 
, - PUNCT O 
and - CCONJ O 
anxiety - NOUN O 
. - PUNCT O 

Management - NOUN O 
of - ADP O 
Tizanidine PROPN - B-MEDICINE 
Withdrawal - PROPN O 
Syndrome - PROPN O 
: - PUNCT O 
A - DET O 
Case - PROPN O 
Report - PROPN O 
. - PUNCT O 

Simultaneous - ADJ O 
Determination - PROPN O 
of - ADP O 
Tizanidine PROPN - B-MEDICINE 
, - PUNCT O 
Nimesulide PROPN - B-ORG 
, - PUNCT O 
Aceclofenac PROPN - B-WORK_OF_ART 
and CCONJ - I-WORK_OF_ART 
Paracetamol PROPN - I-WORK_OF_ART 
in ADP - I-WORK_OF_ART 
Tablets PROPN - I-WORK_OF_ART 
and CCONJ - I-WORK_OF_ART 
Biological PROPN - I-WORK_OF_ART 
Fluids PROPN - I-WORK_OF_ART 
Using VERB - I-WORK_OF_ART 
Micellar PROPN - I-WORK_OF_ART 
Liquid PROPN - I-WORK_OF_ART 
Chromatography PROPN - I-WORK_OF_ART 
. - PUNCT O 

The - DET O 
purpose - NOUN O 
of - ADP O 
the - DET O 
study - NOUN O 
was - VERB O 
to - PART O 
develop - VERB O 
Tizanidine ADJ - B-MEDICINE 
HCl - NOUN O 
( - PUNCT O 
TZN - PROPN O 
) - PUNCT O 
and - CCONJ O 
Meloxicam PROPN - B-PERSON 
( - PUNCT O 
MLX PROPN - B-ORG 
) - PUNCT O 
loaded - VERB O 
bilayer - NOUN O 
mucoadhesive - ADJ O 
films - NOUN O 
intended - VERB O 
for - ADP O 
buccal - ADJ O 
administration - NOUN O 
, - PUNCT O 
aiming - VERB O 
to - PART O 
enhance - VERB O 
the - DET O 
bioavailability - NOUN O 
. - PUNCT O 

Development - NOUN O 
of - ADP O 
Tizanidine PROPN - B-MEDICINE 
HCl - NOUN O 
- - PUNCT O 
Meloxicam - PROPN O 
loaded - VERB O 
mucoadhesive - ADJ O 
buccal - ADJ O 
films - NOUN O 
: - PUNCT O 
In - ADP O 
- - PUNCT O 
vitro - NOUN O 
and - CCONJ O 
in - ADP O 
- - PUNCT O 
vivo - NOUN O 
evaluation - NOUN O 
. - PUNCT O 

Tizanidine ADJ - B-MEDICINE 
hydrochloride - NOUN O 
is - VERB O 
an - DET O 
α2-adrenergic - ADJ O 
agonist - NOUN O 
used - VERB O 
for - ADP O 
the - DET O 
symptomatic - ADJ O 
relief - NOUN O 
of - ADP O 
spasticity - NOUN O 
associated - VERB O 
with - ADP O 
multiple - ADJ O 
sclerosis - NOUN O 
or - CCONJ O 
with - ADP O 
spinal - ADJ O 
cord - NOUN O 
injury - NOUN O 
or - CCONJ O 
disease - NOUN O 
. - PUNCT O 

Tizanidine PROPN - B-MEDICINE 
eluted - VERB O 
at - ADP O 
1.499 NUM - B-CARDINAL 
min - NOUN O 
and - CCONJ O 
the - DET O 
total - ADJ O 
run - NOUN O 
time - NOUN O 
was - VERB O 
2 NUM - B-QUANTITY 
min NOUN - I-QUANTITY 
. - PUNCT O 

Tizanidine PROPN - B-MEDICINE 
is - VERB O 
a - DET O 
centrally - ADV O 
acting - VERB O 
α2-agonist - NOUN O 
with - ADP O 
muscle - NOUN O 
relaxant - ADJ O 
properties - NOUN O 
. - PUNCT O 

Tizanidine VERB - B-MEDICINE 
for - ADP O 
the - DET O 
management - NOUN O 
of - ADP O 
acute - ADJ O 
postoperative - NOUN O 
pain - NOUN O 
after - ADP O 
inguinal - ADJ O 
hernia - NOUN O 
repair - NOUN O 
: - PUNCT O 
A - DET O 
placebo - NOUN O 
- - PUNCT O 
controlled - VERB O 
double - ADJ O 
- - PUNCT O 
blind - ADJ O 
trial - NOUN O 
. - PUNCT O 

In - ADP O 
this - DET O 
work - NOUN O 
, - PUNCT O 
the - DET O 
magnetic - ADJ O 
molecularly - ADJ O 
imprinted - ADJ O 
polymer - NOUN O 
nanoparticles - NOUN O 
( - PUNCT O 
MMIP - PROPN O 
- - PUNCT O 
NPs - NOUN O 
) - PUNCT O 
for - ADP O 
the - DET O 
selective - ADJ O 
pre - ADJ O 
- - ADJ O 
concentration - NOUN O 
of - ADP O 
Tizanidine PROPN - B-MEDICINE 
have - VERB O 
been - VERB O 
described - VERB O 
. - PUNCT O 

The - DET O 
polymer - NOUN O 
nanoparticles - NOUN O 
were - VERB O 
synthesized - VERB O 
by - ADP O 
the - DET O 
polymerization - NOUN O 
of - ADP O 
methacrylic - NOUN O 
acid - NOUN O 
as - ADP O 
a - DET O 
functional - ADJ O 
monomer - NOUN O 
, - PUNCT O 
ethylene - NOUN O 
glycol - NOUN O 
dimethacrylate - VERB O 
as - ADP O 
a - DET O 
cross - NOUN O 
- - ADJ O 
linker - ADJ O 
, - PUNCT O 
2,2-azobisisobutyronitrile NUM - B-CARDINAL 
as - ADP O 
an - DET O 
initiator - NOUN O 
and - CCONJ O 
Tizanidine PROPN - B-MEDICINE 
as - ADP O 
a - DET O 
template - NOUN O 
molecule - NOUN O 
. - PUNCT O 

Imprinted PROPN - B-ORG 
Tizanidine PROPN - I-MEDICINE 
molecules - NOUN O 
were - VERB O 
removed - VERB O 
from - ADP O 
the - DET O 
polymeric - ADJ O 
structure - NOUN O 
using - VERB O 
acetic - ADJ O 
acid - NOUN O 
in - ADP O 
methanol - NOUN O 
( - PUNCT O 
10:90 NUM - B-TIME 
V NOUN - I-TIME 
/ SYM - I-TIME 
V% PROPN - I-TIME 
) - PUNCT O 
, - PUNCT O 
as - ADP O 
the - DET O 
eluent - NOUN O 
solvent - NOUN O 
. - PUNCT O 

The - DET O 
limits - NOUN O 
of - ADP O 
detection - NOUN O 
( - PUNCT O 
L.O.D - PROPN O 
) - PUNCT O 
for - ADP O 
Tizanidine PROPN - B-MEDICINE 
were - VERB O 
1.13×10(-6)M PROPN - B-CARDINAL 
and - CCONJ O 
1.68×10(-6)M PROPN - B-CARDINAL 
in - ADP O 
ultrapure - NOUN O 
water - NOUN O 
and - CCONJ O 
urine - NOUN O 
, - PUNCT O 
respectively - ADV O 
. - PUNCT O 

The - DET O 
method - NOUN O 
was - VERB O 
applied - VERB O 
to - ADP O 
the - DET O 
determination - NOUN O 
of - ADP O 
Tizanidine PROPN - B-MEDICINE 
in - ADP O 
the - DET O 
human - ADJ O 
urine - NOUN O 
samples - NOUN O 
. - PUNCT O 

Tizanidine NOUN - B-MEDICINE 
- - PUNCT O 
induced - VERB O 
acute - ADJ O 
severe - ADJ O 
cystitis - NOUN O 
in - ADP O 
a - DET O 
female - ADJ O 
taking - VERB O 
famotidine - NOUN O 
. - PUNCT O 

Tizanidine ADJ - B-MEDICINE 
withdrawal - NOUN O 
should - VERB O 
be - VERB O 
considered - VERB O 
in - ADP O 
patients - NOUN O 
who - NOUN O 
manifest - VERB O 
signs - NOUN O 
and - CCONJ O 
symptoms - NOUN O 
of - ADP O 
withdrawal - NOUN O 
from - ADP O 
medications - NOUN O 
. - PUNCT O 

[ - PUNCT O 
Tizanidine VERB - B-MEDICINE 
withdrawal - NOUN O 
symptoms - NOUN O 
in - ADP O 
stress - NOUN O 
cardiomyopathy]. - ADJ O 

Successful - ADJ O 
Rituximab - PROPN O 
and - CCONJ O 
Tizanidine PROPN - B-MEDICINE 
Therapy - PROPN O 
. - PUNCT O 

Intermittent - ADJ O 
use - NOUN O 
of - ADP O 
oral - ADJ O 
muscle - NOUN O 
relaxant - ADJ O 
drugs - NOUN O 
, - PUNCT O 
for - ADP O 
example - NOUN O 
, - PUNCT O 
Tizanidine PROPN - B-MEDICINE 
( PUNCT - I-ORG 
Ternelin PROPN - I-ORG 
) - PUNCT O 
, - PUNCT O 
which - ADJ O 
is - VERB O 
a - DET O 
fast - ADV O 
- - PUNCT O 
acting - VERB O 
muscle - NOUN O 
relaxant - NOUN O 
, - PUNCT O 
can - VERB O 
provide - VERB O 
relief - NOUN O 
from - ADP O 
the - DET O 
severe - ADJ O 
hypertonia - NOUN O 
in - ADP O 
these - DET O 
patients - NOUN O 
, - PUNCT O 
but - CCONJ O 
only - ADV O 
for - ADP O 
short - ADJ O 
durations - NOUN O 
. - PUNCT O 

Tizanidine ADJ - B-MEDICINE 
HCl - NOUN O 
is - VERB O 
a - DET O 
skeletal - ADJ O 
muscle - NOUN O 
relaxant - NOUN O 
that - ADJ O 
suffers - VERB O 
from - ADP O 
extensive - ADJ O 
hepatic - ADJ O 
metabolism - NOUN O 
resulting - VERB O 
in - ADP O 
34 NUM - B-PERCENT 
- SYM - I-PERCENT 
40 NUM - I-PERCENT 
% NOUN - I-PERCENT 
oral - ADJ O 
bioavailability - NOUN O 
. - PUNCT O 

Tizanidine NOUN - B-MEDICINE 
, - PUNCT O 
baclofen - ADJ O 
, - PUNCT O 
and - CCONJ O 
placebo - NOUN O 
were - VERB O 
tested - VERB O 
in - ADP O 
this - DET O 
study - NOUN O 
. - PUNCT O 

Muscle - NOUN O 
relaxants - NOUN O 
available - ADJ O 
in - ADP O 
pharmaceutical - ADJ O 
trade - NOUN O 
suppress - NOUN O 
motor - NOUN O 
outflow - NOUN O 
through - ADP O 
different - ADJ O 
mechanisms - NOUN O 
of - ADP O 
action - NOUN O 
, - PUNCT O 
these - DET O 
include - VERB O 
drugs - NOUN O 
such - ADJ O 
as - ADP O 
: - PUNCT O 
Tizanidine ADJ - B-MEDICINE 
, - PUNCT O 
botulinum - ADJ O 
toxin - NOUN O 
, - PUNCT O 
Baclofen PROPN - B-GPE 
, - PUNCT O 
Tolperisone PROPN - B-ORG 
, - PUNCT O 
Methocarbamol PROPN - B-PERSON 
. - PUNCT O 

The - DET O 
morphology - NOUN O 
of - ADP O 
gelatin - ADJ O 
nanoparticles - NOUN O 
loaded - VERB O 
with - ADP O 
three NUM - B-CARDINAL 
different - ADJ O 
drugs - NOUN O 
( - PUNCT O 
Tizanidine ADJ - B-MEDICINE 
hydrochloride - NOUN O 
, - PUNCT O 
Gatifloxacin PROPN - B-PERSON 
and - CCONJ O 
Fluconazole PROPN - B-PERSON 
) - PUNCT O 
and - CCONJ O 
their - ADJ O 
characteristics - NOUN O 
of - ADP O 
entrapment - NOUN O 
and - CCONJ O 
release - NOUN O 
from - ADP O 
gelatin - ADJ O 
nanoparticles - NOUN O 
were - VERB O 
investigated - VERB O 
by - ADP O 
the - DET O 
analysis - NOUN O 
on - ADP O 
nanoparticle - NOUN O 
size - NOUN O 
distribution - NOUN O 
, - PUNCT O 
SEM PROPN - B-ORG 
and - CCONJ O 
FT - PROPN O 
- - PUNCT O 
IR - PROPN O 
in - ADP O 
this - DET O 
study - NOUN O 
. - PUNCT O 

Nonetheless - ADV O 
, - PUNCT O 
the - DET O 
uncrosslinked - ADJ O 
case - NOUN O 
of - ADP O 
Gatifloxacin PROPN - B-ORG 
loading - NOUN O 
generally - ADV O 
led - VERB O 
to - ADP O 
a - DET O 
more - ADV O 
homogeneous - ADJ O 
population - NOUN O 
of - ADP O 
nanoparticles - NOUN O 
than - ADP O 
the - DET O 
uncrosslinked - ADJ O 
case - NOUN O 
of - ADP O 
Tizanidine PROPN - B-MEDICINE 
hydrochloride - NOUN O 
loading - NOUN O 
. - PUNCT O 

No - DET O 
loading - NOUN O 
was - VERB O 
achieved - VERB O 
in - ADP O 
the - DET O 
case - NOUN O 
of - ADP O 
Fluconazole PROPN - B-PERSON 
, - PUNCT O 
whereas - ADP O 
both - DET O 
Tizanidine PROPN - B-MEDICINE 
hydrochloride - NOUN O 
and - CCONJ O 
Gatifloxacin PROPN - B-PERSON 
are - VERB O 
observed - VERB O 
of - ADP O 
being - VERB O 
capable - ADJ O 
of - ADP O 
being - VERB O 
loaded - VERB O 
by - ADP O 
nanoprecipitation - NOUN O 
. - PUNCT O 

Tizanidine ADJ - B-MEDICINE 
hydrochloride - NOUN O 
- - PUNCT O 
loaded - ADJ O 
, - PUNCT O 
blank - ADJ O 
and - CCONJ O 
Gatifloxacin PROPN - B-ORG 
- - PUNCT O 
loaded - VERB O 
nanoparticles - NOUN O 
yielded - VERB O 
, - PUNCT O 
under - ADP O 
crosslinked - ADJ O 
condition - NOUN O 
, - PUNCT O 
59.3 NUM - B-CARDINAL 
, - PUNCT O 
23.1 NUM - B-CARDINAL 
and - CCONJ O 
10.6 NUM - B-PERCENT 
% NOUN - I-PERCENT 
of - ADP O 
the - DET O 
used - VERB O 
dried - VERB O 
mass - NOUN O 
. - PUNCT O 

The - DET O 
crosslinked - VERB O 
Tizanidine PROPN - B-MEDICINE 
hydrochloride - NOUN O 
- - PUNCT O 
loaded - VERB O 
particles - NOUN O 
showed - VERB O 
the - DET O 
loading - NOUN O 
efficiency - NOUN O 
of - ADP O 
13.8 NUM - B-PERCENT 
% NOUN - I-PERCENT 
, - PUNCT O 
which - ADJ O 
was - VERB O 
decreased - VERB O 
to - ADP O 
1.1 NUM - B-PERCENT 
% NOUN - I-PERCENT 
without - ADP O 
crosslinking - NOUN O 
. - PUNCT O 

A - DET O 
crosslinker - NOUN O 
such - ADJ O 
as - ADP O 
glutaraldehyde - NOUN O 
is - VERB O 
indispensable - ADJ O 
to - PART O 
enhance - VERB O 
the - DET O 
Tizanidine PROPN - B-MEDICINE 
hydrochloride - NOUN O 
- - PUNCT O 
loading - VERB O 
efficiency - NOUN O 
. - PUNCT O 

The - DET O 
80 NUM - B-PERCENT 
% NOUN - I-PERCENT 
of - ADP O 
loaded - ADJ O 
Tizanidine PROPN - B-MEDICINE 
hydrochloride - NOUN O 
was - VERB O 
released - VERB O 
around ADP - B-CARDINAL 
15 NUM - I-CARDINAL 
h - NOUN O 
after - ADP O 
start - NOUN O 
- - PUNCT O 
up - NOUN O 
of - ADP O 
the - DET O 
release - NOUN O 
experiment - NOUN O 
, - PUNCT O 
while - ADP O 
the - DET O 
20 NUM - B-PERCENT 
% NOUN - I-PERCENT 
of - ADP O 
loaded - ADJ O 
Gatifloxacin PROPN - B-PERSON 
was - VERB O 
released - VERB O 
more - ADV O 
rapidly - ADV O 
, - PUNCT O 
as - ADP O 
free - ADJ O 
Gatifloxacin PROPN - B-ORG 
, - PUNCT O 
than - ADP O 
the - DET O 
loaded - VERB O 
Tizanidine PROPN - B-MEDICINE 
hydrochloride - NOUN O 
and - CCONJ O 
it - PRON O 
showed - VERB O 
the - DET O 
trend - NOUN O 
of - ADP O 
sustained - VERB O 
slow - ADJ O 
release - NOUN O 
during - ADP O 
the - DET O 
remaining - VERB O 
period - NOUN O 
of - ADP O 
its - ADJ O 
release - NOUN O 
experiment - NOUN O 
. - PUNCT O 

Development - NOUN O 
of - ADP O 
Orodispersible ADJ - B-ORG 
Tizanidine PROPN - I-MEDICINE 
HCl - NOUN O 
Tablets NOUN - B-ORG 
Using VERB - I-ORG 
Spray NOUN - I-ORG 
Dried PROPN - I-ORG 
Coprocessed PROPN - I-ORG 
Exipient PROPN - I-ORG 
Bases PROPN - I-ORG 
. - PUNCT O 

Tizanidine ADJ - B-MEDICINE 
hydrochloride - NOUN O 
is - VERB O 
an - DET O 
orally - ADV O 
administered - VERB O 
prokinetic - ADJ O 
agent - NOUN O 
that - ADJ O 
facilitates - VERB O 
or - CCONJ O 
restores - VERB O 
motility - NOUN O 
through - ADP O 
- - PUNCT O 
out - PART O 
the - DET O 
length - NOUN O 
of - ADP O 
the - DET O 
gastrointestinal - ADJ O 
tract - NOUN O 
. - PUNCT O 

A - DET O 
PLGA - PROPN O 
- - PUNCT O 
PEG - PROPN O 
- - PUNCT O 
PLGA - NOUN O 
Thermosensitive - PROPN O 
Gel - PROPN O 
Enabling - PROPN O 
Sustained - PROPN O 
Delivery - NOUN O 
of - ADP O 
Ropivacaine PROPN - B-MEDICINE 
Hydrochloride PROPN - I-MEDICINE 
for - ADP O 
Postoperative - PROPN O 
Pain - PROPN O 
Relief - PROPN O 
. - PUNCT O 

Comparison NOUN - B-ORG 
Between ADP - I-ORG 
Lignocaine - PROPN O 
Hydrochloride - PROPN O 
and - CCONJ O 
Ropivacaine PROPN - B-PERSON 
Hydrochloride PROPN - I-PERSON 
as - ADP O 
Lumbosacral - PROPN O 
Epidural - PROPN O 
Anaesthetic - PROPN O 
Agents - PROPN O 
in - ADP O 
Goats - PROPN O 

Comparison PROPN - B-ORG 
of ADP - I-ORG 
Two PROPN - I-ORG 
Doses PROPN - I-ORG 
of ADP - I-ORG 
Ropivacaine PROPN - B-MEDICINE 
Hydrochloride PROPN - I-MEDICINE 
for - ADP O 
Lumbosacral - PROPN O 
Epidural - PROPN O 
Anaesthesia - PROPN O 
in - ADP O 
Goats - PROPN O 

Ropivacaine PROPN - B-PERSON 
Hydrochloride PROPN - I-PERSON 
over - ADP O 
a - DET O 
period - NOUN O 
of - ADP O 
2 NUM - B-DATE 
- SYM - I-DATE 
3 NUM - I-DATE 
days NOUN - I-DATE 
, - PUNCT O 
we - PRON O 
achieved - VERB O 
a - DET O 
good - ADJ O 
pain - NOUN O 
reduction - NOUN O 
comparable - ADJ O 
to - ADP O 
a - DET O 
femoral - ADJ O 
catheter - NOUN O 
and - CCONJ O 
perfusor - NOUN O 
application - NOUN O 
of - ADP O 
2,0 NUM - B-QUANTITY 
mg NOUN - I-QUANTITY 
/ SYM - I-QUANTITY 
ml PROPN - I-QUANTITY 
( - PUNCT O 
0,2 - NUM O 
% - NOUN O 
) - PUNCT O 

Erythromycin PROPN - B-MEDICINE 
relaxes - VERB O 
BALB - PROPN O 
/ - SYM O 
c - NOUN O 
mouse - NOUN O 
airway - ADJ O 
smooth - ADJ O 
muscle - NOUN O 
. - PUNCT O 

Erythromycin PROPN - B-MEDICINE 
is - VERB O 
necessary - ADJ O 
in - ADP O 
medical - ADJ O 
treatment - NOUN O 
and - CCONJ O 
known - VERB O 
to - PART O 
be - VERB O 
biosynthesized - VERB O 
with - ADP O 
propionyl - NOUN O 
- - PUNCT O 
CoA - NOUN O 
as - ADP O 
direct - ADJ O 
precursor - NOUN O 
. - PUNCT O 

Erythromycin PROPN - B-MEDICINE 
A - PROPN O 
( - PUNCT O 
Er - PROPN O 
- - PUNCT O 
A - PROPN O 
) - PUNCT O 
produced - VERB O 
by - ADP O 
the - DET O 
actinomycete - ADJ O 
Saccharopolyspora PROPN - B-ORG 
erythraea - NOUN O 
is - VERB O 
an - DET O 
important - ADJ O 
antibiotic - ADJ O 
extensively - ADV O 
used - VERB O 
in - ADP O 
human - ADJ O 
medicine - NOUN O 
. - PUNCT O 

Metabolic PROPN - B-ORG 
Engineering PROPN - I-ORG 
Strategies PROPN - I-ORG 
Based VERB - I-ORG 
on ADP - I-ORG 
Secondary - PROPN O 
Messengers - NOUN O 
( - PUNCT O 
p)ppGpp - NOUN O 
and - CCONJ O 
C - PROPN O 
- - PUNCT O 
di - PROPN O 
- - PUNCT O 
GMP - NOUN O 
To - PART O 
Increase - VERB O 
Erythromycin PROPN - B-MEDICINE 
Yield - PROPN O 
in - ADP O 
Saccharopolyspora PROPN - B-GPE 
erythraea - NOUN O 
. - PUNCT O 

Erythromycin NOUN - B-MEDICINE 
- - PUNCT O 
loaded - VERB O 
solid - ADJ O 
lipid - NOUN O 
microparticles - NOUN O 
( - PUNCT O 
SLM PROPN - B-ORG 
) - PUNCT O 
based - VERB O 
on - ADP O 
solidified - VERB O 
reverse - ADJ O 
micellar - ADJ O 
solution - NOUN O 
( - PUNCT O 
SRMS PROPN - B-ORG 
) - PUNCT O 
as - ADP O 
an - DET O 
oral - ADJ O 
delivery - NOUN O 
formulation - NOUN O 
was - VERB O 
studied - VERB O 
. - PUNCT O 

Erythromycin PROPN - B-MEDICINE 
stearate - NOUN O 
- - PUNCT O 
loaded - ADJ O 
SLMs - NOUN O 
formulation - NOUN O 
could - VERB O 
serve - VERB O 
as - ADP O 
an - DET O 
alternative - NOUN O 
to - ADP O 
conventional - ADJ O 
oral - ADJ O 
formulation - NOUN O 
of - ADP O 
erythromycin NOUN - B-MEDICINE 
. - PUNCT O 

Effects - NOUN O 
of - ADP O 
Erythromycin PROPN - B-MEDICINE 
on - ADP O 
the DET - B-ORG 
Proliferation PROPN - I-ORG 
and CCONJ - I-ORG 
Apoptosis PROPN - I-ORG 
of ADP - I-ORG 
Cultured PROPN - I-ORG 
Nasal PROPN - I-ORG 
Polyp PROPN - I-ORG 
- PUNCT - I-ORG 
Derived VERB - I-ORG 
Cells PROPN - I-ORG 
and - CCONJ O 
the DET - B-ORG 
Extracellular PROPN - I-ORG 
Signal PROPN - I-ORG 
- PUNCT - I-ORG 
Regulated PROPN - I-ORG 
Kinase PROPN - I-ORG 
( - PUNCT O 
ERK)/Mitogen PROPN - B-ORG 
- PUNCT - I-ORG 
Activated VERB - I-ORG 
Protein PROPN - I-ORG 
Kinase PROPN - I-ORG 
( - PUNCT O 
MAPK - PROPN O 
) - PUNCT O 

Erythromycin PROPN - B-MEDICINE 
versus - ADP O 
metoclopramide - NOUN O 
for - ADP O 
post - ADJ O 
- - ADJ O 
pyloric - ADJ O 
spiral - ADJ O 
nasoenteric - ADJ O 
tube - NOUN O 
placement - NOUN O 
: - PUNCT O 
a - DET O 
randomized - ADJ O 
non - ADJ O 
- - ADJ O 
inferiority - ADJ O 
trial - NOUN O 
. - PUNCT O 

Characterization - NOUN O 
of - ADP O 
Erythromycin PROPN - B-MEDICINE 
and - CCONJ O 
Tetracycline PROPN - B-PERSON 
Resistance PROPN - I-PERSON 
in - ADP O 
Lactobacillus - PROPN O 
fermentum - NOUN O 
Strains PROPN - B-PERSON 
. - PUNCT O 

Erythromycin PROPN - B-MEDICINE 
sensitivity - NOUN O 
across - ADP O 
different - ADJ O 
taxa - NOUN O 
of - ADP O 
marine - ADJ O 
phytoplankton - NOUN O 
. - PUNCT O 

Erythromycin PROPN - B-MEDICINE 
intake - NOUN O 
in - ADP O 
the - DET O 
first ADJ - B-ORDINAL 
2 NUM - B-CARDINAL 
  - SPACE O 
weeks NOUN - B-DATE 
of - ADP O 
life - NOUN O 
is - VERB O 
associated - VERB O 
with - ADP O 
an - DET O 
increased - VERB O 
risk - NOUN O 
of - ADP O 
pyloric - ADJ O 
stenosis - NOUN O 
. - PUNCT O 

" - PUNCT O 
In - ADP O 
Vitro - PROPN O 
Activity - PROPN O 
of - ADP O 
Solithromycin PROPN - B-ORG 
against - ADP O 
Erythromycin PROPN - B-MEDICINE 
- - PUNCT O 
Resistant - PROPN O 
Streptococcus PROPN - B-ORG 
agalactiae - NOUN O 
" - PUNCT O 
. - PUNCT O 

Cost - PROPN O 
Analysis - NOUN O 
of - ADP O 
Azithromycin - PROPN O 
versus - ADP O 
Erythromycin PROPN - B-MEDICINE 
in - ADP O 
Pregnancies - PROPN O 
Complicated - VERB O 
by - ADP O 
Preterm - PROPN O 
Premature - PROPN O 
Rupture - PROPN O 
of - ADP O 
Membranes - PROPN O 
. - PUNCT O 

Erythromycin PROPN - B-MEDICINE 
( - PUNCT O 
ERY PROPN - B-ORG 
) - PUNCT O 
is - VERB O 
a - DET O 
macrolide - NOUN O 
antibiotic - NOUN O 
, - PUNCT O 
prescribed - VERB O 
for - ADP O 
human - ADJ O 
and - CCONJ O 
veterinary - ADJ O 
medicines - NOUN O 
but - CCONJ O 
also - ADV O 
used - VERB O 
in - ADP O 
aquaculture - NOUN O 
and - CCONJ O 
livestock - NOUN O 
production - NOUN O 
. - PUNCT O 

Erythromycin PROPN - B-MEDICINE 
is - VERB O 
an - DET O 
antibiotic - ADJ O 
employed - VERB O 
in - ADP O 
the - DET O 
treatment - NOUN O 
of - ADP O 
infections - NOUN O 
caused - VERB O 
by - ADP O 
Gram PROPN - B-ORG 
positive - ADJ O 
microorganisms - NOUN O 
and - CCONJ O 
the - DET O 
increasing - VERB O 
use - NOUN O 
has - VERB O 
made - VERB O 
it - PRON O 
a - DET O 
contaminant - NOUN O 
of - ADP O 
emerging - VERB O 
concern - NOUN O 
in - ADP O 
aqueous - ADJ O 
ecosystems - NOUN O 
. - PUNCT O 

Erythromycin PROPN - B-MEDICINE 
ethylsuccinate - NOUN O 
( - PUNCT O 
EES PROPN - B-ORG 
) - PUNCT O 
, - PUNCT O 
is - VERB O 
often - ADV O 
used - VERB O 
as - ADP O 
a - DET O 
pro - ADJ O 
- - ADJ O 
kinetic - ADJ O 
in - ADP O 
the - DET O 
management - NOUN O 
of - ADP O 
GERD PROPN - B-PERSON 
, - PUNCT O 
despite - ADP O 
lack - NOUN O 
of - ADP O 
evidence - NOUN O 
or - CCONJ O 
safety - NOUN O 
from - ADP O 
randomized - VERB O 
controlled - VERB O 
trials - NOUN O 
. - PUNCT O 

Erythromycin PROPN - B-MEDICINE 
and - CCONJ O 
Reflux PROPN - B-ORG 
Events PROPN - I-ORG 
in - ADP O 
Premature - PROPN O 
Neonates - PROPN O 
: - PUNCT O 
A - DET O 
Randomized VERB - B-ORG 
Clinical PROPN - I-ORG 
Trial PROPN - I-ORG 
. - PUNCT O 

Erythromycin PROPN - B-MEDICINE 
ribosome - ADJ O 
methylase - NOUN O 
B - NOUN O 
- - PUNCT O 
erm(B - PROPN O 
) - PUNCT O 
was - VERB O 
not - ADV O 
detected - VERB O 
in - ADP O 
any - DET O 
strain - NOUN O 
. - PUNCT O 

Erythromycin PROPN - B-MEDICINE 
A - PROPN O 
is - VERB O 
an - DET O 
important - ADJ O 
antibiotic - NOUN O 
. - PUNCT O 

Identification NOUN - B-ORG 
of ADP - I-ORG 
Pharmaceuticals PROPN - I-ORG 
in - ADP O 
The DET - B-ORG 
Aquatic PROPN - I-ORG 
Environment PROPN - I-ORG 
Using VERB - I-ORG 
HPLC PROPN - I-ORG 
- PUNCT - I-ORG 
ESI PROPN - I-ORG 
- PUNCT - I-ORG 
Q PROPN - I-ORG 
- PUNCT - I-ORG 
TOF PROPN - I-ORG 
- PUNCT - I-ORG 
MS PROPN - I-ORG 
and - CCONJ O 
Elimination - NOUN O 
of - ADP O 
Erythromycin PROPN - B-MEDICINE 
Through - ADP O 
Photo - PROPN O 
- - PUNCT O 
Induced - PROPN O 
Degradation - PROPN O 
. - PUNCT O 

Erythromycin PROPN - B-MEDICINE 
was - VERB O 
strongly - ADV O 
correlated - VERB O 
with - ADP O 
ermB - NOUN O 
, - PUNCT O 
ermC - PROPN O 
, - PUNCT O 
ermF - PROPN O 
and - CCONJ O 
ermY - ADJ O 
genes - NOUN O 
( - PUNCT O 
r - NOUN O 
  - SPACE O 
= - SYM O 
  - SPACE O 
0.462 - NUM O 
to - ADP O 
0.667 - NUM O 
, - PUNCT O 
p - X O 
  - SPACE O 
< - X O 
  - SPACE O 
0.05 NUM - B-CARDINAL 
) - PUNCT O 
, - PUNCT O 
but - CCONJ O 
no - DET O 
significant - ADJ O 
correlation - NOUN O 
was - VERB O 
observed - VERB O 
between - ADP O 
macrolides - NOUN O 
and - CCONJ O 
PKS PROPN - B-ORG 
genes - NOUN O 
, - PUNCT O 
suggesting - VERB O 
other - ADJ O 
environmental - ADJ O 
factors - NOUN O 
may - VERB O 
have - VERB O 
contributed - VERB O 
to - ADP O 
detected - VERB O 
macrolides - NOUN O 
. - PUNCT O 

Noninvasive - PROPN O 
Magnetogastrography - PROPN O 
Detects - VERB O 
Erythromycin PROPN - B-MEDICINE 
- - PUNCT O 
Induced - VERB O 
Effects - NOUN O 
on - ADP O 
the - DET O 
Gastric - PROPN O 
Slow - PROPN O 
Wave - PROPN O 
. - PUNCT O 

Erythromycin PROPN - B-MEDICINE 
for - ADP O 
Promoting - VERB O 
the - DET O 
Postpyloric - PROPN O 
Placement - PROPN O 
of - ADP O 
Feeding - PROPN O 
Tubes - PROPN O 
: - PUNCT O 

Erythromycin PROPN - B-MEDICINE 
( - PUNCT O 
ERY PROPN - B-ORG 
) - PUNCT O 
is - VERB O 
one NUM - B-CARDINAL 
of - ADP O 
the - DET O 
most - ADV O 
common - ADJ O 
antibiotics - NOUN O 
used - VERB O 
in - ADP O 
human - ADJ O 
and - CCONJ O 
veterinary - ADJ O 
practices - NOUN O 
, - PUNCT O 
leading - VERB O 
to - ADP O 
ubiquitous - ADJ O 
environmental - ADJ O 
distribution - NOUN O 
and - CCONJ O 
possible - ADJ O 
toxicity - NOUN O 
to - ADP O 
non - ADJ O 
- - ADJ O 
target - ADJ O 
organisms - NOUN O 
. - PUNCT O 

Erythromycin PROPN - B-MEDICINE 
resistance - NOUN O 
rate - NOUN O 
was - VERB O 
79.2 NUM - B-PERCENT 
% NOUN - I-PERCENT 
and - CCONJ O 
the - DET O 
frequencies - NOUN O 
of - ADP O 
ermB - NOUN O 
and - CCONJ O 
ermC - ADJ O 
genes - NOUN O 
were - VERB O 
88.6 NUM - B-PERCENT 
% NOUN - I-PERCENT 
and - CCONJ O 
69.8 NUM - B-PERCENT 
% NOUN - I-PERCENT 
, - PUNCT O 
respectively - ADV O 
. - PUNCT O 

We - PRON O 
assessed - VERB O 
the - DET O 
effect - NOUN O 
of - ADP O 
long - ADJ O 
- - PUNCT O 
term - NOUN O 
erythromycin NOUN - B-MEDICINE 
on - ADP O 
oropharyngeal - ADJ O 
microbiota - NOUN O 
composition - NOUN O 
and - CCONJ O 
the - DET O 
carriage - NOUN O 
of - ADP O 
transmissible - ADJ O 
macrolide - ADJ O 
resistance - NOUN O 
genes - NOUN O 
in - ADP O 
84 NUM - B-CARDINAL 
adults - NOUN O 
with - ADP O 
bronchiectasis - NOUN O 
, - PUNCT O 
enrolled - VERB O 
in - ADP O 
the - DET O 
Bronchiectasis - PROPN O 
and - CCONJ O 
Low - PROPN O 
- - PUNCT O 
dose - NOUN O 
Erythromycin PROPN - B-MEDICINE 
Study PROPN - I-FAC 
( - PUNCT O 
BLESS PROPN - B-ORG 
) - PUNCT O 
48-week NUM - B-CARDINAL 
placebo - NOUN O 
- - PUNCT O 
controlled - VERB O 
trial - NOUN O 
of - ADP O 
twice - ADV O 
- - PUNCT O 
daily ADJ - B-DATE 
erythromycin NOUN - B-MEDICINE 
ethylsuccinate - NOUN O 
( - PUNCT O 
400 NUM - B-CARDINAL 
  - SPACE O 
mg - NOUN O 
) - PUNCT O 
. - PUNCT O 

Erythromycin NOUN - B-MEDICINE 
treatment - NOUN O 
did - VERB O 
not - ADV O 
result - VERB O 
in - ADP O 
a - DET O 
significant - ADJ O 
increase - NOUN O 
in - ADP O 
the - DET O 
number - NOUN O 
of - ADP O 
subjects - NOUN O 
who - NOUN O 
carried - VERB O 
erm(A - PROPN O 
) - PUNCT O 
, - PUNCT O 
erm(B - PROPN O 
) - PUNCT O 

Impact - NOUN O 
of - ADP O 
Long PROPN - B-ORG 
- PUNCT - I-ORG 
Term PROPN - I-ORG 
Erythromycin PROPN - I-MEDICINE 
Therapy PROPN - I-ORG 
on - ADP O 
the DET - B-ORG 
Oropharyngeal PROPN - I-ORG 
Microbiome PROPN - I-ORG 
and CCONJ - I-ORG 
Resistance PROPN - I-ORG 
Gene PROPN - I-ORG 
Reservoir PROPN - I-ORG 
in - ADP O 
Non ADJ - B-ORG 
- ADJ - I-ORG 
Cystic ADJ - I-ORG 
Fibrosis PROPN - I-ORG 
Bronchiectasis PROPN - I-ORG 
. - PUNCT O 

Quantitative - ADJ O 
Screening - VERB O 
Method - PROPN O 
for - ADP O 
Erythromycin PROPN - B-MEDICINE 
and - CCONJ O 
Tylosin PROPN - B-ORG 
in ADP - I-ORG 
Honey PROPN - I-ORG 
Using VERB - I-ORG 
RapidFire PROPN - I-ORG 
Mass PROPN - I-ORG 
Spectrometry PROPN - I-ORG 
. - PUNCT O 

PccD - PROPN O 
Regulates - PROPN O 
Branched - PROPN O 
- - PUNCT O 
Chain - NOUN O 
Amino - PROPN O 
Acid - NOUN O 
Degradation - PROPN O 
and - CCONJ O 
Exerts - VERB O 
a - DET O 
Negative - PROPN O 
Effect - PROPN O 
on - ADP O 
Erythromycin PROPN - B-MEDICINE 
Production - PROPN O 
in - ADP O 
Saccharopolyspora PROPN - B-ORG 
erythraea - NOUN O 
. - PUNCT O 

Erythromycin PROPN - B-MEDICINE 
could - VERB O 
not - ADV O 
alter - VERB O 
the - DET O 
mean - ADJ O 
volume - NOUN O 
of - ADP O 
feeding - NOUN O 
, - PUNCT O 
duration - NOUN O 
of - ADP O 
parental - ADJ O 
feeding - NOUN O 
, - PUNCT O 
length - NOUN O 
of - ADP O 
hospitalization - NOUN O 
, - PUNCT O 
and - CCONJ O 
frequency - NOUN O 
of - ADP O 
feeding - VERB O 
discontinuity - NOUN O 
( - PUNCT O 
p>0.05 - NOUN O 
) - PUNCT O 
; - PUNCT O 
however - ADV O 
, - PUNCT O 
mean - VERB O 
days - NOUN O 
to - PART O 
reach - VERB O 
complete - ADJ O 
feeding - NOUN O 
in - ADP O 
group - NOUN O 
A - PROPN O 
was - VERB O 
significantly - ADV O 
shorter - ADJ O 
than - ADP O 
in - ADP O 
group - NOUN O 
B - NOUN O 
( - PUNCT O 
9.80 NUM - B-CARDINAL 
vs. - ADP O 
16.80 NUM - B-DATE 
days NOUN - I-DATE 
; - PUNCT O 
p=0.001 X - B-DATE 
) - PUNCT O 
. - PUNCT O 

Human PROPN - B-ORG 
Campylobacteriosis PROPN - I-ORG 
in - ADP O 
Italy PROPN - B-GPE 
: - PUNCT O 
Emergence - NOUN O 
of - ADP O 
Multi - PROPN O 
- - PROPN O 
Drug - PROPN O 
Resistance - PROPN O 
to - ADP O 
Ciprofloxacin PROPN - B-ORG 
, - PUNCT O 
Tetracycline PROPN - B-PERSON 
, - PUNCT O 
and - CCONJ O 
Erythromycin PROPN - B-MEDICINE 
. - PUNCT O 

Sensitize - PROPN O 
Group - PROPN O 
B - PROPN O 
Streptococcus - PROPN O 
to - ADP O 
Clindamycin VERB - B-ORG 
, - PUNCT O 
Erythromycin PROPN - B-MEDICINE 
, - PUNCT O 
Gentamicin PROPN - B-ORG 
, - PUNCT O 
and - CCONJ O 
Minocycline PROPN - B-GPE 
on - ADP O 
a - DET O 
Strain - PROPN O 
Specific - PROPN O 
Basis - PROPN O 
. - PUNCT O 

Erythromycin ADJ - B-MEDICINE 
poudrage - NOUN O 
versus - ADP O 
erythromycin ADJ - B-MEDICINE 
slurry - NOUN O 
in - ADP O 
the - DET O 
treatment - NOUN O 
of - ADP O 
refractory - ADJ O 
spontaneous - ADJ O 
pneumothorax - NOUN O 
. - PUNCT O 

Erythromycin PROPN - B-MEDICINE 
resistance - NOUN O 
was - VERB O 
found - VERB O 
in - ADP O 
53 NUM - B-PERCENT 
% NOUN - I-PERCENT 
of - ADP O 
isolates - NOUN O 
with - ADP O 
inducible - ADJ O 
macrolide - NOUN O 
, - PUNCT O 
lincosamide - ADJ O 
and - CCONJ O 
streptogramin - VERB O 
B - NOUN O 
the - DET O 
predominant - ADJ O 
phenotype - NOUN O 
( - PUNCT O 
63 NUM - B-PERCENT 
% NOUN - I-PERCENT 
) - PUNCT O 
with - ADP O 
ermB - ADJ O 
the - DET O 
major - ADJ O 
genetic - ADJ O 
determinant - NOUN O 
. - PUNCT O 

Erythromycin NOUN - B-MEDICINE 
and - CCONJ O 
tetracycline - NOUN O 
co - NOUN O 
- - NOUN O 
resistance - NOUN O 
was - VERB O 
found - VERB O 
in - ADP O 
39 NUM - B-PERCENT 
% NOUN - I-PERCENT 
of - ADP O 
tested - VERB O 
GAS - PROPN O 
isolates - NOUN O 
. - PUNCT O 

A - DET O 
Magnesium NOUN - B-MEDICINE 
Oxide PROPN - I-MEDICINE 
Bezoar - PROPN O 
. - PUNCT O 

Stabilization - NOUN O 
of - ADP O 
NaNO3-Promoted - PROPN O 
Magnesium PROPN - B-MEDICINE 
Oxide PROPN - I-MEDICINE 
for - ADP O 
High - PROPN O 
- - PUNCT O 
Temperature - PROPN O 
CO2 - PROPN O 
Capture - PROPN O 
. - PUNCT O 

Nano - PROPN O 
- - PUNCT O 
Magnesium NOUN - B-MEDICINE 
Oxide NOUN - I-MEDICINE 
: - PUNCT O 

This - DET O 
study - NOUN O 
is - VERB O 
aimed - VERB O 
at - ADP O 
producing - VERB O 
biofilms - NOUN O 
by - ADP O 
reinforcement - NOUN O 
of - ADP O 
Magnesium PROPN - B-ORG 
Oxide PROPN - I-ORG 
( - PUNCT O 
MgO NOUN - B-ORG 
) - PUNCT O 
nanoparticles - NOUN O 
in - ADP O 
polylactic - ADJ O 
acid - NOUN O 
( - PUNCT O 
PLA PROPN - B-ORG 
) - PUNCT O 
biopolymer - NOUN O 
using - VERB O 
the - DET O 
solvent - NOUN O 
casting - NOUN O 
method - NOUN O 
. - PUNCT O 

Cycle PROPN - B-ORG 
Stability PROPN - I-ORG 
and CCONJ - I-ORG 
Hydration PROPN - I-ORG 
Behavior PROPN - I-ORG 
of ADP - I-ORG 
Magnesium PROPN - B-ORG 
Oxide PROPN - I-ORG 
and CCONJ - I-ORG 
Its ADJ - I-ORG 
Dependence NOUN - I-ORG 
on - ADP O 
the - DET O 
Precursor - PROPN O 
- - PUNCT O 
Related - VERB O 
Particle - PROPN O 
Morphology - PROPN O 
. - PUNCT O 

Magnesium PROPN - B-MEDICINE 
Oxide PROPN - I-MEDICINE 
Nanoparticles - PROPN O 
: - PUNCT O 

Effects - NOUN O 
of - ADP O 
Magnesium PROPN - B-ORG 
Oxide PROPN - I-ORG 
on - ADP O 
the - DET O 
Serum - PROPN O 
Duloxetine - PROPN O 
Concentration - PROPN O 
and - CCONJ O 
Antidepressant - PROPN O 
- - PUNCT O 
Like - PROPN O 
Effects - NOUN O 
of - ADP O 
Duloxetine - PROPN O 
in - ADP O 
Rats - PROPN O 
. - PUNCT O 

Recently - ADV O 
, - PUNCT O 
the DET - B-LAW 
" PUNCT - I-LAW 
Revision PROPN - I-LAW 
of ADP - I-LAW 
Precautions PROPN - I-LAW 
on ADP - I-LAW 
the DET - I-LAW 
Use PROPN - I-LAW 
of ADP - I-LAW 
Magnesium PROPN - I-LAW 
Oxide PROPN - I-LAW 
" - PUNCT O 
has - VERB O 
been - VERB O 
issued - VERB O 
by - ADP O 
the DET - B-ORG 
Japanese PROPN - I-ORG 
Pharmaceuticals PROPN - I-ORG 
and CCONJ - I-ORG 
Medical PROPN - I-ORG 
Devices PROPN - I-ORG 
Agency PROPN - I-ORG 
, - PUNCT O 
warning - VERB O 
against - ADP O 
the - DET O 
risk - NOUN O 
of - ADP O 
hypermagnesemia - NOUN O 
with - ADP O 
the - DET O 
use - NOUN O 
of - ADP O 
MgO. - NOUN O 

In - ADP O 
Situ - PROPN O 
Observation - PROPN O 
of - ADP O 
Carbon - PROPN O 
Dioxide - PROPN O 
Capture - PROPN O 
on - ADP O 
Pseudo - PROPN O 
- - PUNCT O 
Liquid - PROPN O 
Eutectic - PROPN O 
Mixture - PROPN O 
- - PUNCT O 
Promoted - PROPN O 
Magnesium PROPN - B-MEDICINE 
Oxide PROPN - I-MEDICINE 
. - PUNCT O 

Hierarchical - PROPN O 
Porous - PROPN O 
Magnesium NOUN - B-MEDICINE 
Oxide PROPN - I-MEDICINE 
( - PUNCT O 
Hr - PROPN O 
- - PUNCT O 
MgO - PROPN O 
) - PUNCT O 

Magnesium PROPN - B-ORG 
Oxide PROPN - I-ORG 
Nanoparticles PROPN - I-ORG 

Demonstrated - PROPN O 
Using - VERB O 
Lithium - PROPN O 
Titanate - PROPN O 
and - CCONJ O 
Magnesium PROPN - B-MEDICINE 
Oxide PROPN - I-MEDICINE 
Nanoparticles - PROPN O 
. - PUNCT O 

Gold PROPN - B-ORG 
Nanoparticles PROPN - I-ORG 
Supported VERB - I-ORG 
on ADP - I-ORG 
Magnesium PROPN - I-ORG 
Oxide PROPN - I-ORG 
Nanorods PROPN - I-ORG 
for ADP - I-ORG 
Oxidation PROPN - I-ORG 
of ADP - I-ORG 
Alcohols PROPN - I-ORG 
. - PUNCT O 

Magnesium PROPN - B-MEDICINE 
Oxide PROPN - I-MEDICINE 
Suppresses - VERB O 
Tablet - PROPN O 
Hardness - PROPN O 
Reduction - PROPN O 
during - ADP O 
Storage - NOUN O 
. - PUNCT O 

Dietary - PROPN O 
Supplementation - PROPN O 
of - ADP O 
Magnesium PROPN - B-MEDICINE 
Oxide PROPN - I-MEDICINE 
( - PUNCT O 
MgO - PROPN O 
) - PUNCT O 

Mesoporous - ADJ O 
Magnesium NOUN - B-MEDICINE 
Oxide PROPN - I-MEDICINE 
Hollow - PROPN O 
Spheres - NOUN O 
as - ADP O 
Superior - PROPN O 
Arsenite - PROPN O 
Adsorbent - NOUN O 
: - PUNCT O 

A - DET O 
Label - PROPN O 
- - PUNCT O 
Free - PROPN O 
Photoluminescence - PROPN O 
Genosensor - PROPN O 
Using - VERB O 
Nanostructured - VERB O 
Magnesium PROPN - B-MEDICINE 
Oxide PROPN - I-MEDICINE 
for - ADP O 
Cholera - PROPN O 
Detection - PROPN O 
. - PUNCT O 

Evaluation - NOUN O 
of - ADP O 
Anticonvulsive - PROPN O 
Effect - PROPN O 
of - ADP O 
Magnesium PROPN - B-ORG 
Oxide PROPN - I-ORG 
Nanoparticles PROPN - I-ORG 
in - ADP O 
Comparison PROPN - B-GPE 
with - ADP O 
Conventional - PROPN O 
MgO - PROPN O 
in - ADP O 
Diabetic - PROPN O 
and - CCONJ O 
Non - ADJ O 
- - ADJ O 
diabetic - ADJ O 
Male PROPN - B-PERSON 
Mice NOUN - I-PERSON 
. - PUNCT O 

Optimization - NOUN O 
of - ADP O 
Ciprofloxacin PROPN - B-MEDICINE 
Hydrochloride PROPN - I-MEDICINE 
Spray - PROPN O 
- - PUNCT O 
Dried - VERB O 
Microparticles - PROPN O 
for - ADP O 
Pulmonary PROPN - B-ORG 
Delivery PROPN - I-ORG 
Using PROPN - I-ORG 
Design PROPN - I-ORG 
of ADP - I-ORG 
Experiments PROPN - I-ORG 
. - PUNCT O 

A - DET O 
Rapid - PROPN O 
Total - PROPN O 
Synthesis - PROPN O 
of - ADP O 
Ciprofloxacin PROPN - B-MEDICINE 
Hydrochloride PROPN - I-MEDICINE 
in - ADP O 
Continuous - PROPN O 
Flow - PROPN O 
. - PUNCT O 

Containing - VERB O 
BCS - PROPN O 
III - PROPN O 
Drugs - NOUN O 
, - PUNCT O 
Acyclovir PROPN - B-ORG 
, PUNCT - I-ORG 
Atenolol PROPN - I-ORG 
, - PUNCT O 
and - CCONJ O 
Ciprofloxacin PROPN - B-ORG 
Hydrochloride PROPN - I-ORG 
, - PUNCT O 
Using - VERB O 
Dissolution - NOUN O 
Testing - PROPN O 
. - PUNCT O 

[ - PUNCT O 
Radiolytic PROPN - B-ORG 
Decomposition PROPN - I-ORG 
of ADP - I-ORG 
Ciprofloxacin PROPN - I-ORG 
Hydrochloride PROPN - I-ORG 
in ADP - I-ORG 
Aqueous PROPN - I-ORG 
Solution PROPN - I-ORG 
Using VERB - I-ORG 
γ ADP - I-ORG 
Irradiation]. - PROPN O 

